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1Abstract
Mitochondrial transport plays an important role in matching mitochondrial distribution
to localised energy production and calcium buffering requirements. Miro is an outer mi-
tochondrial membrane (OMM) protein that, via its interaction with the kinesin motors,
mediates mitochondrial trafficking along the cytoskeletal tracks. Mitochondria, however,
not only need to be delivered to specific cellular sites, but also need to be retrieved when
not functional. PINK1 and Parkin are two Parkinson’s disease (PD)-associated proteins
that work in concert in a mitochondrial quality control system. PINK1 is a mitochondrial
serine-threonine kinase generally present at low levels on the OMM. PINK1 selectively
accumulates on the OMM of damaged mitochondria, and recruits Parkin, a cytosolic E3
ubiquitin ligase from the cytosol. Parkin then ubiquitinates several substrates on the
OMM, leading to the initiation of mitophagy.
In this thesis Miro1 is shown to be a substrate of the PINK1/Parkin pathway in hu-
man dopaminergic neuroblastoma cells. Analysis of the kinetics of Miro1 ubiquitination,
further demonstrates that mitochondrial damage triggers rapid K27-type ubiquitination
of Miro1 on the OMM, dependent on PINK1 and Parkin. Proteasomal degradation of
Miro1 is then seen on a slower timescale. Miro1 ubiquitination in dopaminergic neurob-
lastoma cells is found to be independent of Miro1 phosphorylation at serine 156, but
dependent on the recently identified serine 65 residue within Parkin that is phosphory-
lated by PINK1. Interestingly, Miro1 can stabilise phospho-mutant versions of Parkin on
the OMM, suggesting that Miro is also part of a Parkin receptor complex. These results
provide new insights into the ubiquitination-dependent regulation of the Miro-mediated
mitochondrial transport machinery by PINK1/Parkin and also suggest that disruption
of this regulation may be implicated in PD pathogenesis.
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Chapter 1
Introduction
First described in the XIX century, mitochondria are essential organelles for all eukary-
otic cells. They provide cellular energy by generating adenosine-5’-triphosphate (ATP)
and are therefore fundamental for all the metabolic activities within the cell. According
to the endosymbiotic theory these organelles derive from aerobic bacteria that colonised
anaerobic eukaryotic cells. These bacteria then evolved into mitochondria and the eu-
karyotic cells acquired the ability to metabolically use oxygen. Mitochondria not only
provide cellular energy, but play crucial roles in a wide range of other processes, such as
signalling and calcium buffering, cellular differentiation, cell death, as well as the control
of the cell cycle and cell growth (Alberts, 2008).
Mitochondrial structure
Although mitochondria were first observed at the end of the XIX century, their structure
and their role in the energy transduction started to be elucidated only in the mid 1900s
(Palade, 1952; Sjostrand, 1953; Mitchell and Moyle, 1967). Mitochondria are charac-
terised by an elaborate structure consisting of two highly specialised membranes (the
outer mitochondrial membrane, OMM, and the inner mitochondrial membrane, IMM),
a narrow intermembrane space and a much larger protein rich internal matrix (Fig. 1.1).
On the OMM the presence of porins, integral membrane proteins, allows the diffusion of
18
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ions and small molecules (<5 kDa) between the intermembrane space and the cytosol.
The integrity of this membrane ensures the compartmentalisation of the intermembrane
space proteins, such as cytochrome C, diffusion of which into the cytosol can initiate the
apoptotic cascade (Martinou et al., 2000).
The inner membrane is instead highly convoluted and forms many invaginations called
cristae (Fig. 1.1). These structures extensively expand the surface area of the IMM,
where the oxidative phosphorylation (OXPHOS) occurs, thus enhancing the mitochon-
drial ability to produce ATP (Mannella, 2006). Rather than being simple IMM folds,
3D reconstruction of electron microscopy images has shown that cristae are proper in-
ternal compartments that originate at narrow neck-like segments of the peripheral IMM
portions, called cristae junctions (Fig. 1.1). These structures are highly dynamic and
can change shape and distribution according to the metabolic state of the organelle. As
already mentioned, the OMM is fairly permeable to ions and small molecules, instead
diffusion across the IMM is tightly regulated to allow the complexes of the electron
transport chain (ETC) to create the proton gradient necessary for the oxidative phos-
phorylation, but also to provide the segregation and buffering of calcium ions. The
mitochondrial matrix is a dense compartment where the mitochondrial DNA (mtDNA)
and the mitochondrial ribosomes reside. In fact, although most of the mitochondrial
proteins are encoded by the genomic DNA, translated in the cytosol and only then im-
ported in the mitochondria, 13 of the protein complexes involved in the ETC are encoded
by mtDNA. Notably, the mtDNA is particularly susceptible to oxidative damage, due
to its proximity to the respiratory chain, where reactive oxygen species (ROS) can be
generated (Kotiadis et al., 2014).
Oxidative phosphorylation and energy production
ATP production is achieved within the cell through glycolysis, Krebs cycle (or tricar-
boxylic acid -TCA- cycle) and oxidative phosphorylation. Glycolysis is an anaerobic
process that takes place in the cytosol. Via a series of enzymatic reactions, glucose is
converted into two molecules of pyruvate, resulting in the generation of two molecules of
ATP. Pyruvate can then be oxidatively decarboxylated into acetyl CoA and transported
inside the mitochondrial matrix, where the Krebs cycle takes place. Through this cycle
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Figure 1.1: The mitochondrial compartments
Mitochondria are formed by an outer and an inner membrane (OMM and IMM) sep-
arated by the intermembrane space (IMS). The IMM is characterised by convoluted
invaginations, the cristae, that surround the mitochondrial matrix, a protein rich com-
partment where the mitochondrial DNA (mtDNA) is located. The mitochondrial cristae,
protrude into the matrix from bottle neck structures, called cristae junctions.
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acetyl CoA is completely oxidised into two molecules of carbon dioxide, one molecule of
GTP (or ATP) is produced and importantly three NAD+ and one FADH are reduced
to NADH and FADH2. These are energy-rich molecules, carrying electrons with high
transfer potential, that will be necessary in the ETC of the oxidative phosphorylation,
the major source of ATP in aerobic organisms (Alberts, 2008).
The molecular machinery for energy production, the ETC, is organised within the mi-
tochondrial cristae and consists of five protein complexes. The flow of electrons from
the electron donors, NADH and FADH2, to the electron acceptor O2 through the ETC
protein complexes leads to the pumping of protons out of the mitochondrial matrix.
The resulting uneven distribution of protons across the cristae membrane generates a
transmembrane electrical potential (Δψm) which is utilised by the ATP synthase. In
fact, the energy required for the synthesis of ATP is produced by the protons flowing
back to the mitochondrial matrix through the ATPase protein complex.
The electron transport chain, as illustrated in Fig. 1.2, starts with the NADH dehydro-
genase (complex I) or the succinate dehydrogenase (complex II) transferring electrons
from respectively NADH or FADH2 to ubiquinone. Although both processes can effi-
ciently participate in the electron transfer, only complex I pumps protons out of the
mitochondrial matrix, contributing to the generation of the proton gradient. The re-
duced ubiquinone, named ubiquinol, can freely diffuse across the cristae membrane. At
the cytochrome C oxidoreductase (complex III), the electrons of the reduced ubiquinol
are transferred both to the intermembrane space protein cytochrome C and to another
site within the ubiquinol itself. This is coupled with the transfer of more protons to the
intermembrane space. Subsequently the cytochrome C oxidase (complex IV) removes
the electrons from cytochrome C to transfer them to molecular O2 producing H2O and
further supporting the electrochemical proton gradient by pumping more protons into
the intermembrane space. The movement of these ions back into the matrix through the
F0 subunit of the ATP synthase (complex V), is then used to produce ATP from ADP
and phosphate (Alberts, 2008). The outcome of this mechanism is that the mitochon-
drial matrix generally has a negative potential compared to the cytoplasm estimated
at between -150 to -180 mV, and that through oxidative phosphorylation between 30
and 38 molecules of ATP are generated per glucose molecule (Rich, 2003; MacAskill
and Kittler, 2010). Most of these reactions are reversible, hence to maintain the proton
gradient ATP can be hydrolysed (Campanella et al., 2008). Notably, due to electron
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Figure 1.2: Oxidative phosphorylation and the electron transport chain.
The protein complexes involved in the electron transport chain (ETC) and the oxidative
phosphorylation are located within the IMM cristae. Starting from NADH or FADH2,
via a series of oxidative reactions, electrons are transferred across the protein complexes
of the ETC to produce H2O. While transferring electrons, complex I, III and IV pump
protons from the matrix into the intermembrane space, thus creating the proton gradient
required by the FOF1 ATP synthase to produce ATP.
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leakage (in particular at complex I and complex III) ROS can be produced. At low levels
these reactive molecules are involved in cell signalling events, however when the ROS
levels overcome the mechanisms that are in place to neutralise them, these by-products
can damage the mtDNA, protein and lipids (Zhou et al., 2008a).
Many drugs can selectively uncouple the mitochondrial membrane potential and ATP
production as represented in Fig. 1.3. For example, carbonyl cyanide- p - trifluo-
romethoxyphenylhydrazone (FCCP) or its derivative carbonyl cyanide m-chlorophenyl
hydrazone (CCCP), act as proton ionophores: after binding protons in the intermem-
brane space, these substances diffuse across the IMM and dissociate into the matrix,
hence dissipating the mitochondrial Δψm. In a similar way valinomycin, a potas-
sium ionophore, dissipates the mitochondrial Δψm by determining a leak of potas-
sium ions across the IMM. Antimycin A blocks the ETC by inhibiting complex III,
whereas oligomycin directly affects mitochondrial function by blocking the flow of pro-
tons through the FO subunit of the ATP synthase, thus inhibiting ATP production (Fig.
1.3, Bernardi, 1999; Kondapalli et al., 2012). Overall these drugs have been extensively
used to investigate the role mitochondria play within the cell.
Mitochondria and calcium buffering
Calcium signalling plays a crucial role in a variety cellular processes, from cell growth and
differentiation, to neuronal signalling and apoptosis. Generally present at very low con-
centrations within cytoplasm (nanomolar range), calcium signals by spatio-temporally
confined rises in the ion levels, that lead to the activation of several pathways. This
signalling is tightly regulated and the increases in calcium concentration need to be
quickly buffered, for the signal transduction to be regulated and to allow the transmis-
sion of consecutive stimuli. Moreover, prolonged increases in the calcium levels can lead
to apoptosis, therefore multiple mechanisms are in place to bring the ion concentration
back to steady-state levels (Berridge et al., 2000).
In addition to their function in energy production, mitochondria have an important role
in calcium buffering. These organelles were the first proposed to have a role in the seques-
tration of cytosolic calcium, function that was then directly demonstrated using isolated
mitochondria in 1961 (DeLuca and Engstrom, 1961). Interestingly, these findings were
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Figure 1.3: Mechanism of action of mitochondrial uncouplers.
Mitochondrial uncouplers impair mitochondrial oxidative phosphorylation and ATP pro-
duction. FCCP (and CCCP) act as proton ionophores, being protonated in the inter-
membrane space, these molecules cross the IMM and release the protons into the matrix,
thus impairing the proton gradient. Antimycin A instead blocks the Complex III func-
tion, whereas Oligomycin blocks the proton flow through the FO subunit of the ATP
synthase, inhibiting ATP production.
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reported before the studies on the ETC and the discovery of the proton gradient across
the IMM, which is indeed the driving force for the calcium uptake. Since the IMM is not
permeable to ions, uniporters and exchangers are required for the selective import and
release of calcium. The mitochondrial calcium uniporter (MCU), has long been pharma-
cologically and functionally described, however, the protein was only recently identified
(Baughman et al., 2011; De Stefani et al., 2011). MCU has now been found to be part of
a bigger complex that, sensing extracellular calcium (via the accessory proteins MICU1
and MICU2), mediates calcium intake into the mitochondrial matrix only when the
cytosolic calcium levels are high, ensuring rapid calcium buffering and stimulation of
the oxidative metabolism. Instead, when the calcium concentration in the cytosol is at
resting levels, the activity of this uniporter is very low (De Stefani and Rizzuto, 2014).
Once inside the mitochondrial matrix, calcium is likely to either combine with phosphate
groups imported by the Pi carrier to form insoluble (Ca2+)x(PO4)y(OH)z precipitates,
or be transported back outside the mitochondrion via a Ca2+/Na+ antiporter. This is
enabled by a sodium gradient set up by the Na+/H+ antiporter (Szabadkai and Duchen,
2008).
Mitochondria are often situated in close proximity to the endoplasmic reticulum (ER),
another intracellular calcium store and increasing evidence suggests calcium exchanges
between the two organelles (Malli et al., 2005; Rizzuto et al., 2009). The regions where
the two organelles are tightly juxtaposed are called mitochondria-associated membranes
(MAM) and interestingly, these contacts are regulated by cytoplasmic calcium levels,
with resting calcium levels promoting their dissociation and higher calcium levels in-
ducing their association, further suggesting a functional interchange between the two
organelles (Wang et al., 2000).
Mitochondria dynamics: fission and fusion
Rather than being separate units, mitochondria continuously move, fuse and divide
creating a highly interconnected network that spreads within the cell. Mitochondrial
shape can vary from spherical to tubular. It is not surprising that the word “mitochon-
drion” comes indeed from the Greek words for thread and granule. Morphology, size
and number of mitochondria can change according to the cell type and its metabolic
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status (Detmer and Chan, 2007). Fission and fusion are the processes that determine
respectively the splitting of one mitochondrion into two smaller ones or the fusion of
two mitochondria into one. These processes are not, however, solely responsible for
controlling the number and size of the organelles, but they are thought to be important
to maintain a functional mitochondrial population. In fact, a continuous interchange of
mtDNA and metabolites is required to preserve the mitochondrial network functional.
In agreement with this, mouse embryonic fibroblasts lacking core components of the
fusion machinery have reduced respiratory capacity and individual mitochondria show
great heterogeneity in shape and membrane potential (Chen et al., 2005, 2010).
Mitochondrial fusion involves the coordinated fusion of both the outer and inner mito-
chondrial membranes. In mammalian cells the core components of the fusion machinery
are three dynamin-related GTPases: Mitofusin1 and Mitofusin2 (Mfn1 and Mfn2) for
the outer membrane and the optic atrophy protein 1 (OPA1) for the inner membrane.
The Mitofusins are located on the OMM, and are characterised by a N-terminal GTPase
domain, two hydrophobic heptad repeats (HR) and two transmembrane domains that
mediate the insertion of the proteins into the OMM. They can form homo- or hetero-
oligomers that initially tether adjacent mitochondria and then mediate their fusion.
The GTPase activity of these fusion proteins provides the biochemical energy needed to
overcome the energy barrier and initiate the mixing of the two lipid bilayers (Wester-
mann, 2010). Besides mitochondrial fusion, Mfn2 has also been shown to be implicated
in mitochondrial trafficking and in the mitochondria-ER tethering (Misko et al., 2010;
de Brito and Scorrano, 2008), suggesting a more complex role for this GTPase. The
inner membrane fusion requires the dynamin-related GTPase OPA1 and it is dependent
on the mitochondrial membrane potential. OPA1 is located on the intermembrane space
side of the IMM, to which it is anchored by a N-terminal transmembrane domain. In
humans, OPA1 exists in 8 different splice variants which in turn can undergo proteolytic
cleavage. The model that has been proposed involves the m-AAA protease, paraplegin
(active on the matrix side of the IMM), or the i-AAA protease, Yme1L (active on the
intermembrane space side of the IMM), to produce shorter forms of OPA1, which are
subsequently cleaved by the rhomboid protease PARL. These bi-cleaved products are
then released in the intermembrane space. Little is known about how OPA1 mediates
fusion, however, interestingly this process requires the presence of both uncleaved and
cleaved forms of the protein, suggesting that they act in a complex. In addition to its
role in mitochondrial fusion, the GTPase OPA1 also plays a central role in the main-
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tenance of the IMM structure, in fact, its down-regulation results in abnormal cristae
structure in addition to the widening of the cristae junctions (Scorrano, 2013).
Mitochondrial fission involves the synergicistic activity of the cytosolic dynamin-related
protein 1 (Drp1) and its mitochondrial receptors (hFis1, the mitochondrial fission factor
Mff, or the mitochondrial division proteins MiD, MiD49 and MiD51). Drp1, a cytosolic
protein characterised by a N-terminal GTP binding domain and a C-terminal GTPase
effector domain (GED), is recruited by its mitochondrial anchors to discrete areas onto
the OMM, where fission is initiated. Interestingly such foci have been reported to be
often juxtaposed to ER structures, which are thought to promote the remodelling of the
organelle (Friedman et al., 2011), further supporting a functional coupling between the
two organelles. Once stabilised on the OMM, Drp1 oligomerises and forms spiral chains
that constrict the mitochondrion leading to its fission (Mozdy et al., 2000). Drp1 can be
subjected to post translational modifications to regulate its localisation. For example
mTOR-mediated activation of PKA during starvation induces the phosphorylation of
Drp1 at serine 637, promoting the cytosolic localisation of the protein and consequent
mitochondrial elongation (Gomes et al., 2011). On the other hand calcineurin-dependent
dephosphorylation of serine 637 has been associated with its translocation to the OMM,
which is particularly relevant for mitochondrial remodelling following heart ischaemia
and in Huntington’s disease (Slupe et al., 2013). Interestingly, calcium/calmodulin-
dependent protein kinase (CaMK) Iα has also been reported to phosphorylate serine 637,
however this modification was suggested to have the opposite effect and to induce Drp1
translocation onto mitochondria (Han et al., 2008). Drp1 can also be phosphorylated
by cyclin-dependent kinase 1 (cdk1) on serine 616, which promotes mitochondrial fission
during mitosis. Moreover, stabilisation on the mitochondrion can be promoted by Drp1
SUMOylation, suggested to impede the protein degradation by the proteasome (Harder
et al., 2004), and by S-nitrosylation (Cho et al., 2009).
Other components of this machinery include endophilin B1 and MTP18, both involved in
maintenance of mitochondrial morphology by promoting mitochondrial fission (Tondera
et al., 2005; Karbowski et al., 2004). However the components of the machinery involved
in this process and the steps leading to mitochondrial constriction remain to be fully
elucidated.
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The mitochondrial transport machinery
“By far the most important and interesting are the observations on the living cells. The
mitochondria are almost never at rest, but are continually changing their position and
also their shape” - Mitochondrial transport was first documented by Lewis and Lewis
100 years ago (Lewis and Lewis, 1914). Within the cell, mitochondria respond to spatio-
temporally localised metabolic needs, and to do so they have to be actively transported
to areas of high energy demand or calcium buffering requirements. Mitochondrial traf-
ficking is therefore an important process to allow proper mitochondrial function in every
cell type. In neurons however, due to their complex architecture, comprising of an ex-
tensive dendritic arborisation and a very long axonal process, transport of mitochondria
has an even more crucial role. In fact, in these cells, mitochondria need to be trans-
ported long distances (up to one meter in the human sciatic nerve) in order to be able
to exert their function where needed. Mitochondria are generally found at locations
with high metabolic demand such as pre- and post-synaptic domains, the axon initial
segment, nodes of Ranvier and growth cones (Hollenbeck and Saxton, 2005). However,
these organelles are not only delivered to axons and dendrites, but they are also re-
trieved and therefore transported back to the cell soma. This highlights the need for a
fine mechanism to control mitochondrial localisation and transport.
Among the mitochondrial population, about 20-30% of mitochondria move in cultured
hippocampal neurons (Overly et al., 1996; MacAskill et al., 2009b). Long range mi-
tochondrial trafficking is principally mediated by motor proteins (kinesin and dyneins)
that transport the organelles along the microtubules, whereas the actin cytoskeleton is
believed to be more important for anchoring mitochondria and for short range move-
ments via the myosin motors. Mitochondrial movement along the cytoskeletal tracks is
fast and bi-directional, with transport velocities that mostly fall in the range of 0.3–1.0
μm/second, with rates observed in vivo comparable with those of some neuronal culture
studies. These organelles move, stop, start again and switch direction. It is generally
believed that plus end-directed movement is mediated by the kinesin motors, whereas
minus end-directed movement is mediated by the dyneins (MacAskill and Kittler, 2010).
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Microtubule motor proteins
The kinesin motors
Kinesin motors mediate plus end-directed movement on the microtubules. In axons or
distal dendrites, where the microtubules are polarised, kinesin-mediated transport is re-
ferred as anterograde, from the soma to the periphery. Instead, in proximal dendrites
microtubules have mixed polarity, hence kinesin-mediated transport can traffick cargoes
towards and from the soma. The kinesin motors are formed by a globular motor domain,
generally at the N-terminus of the protein and a globular cargo binding domain, gen-
erally at the C-terminus. These two domains are connected by a linker coiled-coil that
mediates the dimerisation of the protein. Kinesin movement is achieved by the sequential
hydrolysis of ATP which induces a conformational change in the motor domain, making
one domain swing ahead of the other one and resulting in a “walking” mechanism. The
most well studied family of kinesin heavy chains is the kinesin family 1 (KIF5). Ki-
nesin family 1 members are generally associated with two kinesin light chains, which are
thought to play a role in cargo binding. There are currently 45 different kinesin genes
divided into 15 families, and they have distinct localisation, transport properties and
adaptors. Cargo binding to the kinesins is mostly mediated by trafficking adaptors and
scaffolds, that determine the kinesin/cargo selectivity (Hirokawa et al., 2009).
The best characterised kinesin motor involved in mitochondrial trafficking is KIF5. In
Drosophila there is only one isoform of KIF5, in contrast, in mammalian cells, this family
comprises of three different isoforms, KIF5A, KIF5B and KIF5C. KIF5B is widely ex-
pressed, while KIF5A and KIF5C are neuronal specific. However whether these motors
have isoform-specific roles or share similar pathways is still unclear. KIF5 mutations in
Drosophila neurons disrupt anterograde axonal mitochondrial transport (Pilling et al.,
2006), similarly in non-neuronal mouse cells deletion of KIF5B inhibits the transport of
mitochondria to the periphery, resulting in their perinuclear clustering (Tanaka et al.,
1998). Further supporting the role of KIF5 in the trafficking of mitochondria, expres-
sion of KIF5 dominant-negative mutants disrupts mitochondrial trafficking in axons of
rat hippocampal neurons (Cai et al., 2005). In dendrites however, the role of kinesin-
mediated trafficking is less clear. Antibodies that specifically block the kinesin motor
function were found to inhibit mitochondrial transport in both directions in mixed po-
larity microtubules (MacAskill et al., 2009b), however in a recent study, expression of
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dominant-negative KIF5 constructs had little effect on mitochondrial mobility in primary
proximal dendrites (van Spronsen et al., 2013). In mammalian neuronal cells KIF1B (a
member of the kinesin family 3) was also found to have a role in mitochondrial traffick-
ing. This motor was localised on immunopurified mitochondria and, in contrast to the
KIF5 family members, it was shown to mediate transport in a monomeric form (Nangaku
et al., 1994). More recently also Klp6 (kinesin like protein 6) has been also proposed
to play a role in the transport of mitochondria. Dominant negatives of Klp6 were in
fact found to reduce the number of moving mitochondria and silencing of the protein
affected mitochondrial trafficking velocity in neuronal differentiated cell lines (Tanaka
et al., 2011).
Kinesin adaptors
Several kinesin adaptors associated with mitochondrial trafficking have been identified
to date. These include syntabulin, FEZ1 (fasciculation and elongation protein ζ - 1),
RanBP2 (Ran-binding protein 2), TRAKs (trafficking protein kinesin-binding) and Miro
(mitochondrial Rho). Syntabulin, was first discovered as an adaptor linking syntaxin
containing synaptic vesicles to the kinesin motors (Su et al., 2004). Later this adaptor
protein was also reported to associate with mitochondria. Syntabulin silencing was
shown to affect both the anterograde movement of mitochondria (and synaptic vesicles)
and the density of the mitochondria in the distal processes of rat hippocampal neurons
(Cai et al., 2005). FEZ1, another adaptor found in a complex with the kinesin motor
proteins, was shown to promote mitochondrial transport in hippocampal neurons and to
induce the presence of mitochondria in the developing processes in NGF stimulated PC12
cells (Ikuta et al., 2007; Fujita et al., 2007). Moreover, selective knock down of FEZ1
was shown to inhibit mitochondrial movement only in the anterograde direction, further
suggesting a role for this adaptor protein in the anterograde transport of mitochondria
(Blasius et al., 2007). RanBP2, a scaffold protein previously associated with nucleo-
cytoplasmic transport, protein biogenesis and mitosis (Yokoyama et al., 1995), was more
recently associated with mitochondrial function in the central nervous system (CNS) and
then found to bind specifically KIF5A and KIF5B (but not C, Aslanukov et al., 2006;
Cho et al., 2007). This suggests the possibility of different roles for these motor proteins
in neurons. Genetic screens in Drosophila have identified the kinesin binding protein
Milton (the Drosophila orthologue of the TRAK proteins) and the atypical GTPase
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dMiro (Drosophila Miro) as being crucial for anterograde transport of mitochondria
along axons in fruitflies (Stowers et al., 2002; Guo et al., 2005). Miro and the TRAKs
have emerged as key conserved regulators of mitochondrial trafficking in neurons and
will be discussed in further detail in the sections respectively on page 32 and 37.
The dynein motors
Dynein motors mediate movement of cargoes towards the minus end of microtubules,
which corresponds to retrograde transport (from the periphery to the cell soma) in axons
and distal dendrites, where microtubules are polarised. In contrast to the extensive
kinesin family, there are relatively few dynein heavy chains. The cytoplasmic dynein 1
heavy chain (encoded by DYNC1H1 in humans, and hereafter referred as cytoplasmic
dynein) is used for nearly all of the minus end-directed transport in the cytoplasm of
most eukaryotic cells, whereas cytoplasmic dynein 2 (encoded by DYNC2H1 in humans)
is specifically localised in cilia and flagella. The cytoplasmic dynein consists of two
heavy chains, two intermediate chains, two light intermediate chains and a variable
number of light chains. The heavy chains are formed by a C-terminal motor domain
and an N-terminal tail domain. The motor domain contains six AAA+ ATPase domains
arranged in a ring, from which the microtubule binding domain protrudes. The tail
domain mediates the oligomerization of the heavy chains and serves as a platform for
the binding of several associated subunits, which in turn mediate the interaction with the
cargoes either via direct binding or through the recruitment of other adaptor proteins.
Dynein transport requires the presence of dynactin, a multisubunit complex necessary for
dynein activity. Dynein and dynactin exist as a complex and it has been proposed that
dynactin could mediate the interaction between the dynein motors and the cargoes, as
antibodies that inhibit binding of the largest subunit of dynactin, p150Glued to dynein
heavy chain, inhibit dynein mediated retrograde transport of cargo, without altering
dynein processivity along microtubules (Waterman-Storer et al., 1997; Roberts et al.,
2013).
Both dynein and the dynactin components p50 and p150Glued have been detected on
purified mitochondria in Drosophila extracts and mutating the dynein heavy chain or
p150Glued has been shown to inhibit axonal mitochondrial trafficking in both directions
(Pilling et al., 2006; Martin et al., 1999). Moreover, dynein has been localized on both
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anterogradely and retrogradely moving axonal mitochondria (Hirokawa et al., 1990). A
few proteins have been suggested to link mitochondria to dynein-mediated transport.
The dynein light chain Tctex1, involved in the dynein-mediated transport of rhodopsin
channels in photoreceptors (Tai et al., 1999), has been shown to interact with the mito-
chondrial voltage-dependent anion channels (VDAC) located on the OMM (Schwarzer
et al., 2002). Another putative adaptor is APLIP1 (APP -amyloid precursor protein-
like protein interacting protein 1), a Drosophila homologue of the mammalian JIP (JNK
- c-Jun N-terminal kinase- interacting protein). Generally involved in cargo-mediated
kinesin activation (Horiuchi et al., 2007; Blasius et al., 2007), APLIP1 mutations were
found to selectively disrupt retrograde mitochondrial transport, while both retrograde
and anterograde vesicle transport was inhibited (Horiuchi et al., 2005). Recently, dynein
was also found to interact with the TRAK adaptors, raising the possibility that the ki-
nesin adaptor Miro, which binds the TRAKs, is also the adaptor that recruits dynein
motors to these organelles to coordinate dynein-mediated mitochondrial transport (van
Spronsen et al., 2013; Russo et al., 2009). This suggests that Miro proteins may be
important for mediating the cross-talk between dynein and kinesin transport.
Miro proteins
Miro proteins were originally identified as mitochondrial atypical Rho-like small GTPases
(Fransson et al., 2003). Evolutionary conserved (Gem1 is Miro’s yeast orthologue), Miro
exists in two isoforms in mammals (Miro1 and Miro2, which are 60% identical) and one
in Drosophila (dMiro). As shown in Fig. 1.4 A, these proteins are characterised by the
presence of several signalling domains: two GTPase domains flank two calcium sensing
EF hands and a C-terminal transmembrane domain. The first evidence of Miro being
involved in mitochondrial trafficking came from studies in flies where knock out of the
protein resulted in a defect in the transport of mitochondria into neuronal axons (Guo
et al., 2005). These studies were then confirmed by experiments showing that Miro
can bind the kinesin proteins, coupling the mitochondria to the molecular motors, and
overexpression or silencing of Miro were respectively correlated to increased and de-
creased transport of mitochondria (MacAskill et al., 2009b; Wang and Schwarz, 2009).
Mitochondrial transport has been known to be negatively regulated by increased calcium
levels within the cell which can arise from a variety of stimuli such as glutamate receptor
activation, action potentials, calcium release from the ER (Rintoul et al., 2003; Yi et al.,
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Figure 1.4: The mitochondrial trafficking complex.
(A) Schematic representation of Miro1 domains. The protein is characterised by two
GTPase domains flanking two EF calcium-binding domains. At the C-terminus a trans-
membrane domain locates Miro in the OMM. (B) Representation of the mitochondrial
trafficking complex. Miro binds the kinesin motors and the TRAK adaptor molecules
directly, whereas dynein-dependent transport is mediated by the interaction between the
dynactin subunit p150Glued and TRAK. The TRAK adaptors also bind OGT(O-linked
β-N-acetylglucosamine transferase).
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2004). However, the mechanism underlying calcium-dependent mitochondrial stopping
was long unknown. EF hand-containing Miro proteins were a good candidate for this.
EF hand domains are helix-loop-helix domains characterised by a conserved sequence
comprising a negatively charged residue in the loop that is involved in the calcium bind-
ing. These domains are often present in tandem in calcium sensors such as calmodulin
(Lewit-Bentley and Réty, 2000). Calcium binding to Miro1 has been shown to determine
mitochondrial arrest, in fact, expression of calcium insensitive ΔEF (where the calcium
binding ability is lost by the double mutation E208K and E328K) prevented calcium-
dependent mitochondrial arrest (Saotome et al., 2008; MacAskill et al., 2009b; Wang and
Schwarz, 2009). This process is particularly relevant in neurons where localised calcium
rises, following synaptic activation, can promote the stopping of mitochondria. In these
areas of high energy demand, mitochondria play a crucial role by providing the ATP
needed to revert the ion fluxes. Moreover, by buffering the calcium these organelles
can shape the calcium-dependent signalling cascades. Although the role of Miro in
calcium-dependent mitochondrial arrest is generally agreed, the mechanism underlying
this process is debated. MacAskill and colleagues have shown that glutamate-dependent
calcium increase determines the loss of the kinesin motors from purified neuronal mi-
tochondria, suggesting that a conformational change, due to calcium binding on Miro,
impairs its ability to interact with the kinesin motors (Fig. 1.5 A, MacAskill et al.,
2009b), whereas Wang and Schwarz have shown that mitochondrial arrest is due to the
motor domain of the kinesin binding Miro in between its two EF hands, resulting in
the detachment of the motor from the microtubules. Moreover, in this model the cargo
binding domain of the kinesins motors does not interact directly with Miro, but the
interaction is mediated by the TRAK adaptors (Fig. 1.5 B, Wang and Schwarz, 2009).
Both mechanisms, however, involve a fine regulation that determines the stopping of the
organelles where the calcium concentration is higher. A newly reported protein, Alex3,
was recently shown to regulate mitochondrial trafficking in axons and to interact with
Miro and TRAK2 in a calcium-dependent manner. Alex3 is unique to Eutherian mam-
mals and although the exact mechanism of function of this protein is not yet known, its
identification provides another potential level of regulation of the mitochondrial trans-
port machinery and suggests an increased regulatory complexity in the mitochondrial
dynamics in the most evolved mammals (López-Doménech et al., 2012).
In addition to the calcium-dependent regulation, Miro1 can be modulated by its GTPase
function. Miro proteins are able recruit the adaptors TRAK1 and TRAK2 (also known
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as OIP106 and Grif-1 or OIP98) to the mitochondria (Fransson et al., 2006). This
is dependent on the first GTPase domain of Miro, since expression of constitutively
active GTPase1 Miro1 mutant (V13, equivalent to GTP-bound Miro1), prevents the
recruitment of TRAK2 (MacAskill et al., 2009a). Since the TRAK adaptors can bind
both Miro and the kinesin motors (Brickley et al., 2005), these data suggest that TRAK2,
recruited to GDP-bound Miro, might promote mitochondria coupling to the molecular
motors. Moreover, the loss of interaction between Miro1 and TRAK2 (caused by the
expression of a peptide containing the TRAK2 Miro binding domain, which acts as a
dominant negative) leads to a decreased number of mitochondria in neuronal processes,
indicating the importance of the functional coupling between Miro, the TRAKs and the
kinesins in mitochondrial trafficking (MacAskill et al., 2009a).
Little is known about the role of Miro1 in retrograde, dynein-mediated transport. Tuning
Miro1 levels regulates mitochondrial transport in both directions, however it is arguable
that increased anterograde transport, due to Miro1 overexpression, could homeostati-
cally promote the retrograde transport of the organelles (independently of Miro). In-
terestingly however, Miro1 has been recently shown to mediate the coupling between
mitochondria and dynein motor complex in lymphocytes (Morlino et al., 2014), sug-
gesting that this mitochondrial adaptor could indeed have a role in the tuning between
anterograde, kinesin-mediated and retrograde, dynein-dependent, mitochondrial trans-
port.
Although in mammals Miro has two isoforms, most studies have focused on Miro1 func-
tion. The two proteins have been suggested to have a similar function (Fransson et al.,
2006), however some differences have emerged from the work of Misko and colleagues,
that have found knock down of Miro2, but not of Miro1, to affect axonal transport of
mitochondria (Misko et al., 2010).
Miro1, Miro2 and Milton have been recently found to interact with PINK1, a Parkin-
son’s disease-associated protein involved in mitochondrial quality control, raising the
possibility that the Miro trafficking molecules can have a role in the recognition and
processing of damaged mitochondria (Weihofen et al., 2009).
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TRAKs
Milton, the Drosophila homolog of the TRAK proteins, was first identified as a mito-
chondrial adaptor in a genetic screen (Stowers et al., 2002). Milton mutant flies exhibited
no mitochondria in the axons of photoreceptors, indicating that the protein was involved
in the transport of mitochondria into the neuronal processes. Milton was then shown
to be associated with purified mitochondria and to bind the kinesin motors (Stowers
et al., 2002; Brickley et al., 2005). Two mammalian homologues of Milton, the traffick-
ing protein kinesin binding (TRAK) 1 and 2 were then identified. These proteins are
48% identical and share respectively 33.5 % and 35.3 % sequence similarity with Milton.
As their Drosophila orthologue, the TRAK proteins bind the kinesins and this interac-
tion occurs via the C-terminal cargo binding domain of the motor (Brickley et al., 2005;
Smith et al., 2006). The TRAKs are characterised by a N-terminal coiled-coil region,
which shows high homology to the trafficking adaptor HAP1 (huntington associated
protein 1), and is involved in the kinesin binding (residues 124-283), a Hrs (hepatocyte
growth factor-regulated tyrosine kinase substrate) binding region, which links these pro-
teins to the endo-lysosomal pathway, and the Miro binding domain at the C-teminal
(residues 476-913, Smith et al., 2006; Kirk et al., 2006; MacAskill et al., 2009a). Pos-
sibly due to the presence of different domains, the TRAKs have been shown to exert
several functions, for example transport of ion channels (Beck et al., 2002; Smith et al.,
2006; Grishin et al., 2006), endosomes (Kirk et al., 2006; Webber et al., 2008) as well
as mitochondria (MacAskill et al., 2009a; Smith et al., 2006; Brickley and Stephenson,
2011). Via the interaction with Miro and the kinesin motors, the TRAKs have been
shown to modulate mitochondrial trafficking. Disruption of the TRAK/KIF interaction
by expression of a peptide with dominant negative function or silencing of TRAK1 re-
duces the number of moving mitochondria in axons (Brickley and Stephenson, 2011),
however, since Miro itself can bind the kinesins and promote mitochondrial transport,
the contribution of each protein should be further investigated. Interestingly, the levels
of the TRAK acceptors (Miro1 or Hrs) have been shown to shift the localisations of these
proteins (i.e. from mitochondria to endosomes), suggesting that the availability of these
binding partners can influence the TRAKs function (MacAskill et al., 2009a). Recently
van Spronsen and collaborators have demonstrated for the first time that TRAK1 and
TRAK2 exhibit a distinct localisation in neurons, with TRAK1 being more prominent in
axons and TRAK2 in dendrites. This segregation was suggested to be due to a different
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affinity to the kinesin motors, in fact although both TRAK1 and TRAK2 could bind the
dynein/dynactin complex, TRAK2 interaction with the kinesin motors was prevented,
possibly due to a folded head-to-tail conformation that TRAK2 preferentially adopts.
The model proposed by the authors suggests TRAK1 to be delivered to the axons by
the kinesins, whereas TRAK2 can only be trafficked to the dendritic compartment in
a dynein-mediated mechanism (van Spronsen et al., 2013). These results agree with
previous work showing that TRAK1, but not TRAK2, silencing inhibits mitochondrial
trafficking in axons (Brickley and Stephenson, 2011), however these studies do not take
into consideration the TRAK-independent Miro contribution to mitochondrial traffick-
ing.
TRAK1 and TRAK2 have been shown to interact with O-linked β-N-acetylglucosamine
(O-Glc-NAc) transferase (OGT, Iyer et al., 2003), an enzyme that catalyses O-linked
glycosylation of serine and threonine residues. O-Glc-NAcylation is a reversible post
translational modification that has been compared to phosphorylation (Wells et al.,
2003). OGT has been shown to be an integral component of the TRAK/kinesin traffick-
ing complex (Brickley et al., 2011) and since the the levels of O-Glc-NAcylation can be
linked to glucose levels, this suggests a possible association between mitochondrial traf-
ficking and the availability of mitochondrial substrates. Pekkurnaz and colleagues have
indeed recently demonstrated that, in the presence high glucose (30 mM), mitochondrial
trafficking is reduced and this is dependent on TRAK1 O-Glc-NAcylation since muta-
tion of key O-Glc-NAcylated serine residues blocks this glucose-dependent mitochondrial
stopping (Pekkurnaz et al., 2014).
Static anchors
Over two thirds of neuronal mitochondria are stationary, ideally serving as constant
energy suppliers in metabolically active areas within the neuron. This lack of move-
ment could be simply due to the organelles not being bound to the transport machinery,
or it could be an actively regulated mechanism, involving docking proteins and static
anchors. The actin cytoskeleton has been shown to have a role in the mitochondrial
sequestration into the stationary component either by direct anchoring or by delivery
of the mitochondria to docking areas, in fact disruption of the actin filaments prevents
the NGF-dependent arrest of mitochondria (Chada and Hollenbeck, 2004). Stationary
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mitochondria can also be tethered by the intermediate filaments. Interestingly this pro-
cess was reported to be dependent on the organelles membrane potential, suggesting
that only fully functional organelles can be docked to locally provide energy and buffer
calcium (Wagner et al., 2003). More recently Plectrin 1b, a intermediate filament bound
protein, was found to link the filaments to the mitochondria in fibroblasts, however
knock out of the protein did not affect mitochondrial movement in these cells (Win-
ter et al., 2008). Another protein was recently found to have a role in mitochondrial
docking: syntaphilin (SNPH). This protein was shown to bind both mitochondria, via
its C-terminal transmembrane domain, and axonal microtubules, via its N-terminal do-
main. Moreover, interaction with the dynein light chain LC8, was reported to stabilise
the syntaphilin/microtubule interaction (Chen et al., 2009). Syntaphilin was shown to
be specifically localised to axonal stationary mitochondria and over expression of the
protein resulted in stopping of axonal mitochondria. Conversely syntaphilin knock out
resulted in a reduction of the mitochondrial density in axons and a substantially in-
creased number of moving mitochondria in these processes (Kang et al., 2008). More
recently syntaphilin was also proposed to play a key role in Miro-dependent calcium-
induced mitochondrial arrest in a revised ‘engine-switch and brake’ model. In this model,
following the calcium-triggered uncoupling of the Miro/kinesin complex, sytaphilin not
only docks the mitochondrion to the axonal microtubules, but also binds the kinesin,
keeping the whole complex stably tethered (Fig. 1.5 C, Chen and Sheng 2013).
Mitochondria quality control
Increased ROS production, disrupted calcium homeostasis and defective protein turnover
can affect mitochondrial functionality. When mitochondrial damage is limited, mech-
anisms are in place to repair the organelles, such as ROS scavengers that convert and
neutralise the radicals, heat shock proteins that prevent the aggregation of unfolded pro-
teins and promote their degradation (Kotiadis et al., 2014). However, when the damage
is extensive, the mitochondrial membrane potential drops, the proton gradient dissi-
pates and the mitochondrial functionality is lost. Fusion of these impaired organelles
with functional mitochondria in the long term will lead to a diffusion of the damage,
which ultimately will be detrimental for the whole mitochondrial network. To prevent
this scenario a mitochondrial quality control system is in place to recognise, isolate and
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clear damaged mitochondria via a pathway called mitophagy (mitochondrial autophagy).
The key players in the quality control of mitochondria are the proteins PINK1 (PTEN-
induced putative kinase 1) and Parkin. PINK1 is a mitochondrial kinase that, upon
mitochondrial depolarisation, accumulates on the OMM and recruits Parkin, a cytoso-
lic E3 ubiquitin ligase, onto the damaged organelles. Parkin-dependent ubiquitination
of OMM proteins is a crucial step in mitochondrial clearance. PINK1 and Parkin are
both associated with autosomal recessive forms of Parkinson’s disease, indicating the
importance of this system in cellular physiology (Youle and Narendra, 2011).
PINK1
Encoded by the gene PARK6, PINK1 is a mitochondrial serine/threonine kinase. This
protein is characterised by an N-terminal mitochondrial targeting sequence (MTS), a
transmembrane domain and a C-terminal serine/threonine kinase domain with homol-
ogy to the calcium/calmodulin family (Fig. 1.6). The subcellular localisation of PINK1
has long been debated, since the protein has been found on the OMM, in the IMM and in
the cytosol. Recent work has elucidated several aspects of the complex regulation of this
kinase. PINK1 has been reported to be initially targeted to the OMM, where it interacts
with and is rapidly imported by the TOM (translocase of the outer membrane) com-
plex in a membrane potential-dependent manner (Lazarou et al., 2012). Once inside the
mitochondrion PINK1 has been reported to be processed by several proteases including
the mitochondrial processing peptidase (MPP), the presenilin-associated rhomboid-like
protease (PARL), m-AAA and ClpXP (Greene et al., 2012). MPP, a protease respon-
sible for cleaving the MTS of precursor proteins imported into the mitochondrion, has
been shown to cleave the PINK1 MTS. Interestingly, knock down of MPP has been
associated with the accumulation of full length PINK1 on the OMM, suggesting that
MPP-dependent cleavage promotes PINK1 import into the mitochondria. Although un-
expected, MPP-dependent processing of newly imported proteins has been previously
shown to be coupled with the protein import, and the protease itself has been sug-
gested to be important for the protein import. The mechanism by which this occurs
has however remained elusive (Greene et al., 2012). Within the mitochondrion PINK1
has been shown to be further processed. Lin and Kang have demonstrated that within
three minutes from the protein synthesis PINK1 is cleaved into an primary unstable
peptide (Δ1-PINK1, 53 kDa), which has a half life of 30 minutes and is degraded by the
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proteasome, or into a secondary smaller product (Δ2-PINK1, 45 kDa) which has been
shown to be more stable due to its interaction with the chaperone Hsp90 (Lin and Kang,
2008). TheΔ1-PINK1 53 kDa product is formed by the IMM protease PARL (presenilin-
associated rhomboid like protease), which cleaves PINK1 at A103 (Deas et al., 2011; Jin
et al., 2010). Identification of Δ1-PINK1 cleavage sites allowed further investigations
in the role of the full length versus the Δ1 cleaved protein. Interestingly, accumulation
of full-length PINK1 (due to the cleavage site mutation) was shown to cause the loss
of membrane potential, increased ROS production and altered mitochondrial network,
suggesting that this cleaved product is involved in the maintenance of mitochondrial
homeostasis (Deas et al., 2011). The lack of stability of Δ1-PINK1 has been shown to
be due to the phenylalanine 104 (F104), which is the first residue of the PARL-cleaved
Δ1-PINK1. According to the N-terminal rule for degradation the presence of specific
amino acids at the (cleaved) N-terminus of a polypeptide can promote the degradation
of the protein via the proteasome. These destabilising residues are arginine, lysine and
histamine for type-1 degradation, and phenylalanine, tryptophan, tyrosine, isoleucine
and leucine for type-2 (type-1 and type-2 protein degradation differ on the enzymes
involved in the recognition and ubiquitination of the N-terminus). These residues pro-
mote the ubiquitination by specific E3 ubiquitin ligases and the consequent degradation
of the protein (Tasaki et al., 2012). Mutation of F104 to more stable residues increases
the stability of Δ1-PINK1, which is found in the cytosol, in agreement with the cleaved
product being released from the intermembrane space into the cytosol and processed by
the proteasome (Yamano and Youle, 2013). Although the function of cytosolic PINK1
under basal conditions has been long unknown, recent evidence has shown it to poten-
tially regulate the cytosolic pool of Parkin, maintaining the ligase in an inactive state
(Fedorowicz et al., 2014). Moreover, experiments using PINK1 lacking its MTS have
shown that this cytosolic form of the kinase promoted PKA-dependent neurite outgrowth
and dendritic extension (Dagda et al., 2014). The physiological role of the more stable
secondary product Δ2-PINK1 is not clear to date. This smaller polypeptide does not
seem to compensate for Δ1-PINK1 protective role against oxidative stress, however via
its interaction with Hsp90 it has been suggested to regulate the full lengh/Δ-PINK1
ratio (Lin and Kang, 2008).
Due to its rapid import within the mitochondrion PINK1 levels on the OMM are very
low in basal conditions. However, since this process is dependent on the membrane
potential, mitochondrial damage results in the accumulation of PINK1 on the OMM,
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a crucial step in the initiation of mitophagy which will be described in the mitophagy
section on page 48.
PINK1 was originally found to be linked to autosomal recessive Parkinson’s disease in
2004 (Valente et al., 2004). The first evidences of PINK1 function came from studies
in Drosophila, where PINK1 knock out resulted in loss of dopaminergic neurons, male
sterility, muscle degeneration, defective locomotion, altered mitochondrial morphology
(including fragmented cristae) and increased sensitivity to multiple stress (i.e. oxidative
stress). Interestingly, in these experiments it was reported that Parkin overexpression
in PINK1 mutant flies rescued the male sterility and mitochondrial morphology defects
of PINK1 mutants (Clark et al., 2006; Yang et al., 2006; Park et al., 2006), however,
in mammalian cells Parkin overexpression does not compensate for PINK1 loss, sug-
gesting the existence of non conserved mechanisms between species. Since the discovery
of PINK1 as a PD-related gene in 2004, several disease-associated mutations in this
protein have been identified. Most PINK1 mutations affect the kinase activity or the
stability of the protein, resulting in a decreased function of the kinase. PINK1 mutants
have been associated with increased oxidative stress, decreased respiratory activity and
ATP production, mitochondrial calcium overload and synaptic deficits (Deas et al., 2009;
Gandhi et al., 2009; Exner et al., 2012). PINK1 disease-linked mutations and knock out
have been associated with a reduction in complex I function, leading to a decrease in
membrane potential, however the mechanism underlying this was elusive (Morais et al.,
2009). Recently Morais and colleagues have shown that PINK1 is associated with the
phosphorylation of a subunit of complex I, and this modification is crucial to promote
the ubiquinone reduction, which is required for the ETC, thus providing a mechanism
for PINK1-dependent complex I malfunction (Morais et al., 2014). PINK1 has also
been suggested to protect against oxidative stress by phosphorylating the mitochondrial
chaperone TRAP1 (tumor necrosis factor receptor-associated protein 1)/Hsp75. Upon
phosphorylation, this protein has a pro-survival effect, preventing cytochrome C release
and H2O2-induced apoptosis (Pridgeon et al., 2007). Moreover, PINK1 has been shown
to interact with and regulate the mitochondrial protease HtrA2/Omi, a Parkinson’s
disease-associated protein. The protease activity of HtrA2/Omi is dependent on its
phosphorylation state and is regulated by PINK1, although evidence of direct phospho-
rylation is missing. This protease has been suggested to be involved in a quality control
system within the mitochondrion, possibly involving the degradation of misfolded pro-
teins, and to promote the resistance to mitochondrial stess (Plun-Favreau et al., 2007).
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Figure 1.6: Schematic of PINK1 and Parkin structure
PINK1 is characterised by a N-terminal mitochondrial targeting sequence (MTS), a
transmembrane domain (TM) and a C-terminal kinase domain. Parkin is formed by a
N-terminal ubiquitin-like domain (Ubl), a RING0 domain, RING1 domain, a in-between-
ring (IBR) domain and a RING2 domain at the C-terminus.
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The ubiquitination process
Ubiquitination requires the sequential action of three different enzymes: ubiquitin-
activating E1, ubiquitin-conjugating E2, and ubiquitin ligating E3. E1-mediated ubiq-
uitin activation is a two-step reaction dependent on ATP. First the E1 binds to ATP
and ubiquitin to catalyse the acyl-adenylation of the C-terminus of ubiquitin, thus cre-
ating a ubiquitin-adenylate intermediate. Then the AMP is released and ubiquitin is
transferred to a cysteine residue in the E1 active site, to form a high energy thioester in-
termediate (between ubiquitin’s C-terminal carboxyl group and the cysteine sulphydryl
group). Ubiquitin is then trans-thiolated from the E1 to the active-site cysteine of a E2
enzyme. Ubiquitin transfer to the ε-amino group of a substrate lysine occurs in a E3
type-dependent manner. There are several types of E3 ligases, mainly HECT (homol-
ogous to the E6AP carboxyl terminus)-type, RING (really interesting new gene)-type
and RING-related E3s. HECT E3-mediated ubiquitination involves the formation of
a thioester intermediate between ubiquitin and a E3 catalytic cysteine prior to sub-
strate ubiquitination, whereas RING-type and U-box E3s act as scaffolds that bring
ubiquitin-conjugated E2s and target proteins into close proximity, allowing the forma-
tion of an isopeptide bond between the two molecules (Metzger et al., 2012). Substrates
can be modified by the addition of a single ubiquitin moiety on one or more sites (mono-
ubiquitination and multi-mono-ubiquitination) or can be tagged with chains of ubiquitin
(poly-ubiquitination). Chain formation can occur through one of the seven lysines within
ubiquitin (K6, K11, K27, K29, K33, K48 and K63) or via ubiquitin’s N-terminal methio-
nine (M1; Fig. 1.7). The type of ubiquitin modification specifies the cellular outcome
of ubiquitination, and among the eight different chain types, only a few (referred as
typical) have been extensively characterised. K48-mediated linkage, for example, has
been strongly associated with proteasomal degradation (Mallette and Richard, 2012),
whereas K63-linked chains have been shown not to have a degradative function, and
to be primarily associated with signalling and protein-protein interaction (Chen and
Sun, 2009). The remaining chain types are often referred as atypical, due to their poor
characterisation. Only recently these atypical chains are starting to be studied, K6-type
linkage has been suggested to have a non-degradative role, whereas K11-mediated ubiq-
uitination seems to be associated with protein degradation. K27-mediated ubiquitin
chains have been found to accumulate on damaged mitochondria, while K29 and K33
have been associated with both degradative and non-degradative roles (Kulathu and
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Komander, 2012).
In humans there are two E1 enzymes, roughly forty E2s and more than six hundred E3s
(of which thirty are HECT-type, Li et al., 2008). Since E3 ligases recruit the substrates
and mediate the transfer of ubiquitin from the E2, it is highly likely that these enzymes
determine the specificity of ubiquitination. However, whether particular combinations
of activated E2s and E3s are required is not clear and would bring the ubiquitination
process to another level of complexity. Moreover, it is still to be clarified how the chain
linkage is determined. When RING domain or U-Box ligases are involved, it is likely that
the conjugating E2 enzyme defines the linkage type, whereas with HECT domain ligases,
which form a thioester intermediate with the ubiquitin molecules, the ligases themselves
are believed to determine the chain composition (Komander and Rape, 2012).
Parkin
Parkin (coded by the gene PARK2 ) is a cytosolic E3 ubiquitin ligase. This protein
comprises of a N-terminal Ubiquitin like (Ubl) domain, a RING0 domain, a RING1
domain, an in-between-rings (IBR) domain and a RING2 domain (Fig. 1.6). RING
domains are characterised by several cysteines and histidines involved in the coordination
of zinc ions and crucial for the structure and folding of the ligase, moreover in RING-
type E3 these structures facilitate the transfer of ubiquitin from the E2 to the substrate
(Lorick et al., 1999). Due to the presence of these domains Parkin was initially considered
a RING-like E3 ligase, however further investigations classified the protein as part of
the newly reported family of RING in-between-RING RING (RBR), which have been
described as a hybrid between RING and HECT E3 ligases. In fact, in addition to
the presence of RING domains, RBR-type ligases also have a catalytic cysteine (that
in Parkin is C431, within the RING2 domain) that forms a thioester intermediate with
ubiquitin in a HECT-like fashion (Lazarou et al., 2013).
Parkin, normally exists in a closed, autoinhibited conformation. Structural analysis
has shown that the Ubl domain binds the RING1 domain, possibly hindering the E2
binding site, while the RING0 domain blocks the catalytic C431 residue, that is located
on the RING2 domain, and is crucial for the ligase activity (Trempe et al., 2013; Wauer
and Komander, 2013; Riley et al., 2013). Activation of this ligase is therefore a tightly
regulated multi-step process which will be described in the following section.
CHAPTER 1. INTRODUCTION 46
Figure 1.7: Representation of a ubiquitin molecule structure.
3D structure of a ubiquitin molecule generated with PyMOL (PDB=1UBQ). Lysine
residues (K6, K11, K27, K29, K33, K48, K63), that mediate ubiquitin chain linkages,
are represented in pink, the initial methionine in purple and the C-terminal glycine in
yellow.
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Parkin has been first associated with early onset autosomal recessive Parkinson’s dis-
ease in 1998 (Kitada et al., 1998). Since then, many PD-associated mutations have been
found and Parkin is now considered the most common cause of inherited early onset PD.
Since 1998 Parkin’s function and localisation have been extensively studied. Similar to
PINK1 deficient flies, Parkin mutants exhibit locomotor defects, muscle degeneration
and male sterility (Greene et al., 2003). Moreover, mitochondria from Parkin mutant
flies have been described as morphologically abnormal, hyperfused, swollen and with
indistinct cristae and this phenotype was reported to be rescued by favouring mito-
chondrial fission (by overexpression of Drp1 or down regulation of the Mfns or OPA1;
Deng et al., 2008; Greene et al., 2003; Yang et al., 2008; Poole et al., 2008). Mouse
knock out animals for PINK1 or Parkin have a milder phenotype and do not reproduce
the common symptoms of PD, however, mitochondria from these models show defects
in respiration and sensitivity to oxidative stress (Chen and Chan, 2009; Pogson et al.,
2011). Since their discovery, many groups have investigated the role of PINK1 and
Parkin in mitochondrial physiology and pathophysiology, and the role of these proteins
has become clearer, even though there are still some open questions in the dissection of
their regulation.
Although cytosolic, Parkin has been shown to be efficiently recruited (Narendra et al.,
2008) and activated (Kondapalli et al., 2012; Shiba-Fukushima et al., 2012) by the kinase
PINK1 onto damaged mitochondria, where the ligase mediates the ubiquitination of
more than 100 substrates, as reported by a proteomic study (Sarraf et al., 2013). Parkin
has been reported to catalyse K27-, K48- and K63-type ubiquitin linkages (Chan et al.,
2011; Geisler et al., 2010; Narendra et al., 2010a), and this process is believed to be a key
step in the initiation of the autophagosome formation and in mitochondrial clearance by
mitophagy. Disease-associated Parkin mutations not only impact on the protein’s ligase
activity, but also on its recruitment dynamics, since both a lower activity and delayed
recruitment onto damaged mitochondria will affect Parkin-mediated ubiquitination.
Along with its important function in mitophagy, Parkin has also been shown to promote
cell survival, in fact overexpression of the ligase limits the translocation of pro-apoptotic
Bax to the mitochondrial surface (Johnson et al., 2012) and increases the threshold for
cytochrome C release from mitochondria (Berger et al., 2009). Furthermore, Parkin
has been associated with neuronal physiology, although its role is debated. Staropoli
and colleagues had initially found Parkin to protect neurons from kainate-triggered ex-
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citotoxicity by blocking cyclin E accumulation and apoptosis (Staropoli et al., 2003),
while Helton and coworkers have reported Parkin to negatively regulate the number and
strength of glutamatergic synapses (Helton et al., 2008).
Notably Parkin also stimulates mitochondrial biogenesis, in fact upon depolarization,
Parkin promotes the degradation of the transcriptional repressor PARIS, which causes
the release of the mitochondrial biogenesis transcription factor PGC1α (Shin et al., 2011),
possibly to replace the damaged mitochondria with functional ones.
PINK1 and Parkin in mitochondrial quality control
As previously described, PINK1 processing includes the kinase import from the OMM
through the TOM complex and the subsequent proteolytic cleavage of the kinase by
several mitochondrial proteases followed by proteasomal-dependent degradation of the
protein. Since PINK1 import occurs in a membrane potential-dependent manner, when
mitochondria are impaired and their membrane potential is low, PINK1 accumulates on
the OMM (Fig. 1.9 A). This is a crucial step in the activation of the mitophagy cascade.
Once stabilised on the OMM, PINK1 recruits Parkin from the cytosol and promptly
activates it by phosphorylation of serine 65 within the Ubl domain (Fig. 1.9 B). Parkin
phosphorylation has been detected within 10 minutes from mitochondrial damage, it is
maximal after 40 minutes and it is sustained up to 6 hours from mitochondrial uncou-
pling. Parkin S65 phosphorylation is thought to release the ligase Ubl domain, thus
allowing Parkin to be active (Kondapalli et al., 2012; Shiba-Fukushima et al., 2012).
Supporting this theory phosphorylated Parkin has been shown to catalyse the forma-
tion of free ubiquitin chains (Kondapalli et al., 2012) and oxyester intermediates were
found between ubiquitin and wild type and phospho-mimic, but not phospho-null Parkin
(on a C431S backbone to allow the formation of a stable oxyester bond, Iguchi et al.,
2013). However, no studies have shown the role of this phosphorylation on substrate
ubiquitination. Interestingly, previous experiments by Lazarou and colleagues aimed to
understand the role of PINK1 in Parkin activation have taken advantage of a rapalog-
induced heterodimerisation system to force the recruitment of Parkin to polarised mi-
tochondria. This system uses a FKBP (FK506 binding protein) and FRB (a portion of
FRAP/mTOR sufficient to bind the FKBP/rapalog complex) domains, which are used
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as tags to the proteins of interest, and the drug rapalog (homologue of rapamycin). Ex-
posure to this drug promotes the stable interaction of the two domains. Lazarou and
colleagues have elegantly shown that Parkin translocation to functional mitochondria
was not sufficient to induce ubiquitination of the organelles and mitophagy. Oppo-
sitely, rapalog-dependent translocation and accumulation of PINK1 (lacking its MTS)
on the mitochondria induced Parkin recruitment, ubiquitination of the organelles and
mitophagy (Lazarou et al., 2012), therefore suggesting that PINK1 not only physically
recruits Parkin, but it is also necessary for the ligase activation.
Recruitment and activation of Parkin are not, however, the only steps controlled by
the mitochondrial kinase PINK1. Three independent reports have recently identified
PINK1 as the first kinase to phosphorylate ubiquitin (Fig. 1.9 A and B; Koyano et al.,
2014; Kazlauskaite et al., 2014b; Kane et al., 2014), adding another level of complexity
to the regulation of mitophagy. Once accumulated at the OMM, PINK1 phosphory-
lates both Parkin and ubiquitin at the same conserved serine 65 (in the Ubl on Parkin,
Fig. 1.8). Koyano and colleagues have shown that expression of phospho-mimic S65D
ubiquitin promotes the activity of phospho-mimic S65E Parkin by analysing its auto-
ubiquitination state in vitro and in vivo. However expression of the ubiquitin phospho-
mimic mutant failed to recruit Parkin to mitochondria in the absence of mitochondrial
damage (Koyano et al., 2014). These data suggest that PINK1 promotes the activation
of Parkin and ubiquitin only surrounding damaged mitochondria (just 0.05% of total
ubiquitin is in fact phosphorylated upon damage, Koyano et al., 2014) to promote the
ubiquitination of the OMM proteins and therefore mitophagy. Ubiquitin phosphoryla-
tion is yet another step in the complex activation of Parkin, but whether this modifica-
tion is also crucial for ubiquitin incorporation into multimeric chains, or whether specific
ubiquitin chains can be favoured by this post-translational modification has not been
explored to date.
Once Parkin is fully activated and stabilised on damaged mitochondria, it can ubiqui-
tinate its substrates. Proteomic studies revealed that Parkin may directly or indirectly
regulate ubiquitination of more than 100 mitochondrial proteins upon mitochondrial de-
polarisation (Sarraf et al., 2013), of which the most well characterised are the Mfn1 and
Mfn2, VDAC1, Drp1, Tom20 and 40 (Geisler et al., 2010; Wang et al., 2011a; Ziviani
et al., 2010; Yoshii et al., 2011; Poole et al., 2010; Sarraf et al., 2013). Recent studies
have found two deubiquitinases (DUBs), enzymes that hydrolyse ubiquitin chains, to
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Figure 1.8: Parkin ubiquitin alignment.
Clustal Ω alignment of human Parkin (first 120 residues) and ubiquitin amino acid
sequences. The conserved serine 65, target of PINK1-dependent phosphorylation on
both proteins, is indicated by an arrow.
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counteract Parkin function: USP30, a mitochondrial DUB and USP15 a cytosolic en-
zyme (Bingol et al., 2014; Cornelissen et al., 2014). Silencing of both proteins favours
Parkin-mediated ubiquitination and mitochondrial clearance upon damage, hence these
enzymes can be good targets to promote the ubiquitination mediated by defective, PD-
associated Parkin mutants.
Whether ubiquitination of specific proteins exerts a distinctive function during mi-
tophagy or it is the overall ubiquitination of the mitochondrion to be essential for the
autophagic signalling cascade is not clear. The presence of several ubiquitinated proteins
on the mitochondrion drives the recruitment of elements of the autophagic machinery
and the formation of autophagosome-like structures, that will result in the formation and
maturation of the autophagosome. This autophagic organelle will then fuse with acidi-
fied lysosomes causing the degradation of the mitochondrion. Parkin-mediated protein
ubiquitination on damaged mitochondria, has however also been associated with protein
degradation by the proteasome. For example ubiquitination of the mitofusins, one of
the most well characterised targets of Parkin, determines their retrotranslocation from
the damaged mitochondria by the ATPase valsolin containing protein (VCP or p97), fol-
lowed by their degradation by the proteasome (Tanaka et al., 2010). This is a key step
in the initiation of mitophagy, since on one hand the damaged mitochondria are unable
fuse with the functional mitochondrial network, and on the other hand the elimination
of the fusion proteins favours the fragmentation of the mitochondria, thus promoting
their clearance. Recent studies have shown that several proteins are degraded in a
proteasome-dependent manner, and in addition proteasomal subunits have been shown
to be recruited to damaged mitochondria (Tanaka et al., 2010; Chan et al., 2011). This
raises the interesting question on whether the mitochondrial ubiquitinated proteins are
required to recruit the autophagic machinery, but are also needed to be degraded before
the formation/maturation of the phagosome. Or more specifically if specific proteins
(i.e. Mfn) need to be rapidly degraded to allow another subset of proteins to induce the
formation of the autophagosome.
Regulators of Parkin recruitment onto damaged mitochondria
Since the importance of the mitochondrial quality control system, there is a great inter-
est in thoroughly investigating this pathway and finding its possible regulators. Recently
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Hasson and colleagues via a high throughput screen have identified several positive and
negative regulators of mitophagy. In particular, TOMM7 (a component of the TOM
complex) and HSPA1L (a member of the Hsp70 family) are two positive regulators of
Parkin recruitment to mitochondria, and BAG4, SIAH3 are two negative ones. TOMM7
was shown to be essential for depolarisation-dependent PINK1 accumulation on the
OMM, suggesting that this protein might sense the mitochondrial membrane poten-
tial and block PINK1 import, however how HSPA1L, BAG4 and SIAH3 regulate this
pathway is yet to be investigated (Hasson et al., 2013).
Moreover the Bcl family of proteins has been recently shown to affect mitophagy. Bcl
family members are both pro- and anti-apoptotic. Interestingly, overexpression of pro-
survival Bcl proteins such as Bcl-XL and Mcl1 inhibit the translocation of Parkin to
damaged mitochondria, whereas overexpression of pro-apoptotic members of the family
such as Bad, Bim, Nox or Puma favour the translocation of the ligase and therefore
mitochondrial clearance (Hollville et al., 2014). Although Hollville and coworkers did
find Beclin1, another member of the pro-survival Bcl proteins known to promote the
autophagosome formation, to have a role in the regulation of mitophagy, Choubey and
colleagues have shown that this protein interacts with the cytosolic pool of Parkin and
its knock down inhibits Parkin translocation to impair mitochondria (Choubey et al.,
2014; Hollville et al., 2014). Moreover, Mcl1 has been shown to be a target of Parkin, in
fact following extensive mitochondrial damage, Parkin, together with PINK1, promotes
apoptosis by ubiquitinating this anti-apoptotic protein (Zhang et al., 2014). This sug-
gests that these pathways are intimately linked. It would be interesting to investigate
whether the level of mitochondrial damage makes one or the other pathway prevail,
and what mechanism could act as a sensor to determine the switch from survival to
apoptosis.
Treatment of mitochondria with uncouplers and toxins drives extensive mitochondrial
depolarization. It is likely, however, that mitochondria often undergo variations in their
membrane potential in physiological conditions, for example mitochondrial calcium up-
take has been associated with mitochondrial depolarisation (Duchen et al., 1998), and
autonomous pacemaking activity of dopaminergic neurons of the substantia nigra pars
compacta (SNpc), has been associated with transient and slight mitochondrial depolar-
isation (Guzman et al., 2010). To recover the mitochondrial membrane potential, the
mitochondrial ATP synthase complex reverts its function to hydrolyse ATP and sustain
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the proton gradient. However, to avoid the risk of depleting the ATP reservoir to sustain
the proton gradient of severely impaired mitochondria, the ATPase inhibitory factor 1
(ATPIF1) blocks this ATPasic activity of complex V. Although it is not clear how AT-
PIF1 is activated or how it senses the level of damage, by blocking the rescue of the
mitochondrial membrane potential, ATPIF1 favours PINK1 stabilisation on the OMM,
Parkin recruitment and ultimately mitophagy of the damaged organelle. Mitochondrial
damage of ATPIF1 knock down cells results in higher mitochondrial membrane poten-
tial (compared to control) associated with the lack of accumulation of PINK1 (Lefebvre
et al., 2013).
In addition to mitochondrial damage, an increased amount of mitochondrial unfolded
proteins activates the unfolded protein response. This generally promotes the expression
of chaperones (Hsp60 and Hsp70) and mitochondrial proteases to counteract and process
the unfolded proteins, thus providing an inner mitochondrial quality control. It has
been recently shown that accumulation in the mitochondrial matrix of unfolded proteins
(due to the expression of a non cleavable mutant of ornithine carbamyl transferase)
activates the PINK1/Parkin pathway on polarised mitochondria (Jin and Youle, 2013).
The mechanism by which PINK1 accumulates on the OMM of polarised organelles is
unclear, however it is interesting that different levels of quality control cooperate to
segregate and remove dysfunctional mitochondria.
Mitophagy
There are three main types of autophagy: microautophagy, chaperone-mediated au-
tophagy (CMA), and macroautophagy. Microautophagy involves invaginations of the
lysosomal membrane to directly engulf molecules from the cytoplasm. CMA instead re-
quires the chaperone Hsc70 to recognise and unfold substrate proteins characterised by
the specific sequence KFERQ (Dice, 1990). These substrates bind to the lysosomal pro-
tein LAMP-2A, are translocated within the lysosome and degraded . Macroautophagy
is often directly referred to as autophagy, this process has been firstly described in yeast
and it is highly conserved. Non specific macroautophagy is often used by the cell as
a catabolic reaction to rescue nutrients and amino acids by digesting cytosolic cargoes,
for example during starvation (Schneider and Cuervo, 2014). However, macroautophagy
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can be selective and in this case it is used by the cell to clear damaged or malfunc-
tional organelles such as mitochondria. Mitochondrial autophagy is termed mitophagy
(Kim et al., 2007). During this process a bilayered isolation membrane is formed, it ex-
pands and engulfs the targeted organelle, forming a structure called the autophagosome.
This autophagosome then matures and eventually fuses with a lysosome, promoting the
degradation of its content by the lysosomal proteases. The latest stages of mitophagy
generally take place at perinuclear level. This process has been shown to involve the
coordinated action of up to 30 distinct proteins which, in yeast, are named autophagy-
related proteins, ATGs. Specifically, knocking down ATG3, ATG5 or ATG7 prevents
degradation of impaired mitochondria (Narendra et al., 2008).
Parkin-dependent mitochondrial ubiquitination triggers the induction of mitophagy by
the recruitment of several adaptors that bind both poly-ubiquitinated proteins and
autophagy-related adaptors, such as p62 and HDAC6. P62, also known as sequesto-
some1, has been reported to accumulate on depolarised mitochondria, and due to its
ability to bind the autophagosomal protein LC3 (MAP1 light chain 3, homologue of
the yeast Atg8), has been suggested to promote the autophagosome formation. However
whether p62 is or is not dispensable for mitochondrial clearance is debated (Geisler et al.,
2010; Narendra et al., 2010a). A possibility is that the newly described protein NBR1,
by binding LC3 and ubiquitinated cargoes compensates for p62 loss (Kirkin et al., 2009).
The histone deacetylase HDAC6 also binds ubiquitinated proteins and links them to the
dynein motors. Recruitment of this protein to damaged mitochondria suggests a pos-
sible link between mitochondrial transport and mitophagy. Interestingly, p62, NBR1
and HDAC6 have all been found to be upregulated in mitophagy (Chan et al., 2011).
Moreover Parkin could itself promote the autophagosome formation. Van Humbeek and
colleagues have found by mass spectrometry the autophagy promoting protein Ambra1
(activating molecule in Beclin1-regulated autophagy) to interact with Parkin. Ambra1
activates the class III phophatidylinositol 3-kinase (PI3K) complex, which is essential
for the formation of the autophagosome, and interestingly the interaction between Am-
bra1 and Parkin increases following mitochondrial damage, suggesting that the ligase
itself may have a role in the recruitment of the autophagic machinery (Van Humbeeck
et al., 2011). Similarly, full length PINK1 has been found to interact with Beclin1, that
together with its interactor class III PI3K, is required for the initiation of the autophago-
some (Michiorri et al., 2010). More recently, Yamano and colleagues have shown that
TBC1D15 and TBC1D17, two members of of the TBC (Tre-2/Bub2/Cdc16) family, that
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function as Rab GTPase activating proteins (RabGAP) act together with Fis1 to con-
trol the autophagosome formation following mitochondrial damage. In particular these
RabGAPs bind Fis1 and LC3 homologue proteins (LC3 and GABARAP) and regulate
the activity of Rab7, a key protein involved in the shaping of the forming phagosome
(Yamano et al., 2014).
Most of the investigations on the mitophagic pathway have been done in morpholog-
ically simple, non neuronal cells, however an important question is where mitophagy
occurs in complex cells such as neurons. In neuronal cells most of the mature acidified
lysosomes are localised in the somatic region, therefore in order to degrade their com-
ponents autophagosomes need to be actively transported to the soma to fuse with these
degradative organelles. Accordingly, Maday and colleagues have shown that in axons,
peripheral autophagosomes mature while trafficked back from the neuronal periphery to
the cell soma, where they fuse with acidified lysosomes (Maday et al., 2012). In agree-
ment, Cai and collaborators have shown that damaged mitochondria colocalise with the
autophagosomal marker LC3 only in the somatic compartment (Cai et al., 2012). How-
ever, recently Ashrafi and colleagues have shown that damaged mitochondria can be
cleared at axonal level (Ashrafi et al., 2014). It is possible that both mechanisms occur,
likely depending on the extent of damage and on the overall health of the cell.
Mitochondrial-derived vesicles (MDV)
More recently a new type of mitochondrial quality control has been described, the
mitochondrial-derived vesicles (MDV, Sugiura et al., 2014; Soubannier et al., 2012;
Neuspiel et al., 2008). These are small vesicles (between 70 and 150 nm) that origi-
nate from the mitochondria and can either contain only OMM, or both mitochondrial
membranes and matrix portions. These vesicles are formed in a Drp1-independent man-
ner and often contain oxidised cargoes. MDV were reported to be formed under oxidative
stress and to precede the induction of mitophagy, suggesting that this could be an early
type of quality control. More importantly MDV generation does not require membrane
depolarisation, and PINK1 and Parkin have been shown to be necessary for the forma-
tion of these vesicles (Mclelland et al., 2014). It has been proposed that this mechanism
involves PINK1 activity at a very localised level. Local damage (i.e. local protein aggre-
gation, impairment of the import machinery, limited protein oxidation) would cause the
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Figure 1.9: Model of PINK1-dependent Parkin activation and ubiquitination of mito-
chondrial proteins.
(A) Upon mitochondrial damage the kinase PINK1 accumulates on the OMM, trig-
gers the recruitment of the cytosolic E3 ubiquitin ligase Parkin and phosphorylates the
ubiquitin molecules surrounding the mitochondrion (Narendra et al., 2008; Kane et al.,
2014; Kazlauskaite et al., 2014b; Koyano et al., 2014). (B) Parkin translocates on the
damaged mitochondrion, is activated by PINK1-dependent phosphorylation of S65 and
further stabilised/activated by the interaction with phospho-ubiquitin (Kondapalli et al.,
2012; Shiba-Fukushima et al., 2012). (C) Fully activated Parkin ubiquitinates its mito-
chondrial substrates, such as Mfns and VDAC1 (Geisler et al., 2010; Gegg et al., 2010;
Poole et al., 2010; Ziviani et al., 2010).
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accumulation of PINK1 at specific import sites, causing the local recruitment of Parkin.
Although the budding mechanism is not known, it has been suggested that protein oxi-
dation could promote protein aggregation and curvature of the mitochondrial membrane.
MDV have been shown to be integrated into multi-vesicular bodies (MVB), or directly
fuse with lysosomes for degradation. According to this mechanism being parallel to (and
preceding) mitophagy, MDV degradation is independent from the autophagic proteins
ATG5 and LC3 (Soubannier et al., 2012; Sugiura et al., 2014). MDV have also been
shown to be delivered to peroxisomes although the function of this is unknown (Sugiura
et al., 2014). Likely, upon complete depolarisation of the mitochondrion, there would be
a switch from local removal to general mitochondrial clearance, with PINK1 and Parkin
taking part not only in mitophagy, but also in the physiological removal of damaged
parts of the mitochondrion.
Parkin independent mitophagy
Most of the studies conducted so far on mitochondrial quality control and mitophagy
have converged on the critical function of PINK1 and Parkin. Recently however, some
reports have described a Parkin-independent mitophagy. Fu and colleagues have iden-
tified gp78 (or AMFR, autocrine motility factor receptor), a ER anchored E3 ubiquitin
ligase, generally involved in the ER-associated degradation (ERAD), to play a role in
mitophagy. Gp78, localised on mitochondria-associated ER domains (MAMs), has been
shown to induce the degradation of the mitochondrial OMM fusion machinery (Mfn1
and Mfn2) and to promote the recruitment of the autophagosomal marker LC3 upon
mitochondrial damage. Moreover gp78 function in mitophagy resulted to be dependent
on the expression of Mfn1, but not of Mfn2 (Fu et al., 2013). Although the authors
show that gp78-mediated mitophagy is Parkin independent, since knock down of Parkin
or usage of HeLa cells where the ligase is not expressed did not alter this process, it is
puzzling why gp78-mediated mitophagy is not able to compensate for the loss of Parkin
function in PD. Notably however, gp78 is only expressed on the ER membranes its
function might depend on the number of ER/mitochondria contacts, which can vary
according to local calcium levels and cellular stressors (Wang et al., 2000; Raturi and
Simmen, 2013). Moreover overexpression of the protein could impact on the number of
these contacts favouring its function in mitophagy. Another report demonstrated that
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iron chelation can induce PINK1/Parkin-independent mitophagy in fibroblasts. This
process was detected by LC3 decoration of mitochondria and quenching of GFP signal
in a GFP-mCherry tandem reporter (GFP fluorescence, but not the mCherry one is
quenched by the low pH of the autophagosomes) often used to study autophagy. The
mechanism by which loss of iron induces mitophagy and how the autophagy machinery
is recruited to the mitochondria is not clear, however this seem to be dependent on a
decrease in the mitochondrial respiration and on the switch to a glycolytic metabolism
(Allen et al., 2013).
Parkinson’s disease
Parkinson’s disease was first described by James Parkinson in “An Essay of the Shak-
ing Palsy”, 1817. PD is the second most common neurodegenerative disorder, affect-
ing 1-2% of the population over the age of 60. While palliative treatments exist, up
to date there is no cure available. Clinical features of PD include motor impairment
such as resting tremor, bradykinesia, postural instability and rigidity, and non-motor
symptoms, comprising autonomic, cognitive and psychiatric problems. The pathologi-
cal hallmarks of Parkinson’s are characterized by the progressive loss of neuromelanin-
containing dopaminergic neurons in the substantia nigra pars compacta (SNpc). Cy-
toplasmic proteinaceous inclusions named Lewy bodies, and dystrophic Lewy neurites
are often found in surviving neurons. Notably however, there are cases of PD patients
which do not display such aggregates, while Lewy bodies can be found in patients car-
rying other diseases (e.g. Lewy body dementia) as well as clinically normal people.
Although, neuronal loss in SNpc is pronounced, there is a widespread neurodegenera-
tion in the central nervous system (CNS) with the pars compacta being the most affected
(Corti et al., 2011).
The majority of Parkinson’s disease cases are sporadic, with only <10% of the cases
being inherited. The pathophysiological basis for the progressive cellular dysfunction
that causes Parkinson’s disease have long remained elusive, however age, use of drugs
(exposure to MPTP is capable of inducing parkinsonism) and pesticides (rotenone and
paraquat) have been described as risk factors for the disease. Although the inherited
cases are rare, the discovery of genes linked to these familial forms of PD have provided
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a huge progress in understanding molecular pathogenesis of PD, leading to the iden-
tification of several molecular pathways that are affected in the disorder (Corti et al.,
2011).
Genetic studies in families with mendelian inheritance of Parkinson’s disease have lead
to the discovery and cloning of several disease-associated genes. The first reported
gene associated with autosomal dominant PD was PARK1 (encoding α-synuclein, a
major component of Lewy bodies, Polymeropoulos et al., 1996). Since then, at least 16
loci (PARK1 to PARK16 ) and 11 genes have been associated with inherited forms of
parkinsonism. PARK1 together with PARK8 (LRRK2), are associated to autosomal
dominant PD. While PARK2 (Parkin), PARK6 (PINK1), PARK7 (DJ-1) and PARK9
(ATP13A2) are associated with the autosomal recessive form of the disease (Martin
et al., 2011).
Mitochondrial dysfunction was first associated with PD in the early 1980s following the
discovery of the mechanism of action of the MPTP, which causes parkinsonism. Once
through the blood brain barrier, MPTP is converted into MPP+ in glial cells, which is
then taken up by the dopamine transporter of monoaminergic neurons. In these cells it
concentrates in mitochondria, where it specifically inhibits complex I of the respiratory
chain, leading to ATP depletion, oxidative stress, and apoptotic cell death (Langston
et al., 1984; Martinez and Greenamyre, 2012).
From cellular to animal models mitochondrial dysfunction, oxidative stress and impaired
clearance of misfolded proteins and damaged organelles have emerged as common fea-
tures of familial PD, and increasing evidence shows that mitochondrial impairment is
associated with both inherited (particularly in the recessive forms) and sporadic PD
(Trancikova et al., 2012).
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Aim of the thesis
Mitochondrial dysfunction, impaired trafficking and calcium homeostasis have been as-
sociated with several neurodegenerative diseased, including Parkinson’s. Miro, a key
component of the mitochondrial trafficking complex, has been shown to interact with
PINK1, a PD-associated protein, playing a major role in the mitochondrial quality con-
trol. This suggests that Miro could be a substrate of the PINK1 and Parkin pathway,
and more importantly raises the possibility of it being important for the retrieval and
clearance of damaged mitochondria.
The aim of this thesis is therefore to investigate the contribution of Miro in mitochondrial
quality control, and in particular to study:
• The role Miro1 as a substrate of the PINK1/Parkin pathway following mitochon-
drial damage
• The characterisation of the Parkin-dependent Miro1 ubiquitination
• The role of Miro1 in the recruitment and stabilisation dynamics of Parkin on
damaged mitochondria
Chapter 2
Materials and Methods
Antibodies
The following primary antibodies were used: anti-Miro1 (cat. no. HPA010687, recog-
nising Miro1 and 2, 1:1000), anti-Miro2 (cat. no. HPA012624. 1:1000) and anti-TRAK1
(cat. no. HPA005853, 1:500) antibodies were from Atlas (rabbit), anti-Mfn1 and Apo-
Track™ Cytochrome C Apoptosis WB Antibody Cocktail (CValpha, PDH E1alpha, cy-
tochrome C, GAPDH) were from Abcam (1:1000, mouse), anti-Actin (1:2000, rabbit)
and anti-Flag (1:1000, rabbit) were from Sigma, anti-Tom20 (1:500, rabbit) was from
Santa Cruz Biotechnology, anti mono- and poly-ubiquitinylated conjugates (FK2) was
from Enzo Life Sciences (1:1000, mouse), anti-green fluorescent protein (GFP) antibody
was from Neuromab (clone N86/8, 1:100, mouse) or Nacalai tesque (1:2000, rat).
The monoclonal antibodies 9E10 (recognising myc) and 12CA5 (recognising HA) were
obtained from 9E10 and 12CA5 hybridomas respectively and used directly as super-
natant for western blotting and immunofluorescence (1:100). Monoclonal 9E10 and
12CA5 antibodies were produced by growing hybridoma cultures in Integra CL350 flasks.
Cells were maintained in the cell compartment in DMEM containing 20 % foetal bovine
serum and 0.1 % Gentamicin. The nutrient compartment contained serum free DMEM
containing 0.1 % Gentamicin. Cells were harvested every 3-5 days by removal of 4/5
of the media from the cell compartment and its replacement with fresh media. Cells
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were pelleted and the antibody containing supernatant was kept, filtered through a 0.45
µm filter and frozen at -20°C. 9E10 and 12CA5 antibodies were produced by Alison
Twelvetrees and Rosalind Norkett.
Horseradish peroxidase (HRP) conjugated secondary antibodies were purchased from
Rockland and used at 1:5000. Light chain specific HRP conjugated secondary antibodies
were from Jackson Immunoresearch (1:5000). Secondary antibodies Alexa-488, Alexa-
564 and Alexa-633 or Alexa-647 were purchased from Invitrogen and used at 1:1000.
Dylight-405 was from Jackson ImmunoResearch and used at 1:500.
Constructs
cDNA constructs encoding mtDsRed2, GFPMiro1 and mycMiro1 have been previously
described ((MacAskill et al., 2009a; Fransson et al., 2003, 2006)). GFPMiro1 S156A and
S156E mutations were made by site-directed mutagenesis on the GFPMiro1 backbone,
GFPTRAK1 was cloned by insertion of the mouse TRAK1 sequence in the EGFP-C1
vector. mito-LSS-mKate2-N1 (large stokes shift mKate2) [plasmid # 31879 (Piatkevich
et al., 2010)], pRK5-Parkin-myc [plasmid #17612 (Zhang et al., 2000)], EYFP-Parkin
[plasmid #23955 (Narendra et al., 2008)], pRK5-HA-Ubiquitin [plasmid #17608 (Lim
et al., 2005)] and Ubiquitin K27 [plasmid #22902 (Livingston et al., 2009)], K29 [plasmid
#22903 (Livingston et al., 2009)], K33 [plasmid #17607 (Lim et al., 2005)], K48 [plasmid
# 17605 (Lim et al., 2005)], K63 [plasmid # 17606 (Lim et al., 2005)], K48R [plasmid
# 17604 (Lim et al., 2005)], K29R [plasmid # 17602 (Lim et al., 2005)] mutants were
from Addgene. HAUbiquitin K6, K11, K6R, K11R, K27R and K27R-K29R mutants
were made by site-directed mutagenesis on the pRK5-HA-Ubiquitin or on the pRK5-
HA-Ubiquitin KO [plasmid # 17603 (Lim et al., 2005)] backbone. HAUbiquitin S65A
and S65E mutants were made by site-directed mutagenesis on the pRK5-HA-Ubiquitin
backbone. YFPParkin S65A and S65E mutations were made by site-directed mutagenesis
on the YFPParkin backbone. EGFP-C1 was from Clontech. pcDNA4-PINK1-myc was a
gift from Hélène Plun-Favreau and pSC2-mCherry-Miro1 was a gift from John Carroll.
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Molecular Biology
Polymerase Chain Reaction (PCR)
PCR was carried out using Phusion polymerase (Finnzymes) following the manufac-
turer’s instructions. The PCR reaction was assembled as described in Table 2.1, and
then subjected to a PCR programme with appropriate annealing temperature and ex-
tension time depending on the experiment (annealing time is 30 seconds/kb for normal
PCR and 1 minute/kb for reverse PCR).
PCR reaction - components: Final concentrations:
10 µL 5x HF-buffer 1x
2.5 µL forward primer 0.5 µM
2.5 µL reverse primer 0.5 µM
1 µL dNTPs mix 200 µM each
1 µL template DNA (50 ng/µL) 1 ng/µL
32.5 µL milliQ water –
0.5 µL Phusion 0.02 U/µL
Table 2.1: PCR reaction composition.
5 µL of the resulting PCR product was run on an agarose gel to check for the quality
of the amplification. If the PCR product consisted in one single band the remaining
PCR was purified using a PCR purification kit (Qiagen) following the manifacturer’s
instructions. If the PCR amplification resulted in multiple bands, 20-40 µL of the
PCR were run on an agarose gel, the DNA band at the correct weight was excised,
the DNA was extracted and purified with a gel extraction kit (Qiagen) following the
manufacturer’s instructions.
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Figure 2.1: PCR protocol.
Agarose gel
Agarose gels were made by melting 1% agarose in 1x TBE buffer. 1 µL of ethidium
bromide or 5 µL of StarSafe (Lonza) was added to visualise the DNA. Gels were let to
set, and then loaded with DNA samples and DNA ladder (Hyperladder I, Bioline) and
resolved at 90-100V for the required time (approximately 1 hour).
Digestion and purification
5 µL of the purified insert and 1 µg of the vector were digested with the selected re-
striction enzymes (NEB) in the appropriate digestion buffer (NEB), supplemented with
BSA for 1 hour. Digests were resolved on an agarose gel and insert and vector bands
were excised and purified using gel extraction kit (Qiagen) following the manufacturer’s
instructions.
Ligation
Purified insert and vector were combined at a 3:1 ratio and incubated with 2 µL of T4
ligase buffer and 1 µL of T4 ligase (total reaction volume 20 µL) at room temperature
(RT) for 30 minutes and at 4°C O/N.
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Chemically competent cells
Competent cells were prepared by the Inoue method (Inoue et al., 1990) by Katharine
Smith and Nathalie Higgs.
Transformation of competent cells
Competent cells were thawed on ice. 50 μL of cells were transferred to a 14 mL round
bottom falcon tube (BD). Following incubation for 30 minutes on ice with the appro-
priate amount of DNA (3 µL of ligations or 10 pg of plasmid DNA), bacteria were heat
shocked at 42°C for 45 seconds. Cells were then incubated on ice for 2 minutes, 200 μL
of RT LB media supplemented with 0.4% glucose were added, and cells incubated in a
bacterial shaker (230 rpm) at 37°C for 1 hour before plating onto agar plates with the
appropriate resistance. Plates were then incubated O/N at 37°C.
The next day, colonies were picked and grown O/N in 10 mL of LB media with the
appropriate resistance. DNA was extracted with a mini prep kit (Sigma) and sequenced.
Positive bacterial clones were stored as glycerol stocks (750 μL of bacteria supplemented
with 250 μL of 60% glycerol) at -80°C.
Site-directed mutagenesis by Reverse PCR
Site-directed mutagenesis was achieved by reverse PCR. Primers used for mutagenesis
are listed in Table 2.2, and were designed as shown in Fig. 2.2. The PCR reaction
was assembled as described in Table 2.1. The purified PCR product was subjected to
phosphorylation to allow the ligase activity. 16 μL of the purified PCR was linearised
by incubation at 60°C for 5 minutes. The DNA was then incubated on ice for 2 minutes
and 2 μL of T4 ligase buffer and 1 μL of T4 polynucleotide kinase (PNK) were added.
The reaction carried out by incubation at 37°C for 30 minutes. 1 μL of T4 ligase was
added and the sample was incubated at RT for 30 minutes and at 4°C O/N.
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Figure 2.2: Oligonucleotide design for site directed mutagenesis.
Forward and reverse primers were designed so that the forward one carried the mutation
of interest between the nucleotides +4 and +6. Primers were ~20nt long, with a GC
content of 50% when possible, and with similar melting temperatures (Tm, between
58-70ºC).
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Mutation sense sequence 5’ -> 3’
Miro1 S156A forward ataGCAgagctcttttattacgc
reverse gttcttcaggtttttcgct
Miro1 S156E forward ataGAAgagctcttttattacgc
reverse gttcttcaggtttttcgct
Parkin S65A forward cagGCcattgttcacattgt
reverse ctgatccaggtcacaattct
Parkin S65E forward caggAAattgttcacattgt
reverse ctgatccaggtcacaattct
R6K ubiquitin (on K0) forward gtcaAaacgttaaccggtaga
reverse gaagatctgcatggtcga
R11K ubiquitin (on K0) forward ggtaAaaccataactctagaagt
reverse ggttaacgttctgacgaa
K6R ubiquitin forward cgtgaGgaccctgactggtaag
reverse aagatctgcatggtcgaccc
K11R ubiquitin forward ggtaGgaccatcactctcga
reverse agtcagggtcttcacgaag
K27R ubiquitin forward gtcaGggcaaagatccaagaca
reverse attctcaatggtgtcactcggc
K27R ubiquitin (on K29R) forward gtcaGggcaaGgatccaagaca
reverse attctcaatggtgtcactcggc
S65A ubiquitin forward agGccaccctgcacctgg
reverse ctttctggatgttgtagtcagaca
S65E ubiquitin forward agGAAaccctgcacctgg
reverse ctttctggatgttgtagtcagaca
Table 2.2: List of primers used for site-directed mutagenesis by reverse PCR.
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Maxi preparation of plasmid DNA
Plasmid DNA was purified from bacterial cultures with Pure Yield Maxi prep Kit
(Promega) following the manufacturer’s instructions.
Molecular biology solutions
Luria-Bertani Broth (LB) 10 g NaCl
10 g Tryptone
5 g Yeast extract
H2O up to 1 L
Luria Broth Agar (LBA) 10 g NaCl
10 g Tryptone
5 g Yeast extract
10 g Agar
H2O up to 1 L
Ampicillin 100 μg/mL
Kanamycin 30 μg/mL
TBE 89 mM Tris
89 mM Boric acid pH 8.3
2 mM Na2EDTA
Loading dye (6x) 40% sucrose
0.25% bromophenol blue
H2O
Table 2.3: Bacterial culture and molecular biology solutions.
Cell culture
Cell lines
SH-SY5Y, COS-7, HeLa and HEK 293 cells were maintained in Dulbecco’s Modified
Eagles Medium (DMEM, Gibco) supplemented with 10% heat inactivated FBS, peni-
cillin and streptomycin (2 µg/mL puromycin was added to the SH-SY5Y non-silencing
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or PINK1 shRNA overexpressing cells media as a selection antibiotic). Cells were in-
cubated at 37 °C, in a humidified 5% CO2 atmosphere. When 80-100% confluent cell
cultures were divided. Cells were first washed with PBS and then allowed to detach
by incubation with trypsin solution at 37 °C. Cells were pelleted by centrifugation and
resuspended in complete DMEM for plating onto new dishes. FlagParkin stably overex-
pressing SH-SY5Y cells were a gift from Dr. Helen Ardley (Leeds Institute of Molecular
Medicine) and were previously described (Ardley et al., 2003). VCP scrambled and
specific shRNAi overexpressing cells were a gift from Helene Plun-Favreau and were
previously described (Bartolome et al., 2013). PINK1 and non-silencing shRNA stably
expressing SH-SY5Y were previously described (Wood-Kaczmar et al., 2008; Gandhi
et al., 2009). Human fibroblasts were derived from punch biopsies taken with informed
consent from a control patient or from a patient carrying a homozygous deletion of exons
3 and 4 of the PARK2 gene by Thomas Foltynie and Kailash Bhatia (Institute of Neu-
rology, UCL, London). The ethics for this study were approved by the London – City
Road and Hampstead REC committee. The tissue was dissected by Hsiu-Chuan Wu
and fibroblasts cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% heat inactivated FBS, penicillin and streptomycin. Cells were kept in 5% CO2
at 37°C, in a humidified incubator.
Neurons
Neuronal cultures were prepared from E18 Sprague Dawley rat embryos. Time pregnant
rats were killed following United Kingdom regulations. Embryos of either sex were
removed and placed onto ice-cold dissection media (HEPES-buffered Hank’s Balanced
Salt Solution HBSS, Invitrogen). Brains were isolated, meninges were removed and
hippocampi were dissected. Hippocampi were incubated in 0.125% trypsin diluted in
dissection media (5 mL) for 15 minutes at 37°C. Neurons were cleared from further
trypsin enzymatic activity by three washes in pre-warmed attachment media (Minimum
Essential Medium supplemented with 10% horse serum, 1 mM sodium pyruvate, and
33 mM glucose). Hippocampi were gently triturated with a fire-polished glass pasteur
pipette, followed by trituration with a second fire-polished pipette with a 60% diameter
of the first one. Cells were counted using a Neubauer Haemocytometer and cell viability
was assessed by erythrosin B exclusion. 350.000 hippocampal neurons were plated in
6 cm dishes containing 13 mm coverslips coated with 500 µg/mL (PLL). Neurons were
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allowed to attach and 4 to 6 hours after plating, media was replaced with neuronal
maintenance media (Neurobasal supplemented with 2% B27, 1% glutamine, and 33 mM
glucose) and cultures were kept in 5% CO2 at 37°C, in a humidified incubator.
Transient Transfection
Nucleofection (cell lines)
Pelleted cells obtained after trypsinization were resuspended in 100 µL of WT-EM solu-
tion, the appropriate amount of DNA was added (1 µg per 3 cm dish, 2-3 µg per 6 cm
dish, 4-5 µg per 10 cm dish), cells were transferred in cuvettes and nucleofected using
the appropriate Amaxa program. Nucleofected cells were then immediately plated into
DMEM complete media-containing plates and left to express for 48 hours.
Electroporation
Pelleted COS-7 cells obtained after trypsinization were washed in Opti-MEM® (Gibco).
After re-pelleting cells were resuspended in 500 µL Opti-MEM®/transfection and 5 µg
of DNA was added (10 cm dish). Cells were transferred into a cuvette and electroporated
using a Capacitance Extender II accessory module. Voltage was set at 400 mV and high
capacitance at 125 µF. Cells were then plated in DMEM complete media and left to
express for 24-48 hours.
Calcium phosphate
7-9 days in vitro (DIV) hippocampal neurons were transfected by calcium phosphate
method (Graham and Van Der Eb, 1973). 2.5 µg DNA were diluted in 27 µL of MilliQ
water. 3 µL of 2.5 M CaCl2 were added and this mixture was transferred in a new
tube containing 30 µL of 2x HBS. This was added dropwise to the neuronal culture (on
coverslips) previously placed in a 3 cm dish containing 1 mL of prewarmed neurobasal
media. The DNA precipitates were checked on a light microscope and neurons were
placed in the incubator for 7-15 minutes. The media was removed and replaced with
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conditioned maintenance media. Cells were left to express for 24-48h unless otherwise
stated.
Treatments
Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, Sigma) was used at 10
µM, MG-132 (Cayman Chemical) was used at 30 µM for 30 minutes before and during
FCCP treatment, Bafilomycin 1A (Biovitica) was used at 1 μM for 30 minutes before and
during FCCP treatment, valinomycin (Sigma) was used at 2 µM in neurobasal medium
(Gibco) supplemented with 0.6% D-glucose.
CHAPTER 2. MATERIALS AND METHODS 72
Cell culture media and reagents
PBS 137 mM NaCl
2.7 mM KCl
10 mM Na2HPO4
2 mM KH2PO4
Trypsin solution 137 mM NaCl
2.7 mM KCl
8 mM Na2HPO4
1.5 mM KH2PO4
2.5 g/L trypsin (from porcine pancreas)
200 mg/L EDTA
Dissection media HBSS (Gibco)
10 mM HEPES
Attachment media MEM (Gibco)
10% horse serum
1 mM sodium pyruvate, and
33 mM glucose
Maintenance media Neurobasal (Gibco)
2% B27 supplement (Gibco)
1% glutamine
WT-EM 15 mM NaH2PO4
35 mM Na2HPO4
5 mM KCl
10 mM MgCl2
11 mM Glucose
100 mM NaCl
20 mM HEPES
2x HBS pH 7.11 274 mM NaCl
10 mM KCl
1.4 mM Na2HPO4
15 mM D-Glucose
42 mM HEPES
Table 2.4: Cell culture and transfection solutions.
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Biochemistry
Cell lysis
For protein analysis confluent cells were lysed in the appropriate buffer. Briefly, cells
were washed twice in PBS to remove the media, lysis solution was added (Laemmli
sample buffer, radioimmunoprecipitation assay -RIPA- buffer or Tris-based Triton-X
buffer) and cells were scraped from the plate. When whole protein lysates were analysed
cells were directly lysed in 1x Laemmli sample buffer, transferred in Eppendorf tubes and
genomic DNA was broken down by homogenization with a 1 mL syringe provided with
a 25 Gauge needle prior to protein denaturation at 95°C. When proteins needed to be
immunopurified either for post-translational modification (PTM) analysis or for protein-
protein interaction analysis, cells were lysed in RIPA (PTM analysis) or Tris-based
Triton-X 100 buffer (protein-protein interaction analysis). Lysates were transferred into
new Eppendorf tubes and were then incubated on a rotating wheel at 4°C for 1 hour prior
to nuclei and cellular debris elimination by centrifugation at 20000 g for 10 minutes.
Immunoprecipitation
To immunopurify endogenous proteins, nuclei-cleared cell lysates were incubated with
0.5 µg of primary antibody (Miro1, rabbit) in parallel with a non immune rabbit IgG
control antibody for 1.5-2 hours. Protein/antibody complexes were then precipitated
for 1.5 hours with 15 µL of a 50% protein A-Sepharose bead slurry (Generon). When
GFP-tagged or myc-tagged proteins were to be immunopurified, nuclei-free lysates were
incubated with 10 µL of a 50% slurry of either GFP-TRAP beads (Chromotek) or
anti-myc beads (Sigma) at 4°C for 2 hours. Bound material was washed three times (co-
immunopurification) or five times (immunopurification) in the appropriate lysis buffer
before elution with 3x Laemmli sample buffer. Protein samples were then denatured at
100°C for 5 minutes.
Ubiquitin Chain Restriction (UbiCRest) Analysis
UbiCRest assays were performed as previously described (Mevissen et al., 2013). Briefly,
ubiquitinated GFPMiro1 (expressed in FlagParkin overexpressing cells, treated with 10
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µM FCCP for 1 hour) was immunopurified on GFP-TRAP beads and resuspended in
2x deubiquitinase (DUB) reaction buffer (100 mM Tris pH 7.4, 100 mM NaCl, 10 mM
DTT). USP21, OTUD2 and Otulin (produced and purified by Tycho Mevissen, David
Komander lab, LMB, Cambridge, UK), diluted in 2x DUB dilution buffer (50 mM Tris
pH 7.4, 300 mM NaCl, 20 mM DTT), were incubated for 10 minutes at RT. DUBs were
then added to equal amounts of the immunoprecipitated GFPMiro1 and the reaction was
carried out for 30 minutes at 37°C. The reaction was stopped by the addition of Laemmli
sample buffer, and samples were separated on a half 8% and half 15% SDS-PAGE gel
and blotted on PVDF membrane (Amersham Biosciences).
SDS-Polyacrylamide Gel Electrophoresis (PAGE)
Polyacrylamide gels were generally made using 10% separating gels and 5% stacking
gels in Novex 1.5 mm cassettes. Gels were submerged in running buffer in a Novex
XCell SureLock Mini-Cell system. Samples resuspended in Laemmli sample buffer and
denatured (5 minutes, 100°C) were loaded on the gel and were run at 130-150 V until
the dye front reached the end of the cassette.
PhosTag™ SDS-Polyacrylamide Gel Electrophoresis
PhosTag™(Wako), a phosphate binding tag, was used to detect phosphorylated pro-
teins. As illustrated in Fig. 5.1 Chapter 5, this technique is based on a mobility shift
caused by binding of the phosphate groups of phosphorylated proteins to the PhosTag™,
which determines a slower migration of these proteins and consequent separation from
the unphosphorylated species. 20 μM PhosTag™and 20 μM MnCl2 were added to 7%
acrylamide gels and solution poured in in Novex 1.5 mm cassettes. 5% stacking gels
were cast onto the PhosTag™ resolving gels. Gels were submerged in running buffer in a
Novex XCell SureLock Mini-Cell system. Samples, lysed in Laemmli sample buffer, were
denatured (5 minutes, 100°C) and loaded on the gel the day of the preparation. Gels
were resolved at 140 V until the dye front reached the end of the cassette. Cassettes were
opened and the gel submerged in transfer buffer supplemented with 10 mM EDTA for
10 minutes in agitation to remove the MnCl2. Gels were subsequently western blotted.
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Western blotting
Gels were transferred onto a Hybond-ECL nitrocellulose membrane (GE Healthcare)
or polyvinylidene difluoride (PVDF) membrane (when small proteins such as mono-
ubiquitin needed to be detected, Amersham Biosciences) using the Novex system. PVDF
membranes were pre-activated in methanol and membrane/gel sandwiches were soaked
in transfer buffer. Transfer was carried out at 30 V for 2 hours. Membranes were
probed with Ponceau staining and then blocked for 1 hour with 4% milk in PBS-T (1x
PBS - 0.05% Tween). Blocked membranes were incubated O /N at 4°C with primary
antibodies, then washed 3 times (5 minutes each) with 4% milk PBS-T and incubated for
1 hour with secondary antibodies. After 3 washes (10 minutes each) with 4% milk PBS-
T, a final wash with PBS-T was done and membranes were incubated with the Luminata
Crescendo or Forte substrate (Millipore) for 1 minute. Bands were then detected using
an ImageQuant LAS 4000 CCD camera system (GE Healthcare) and analysed using the
QuantityOne Biorad software.
Stripping
Membranes were first washed two times with PBS-T for 10 minutes and then incubated
in pre-warmed (37°C) stripping buffer for 20 minutes. Membranes were washed in PBS-
T 3 times for 10 minutes and blocked in 4% milk in PBS-T for 1 hour before incubation
with the primary antibody.
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RIPA buffer 50 mMTris pH 7.4
150 mM NaCl
1 mM EDTA
2 mM EGTA
0.5% deoxycholic acid
1% NP40
0.1% SDS
1 mM PMSF (phenylmethylsulfonyl fluoride)
10 μg/mL antipain
10 μg/mL leupeptin
10 μg/mL pepstatin
Tris/Triton buffer 50 mMTris pH 7.4
150 mM NaCl
1 mM EDTA
0.5% Triton X-100
1 mM PMSF
10 μg/mL antipain
10 μg/mL leupeptin
10 μg/mL pepstatin
3x Lammli sample buffer 150 mM Tris pH 8.0
6% SDS
300 mM dithiothreitol (DTT)
30% glycerol
0.3% bromophenol blue
DUB reaction buffer 100 mM Tris pH 7.4
100 mM NaCl
10 mM DTT
Table 2.5: Cell lysis and biochemical assays buffers.
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Biochemistry buffers and reagents
10% resolving gel 10% Protogel (acrylamide solution)
375 mM Tris pH 8.8
1% SDS
1% ammonium persulphate (APS)
0.04% TEMED
Stacking gel 5% Protogel (acrylamide solution)
125 mM Tris pH 6.8
1% SDS
1% APS
10x Running buffer 250 mM Tris
1.92 M glycine
1% SDS
10x Transfer buffer 250 mM Tris
1.92 M glycine
20% methanol
0.35% SDS
Ponceau stain 5% acetic acid
0.1% Ponceau S
Membrane blocking solution 4% non fat milk
0.05% Tween
in 1x PBS
Stripping buffer 6.25 mM Tris pH 6.8
2% SDS
0.7% β-mercapto-ethanol
in 1x PBS
Table 2.6: SDS-PAGE and western blotting buffers and solutions.
Immunofluorescence and Microscopy
Immunocytochemistry
For fixed imaging, cells grown on coverslips were washed in 1x PBS, and fixed in 4%
paraformaldehyde (PFA) solution (4% PFA, 4% sucrose in 1x PBS, pH 7.0) for 10
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minutes. After 3 further washes in 1x PBS coverslips were incubated for 10 minutes in
blocking solution (0.5% bovine serum albumine (BSA), 10% Horse serum, 0.2% Triton
X-100 in 1x PBS). Coverslips were then incubated for 1 hour with primary antibodies
diluted in blocking solution, washed 5 times in 1x PBS and incubated with secondary
antibodies. After further 5 washes in 1x PBS coverslips were mounted on glass slides
using ProGold anti fade reagent (Invitrogen) and later sealed with nail varnish.
Confocal Microscopy
Cells were imaged on a Zeiss LSM700 upright confocal microscope, with an Achroplan
63× oil-immersion lens with 1.4 numerical aperture. Images were digitally captured
using ZEN 2010 software.
Image processing
Images were processed in ImageJ for fluorescence intensity quantification, or in Meta-
morph for colocalisation analysis. For colocalisation studies, cells displying similar fluo-
rescence (indicating comparable transfection levels) were considered. Images were taken
with comparable Hi (red)/Low (blue) ratio and then arbitrarily thresholded. The inte-
grated colocalisation function was used to measure the colocalisation.
Immunohistochemistry solutions
PFA solution pH 7.0 4% PFA
4% sucrose
in 1x PBS
IF blocking solution 10% horse serum
0.5% bovine serum albumine (BSA)
0.2% Triton X-100
in 1x PBS
Table 2.7: Immunohistochemistry solutions.
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Live cell imaging
For neuronal imaging of mitochondria, primary hippocampal neurons were transfected
at 7-8 DIV and imaged at 9-10 DIV under continuous perfusion with imaging media
warmed to 37°C and flowed at a rate of 1-2 mL/minute throughout the duration of the
experiment. For acquisition, fluorescence was captured using an Olympus microscope
(BX60M) with a 60× Olympus objective coupled to an EM-CCD camera (Ixon, Andor).
Excitation was provided by a mercury arc lamp (Cairn) with the appropriate filters.
Images were acquired at 1 frame per second for two minutes throughout. Axonal regions
were acquired at a distance of 100 to 200 µm from the cell body. The length of process
assayed was ≈ 150 µm.
Imaging solution (ACSF) 125 mM NaCl
pH 7.4 10 mM HEPES
10 mM glucose
5 mM KCl
2 mM CaCl2
1 mM MgCl2
Table 2.8: Live imaging solution.
Live imaging processing
Mitochondrial movement was analysed utilising kymographs, which allow the projection
of the spatial displacement along a line-scan of a particle (mitochondrion) across time.
The x axis therefore represents the position of particles within the process, and the y
axis plots their position changes over time. Live imaging recording files were opened
in ImageJ, curved processes were straightened using the “straighten” plug-in and kymo-
graphs created by the “multiple kymograph” plug-in. Straight vertical lines represent
stationary mitochondria, while oblique lines represent moving mitochondria. Mobility
was assessed by counting the percentage of mitochondria moving during the imaging
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recording (2 minutes). Mitochondria in a field of view were classed as moving if they
moved more than 2 μm.
Statistical analysis
All data were obtained using cells from at least three different preparations. Numbers of
cells studied are given in the text or figure legends. Statistical significance across groups
was analysed using one-way ANOVA and Dunnett’s post hoc test to compare the data
groups to their reference group or the Bonferroni’s post hoc test to compare all data
groups. Individual differences were assessed using individual student’s t-tests. Data are
shown as mean ± SEM.
Chapter 3
Miro1 regulation by the ubiquitin
ligase Parkin
Introduction
Mitochondria are dynamic organelles, they fuse, divide and are actively transported
within the cell to areas of high energy demand and calcium buffering requirements. When
damaged, these organelles lose functionality and their fusion with the mitochondrial
network would cause an overall dilution of the damage, that would ultimately turn
into the impairment of the whole mitochondrial network. To prevent this scenario a
set of tightly regulated proteins act as a mitochondrial quality control system that
recognises, segregates and clears impaired mitochondria, preventing their fusion with the
cell’s functional mitochondrial network. The principal proteins involved in the detection
of damaged mitochondria are PINK1 and Parkin, two proteins associated with early
onset autosomal recessive Parkinson’s disease (PD). PINK1 is a mitochondrial serine
threonine kinase. Although being located on the OMM, the kinase is rapidly imported
within the mitochondrion through the TOM complex (Lazarou et al., 2012), cleaved by
several proteases including PARL and the fragment degraded by the proteasome (Deas
et al., 2011; Jin et al., 2010). Thus, in basal conditions, due to its rapid processing and
turnover the levels of PINK1 on the OMM are very low. However, when mitochondria
are damaged, their membrane potential drops and PINK1 import is blocked. PINK1
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therefore accumulates on the OMM and this is a crucial step in the targeting of damaged
mitochondria. Once accumulated, PINK1 recruits Parkin, a cytosolic E3 ubiquitin ligase,
and activates it by phosphorylation of serine 65 on its N-terminal Ubl domain. Parkin is
then activated and stabilised on damaged mitochondria to ubiquitinate several proteins
(including Mfns, VDAC1, Tom20, Drp1; Geisler et al., 2010; Wang et al., 2011a; Ziviani
et al., 2010; Yoshii et al., 2011; Poole et al., 2010; Sarraf et al., 2013.). Ubiquitination of
these proteins not only prevents mitochondrial fusion with neighbouring mitochondria,
but also signals to ubiquitin binding proteins, such as p62, to induce the formation of
the autophagosome, a crucial step for mitochondrial autophagy.
In recent years there has been a great interest in further understanding this pathway, and
in particular the mechanisms by which malfunctional mitochondria are retrieved from
the cell periphery and degraded. In 2009 Weihofen and collaborators have shown by
mass spectrometry the interaction between PINK1, Miro and TRAK1, two key proteins
of the mitochondrial transport machinery (Weihofen et al., 2009). Miro is a mitochon-
drial atypical Rho GTPase that, via its interaction with the kinesin motors, mediates
mitochondrial trafficking along the cytoskeletal tracks (MacAskill et al., 2009b; Wang
and Schwarz, 2009), whereas TRAK1 is a trafficking adaptor that binds both Miro
the kinesin and dynein motors (Brickley et al., 2005; Glater et al., 2006; van Spronsen
et al., 2013). The interaction between the mitochondrial quality control protein, PINK1
and the trafficking proteins, Miro and TRAK1, suggests the interesting possibility of a
functional cross-talk between the two machineries. In fact, mitochondrial damage could
induce a PINK1/Parkin-dependent modulation of Miro and/or the TRAKs to favour the
transport of the organelles towards the cell soma, in agreement with the directionality
of mitochondrial transport being coupled to the functionality of the organelles (Miller
and Sheetz, 2004). Another possibility is that damaged mitochondria need to be iso-
lated, which could occur by their uncoupling from the molecular motors. Therefore by
modifying Miro, PINK1 and Parkin could induce mitochondrial arrest, in conjunction
with the recruitment of the autophagic machinery.
In this Chapter Miro regulation upon mitochondrial damage will be discussed. Anal-
ysis of the dynamics of Miro ubiquitination and degradation and the dependency on
the kinase PINK1 and the E3 ubiquitin ligase Parkin will be investigated in neuronal
dopaminergic SH-SY5Y cell line as well as in human fibroblasts derived from a Parkin-
son’s disease patient carrying a homozygous deletion of exons 3 and 4 of the PARK2
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gene encoding Parkin. Moreover the stability of the trafficking adaptors, TRAK1 and
TRAK2, and their interaction with Miro upon mitochondrial damage will be analysed.
Results
PINK1 and Parkin regulate Miro loss upon mitochondrial damage in
human dopaminergic neuroblastoma cells and fibroblasts
To investigate the role of PINK1 and Parkin in the regulation and processing of Miro pro-
teins in neuronal cells, human derived dopaminergic neuroblastoma SH-SY5Y cells were
used. In these cells Parkin has been shown to translocate to mitochondria following mi-
tochondrial damage, and to promote their clearance by mitophagy (Geisler et al., 2010).
To study the damage-induced regulation of Miro, SH-SY5Y cells, in which endogenous
Parkin levels are relatively high (Zhou et al., 2008b), were incubated with the mitochon-
drial uncoupler FCCP, a proton ionophore that disrupts the mitochondrial membrane
potential, therefore causing extensive mitochondrial damage. Cells were treated for in-
creasing amounts of time (from 1 hour to 6 hours) with FCCP (10 μM), lysates were
then collected and resolved by SDS-PAGE. Following western blotting, membranes were
probed with different antibodies. Miro was detected with an anti-Miro1 antibody (Atlas,
cat. no. HPA010687) which is the best available to detect the protein, even though it
cross-reacts with Miro2 (Fig. 3.1). Analysis of these time-course experiments, showed
a loss of endogenous Miro1/2 protein at its expected molecular weight (70 kDa) within
2 hours of FCCP treatment (Fig. 3.2 A, top panel and B, Miro1/2 normalised mean
intensity after 2 hours FCCP 0.53 ± 0.13 compared to Miro1/2 intensity in control con-
ditions 1.0, n=6), while the mitochondrial matrix protein, pyruvate dehydrogenase E1,
subunit alpha (PDH E1α), used as control, was unaffected.
To specifically investigate the role of Parkin in the loss of Miro proteins following mi-
tochondrial damage, previously characterised SH-SY5Y cells that stably overexpressed
FlagParkin (FlagParkin OE, Ardley et al., 2003) were used. Analysis of the degradation
of Miro1/2 over time in experiments performed using FlagParkin overexpressing cells
and compared to control SH-SY5Y cells, showed that Miro1/2 loss was significantly
facilitated by the increased expression of Parkin (Fig. 3.2, Miro1/2 normalised mean
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Figure 3.1: Miro antibody characterisation.
COS-7 cells either untransfected (UT) or expressing mycMiro1 or mycMiro2 were lysed,
proteins resolved by SDS-PAGE and western blotted. Samples were probed with an anti-
Miro1 antibody (Atlas, cat. no. HPA010687, top blot), an anti-Miro2 antibody (Atlas,
cat. no. HPA012624, second blot from top), and an anti-myc antibody to confirm
expression of the two constructs (third blot from top). As shown in the top blot the
anti-Miro1 antibody recognised both Miro1 and Miro2 (Miro1/2), while the anti-Miro2
antibody is isoform specific. Both antibodies failed to recognise the endogenous protein
in COS-7 cells. Similar loading is confirmed by actin staining.
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Figure 3.2: Mitochondrial damage triggers Parkin-mediated Miro1 loss.
Control SH-SY5Y cells or cells stably overexpressing FlagParkin SH-SY5Y (FlagParkin
OE) cells were incubated with FCCP (10 μM) for the indicated time. (A) shows a FCCP
time course experiment indicating the loss of the outer membrane proteins Miro1/2 and
Mfn1, but not of the trafficking adaptor TRAK1 or the mitochondrial matrix protein
PDH E1α. Loss of Miro1/2 and Mfn1 is favoured by Parkin overexpression. (B) Quantifi-
cation of Miro1/2 bands (ctr n=6, Parkin OE n=3 independent experiments, *p<0.05,
**p<0.01, ***p<0.001).
CHAPTER 3. MIRO1 REGULATION BY THE UBIQUITIN LIGASE PARKIN 86
intensity in control SH-SY5Y cells at 1 hour FCCP 0.67 ± 0.12 SEM, at 2 hours 0.52
± 0.13 SEM, at 3 hours 0.52 ± 0.12 SEM, at 6 hours 0.62 ± 0.08 SEM; n=6. Miro1/2
mean intensity in FlagParkin OE SH-SY5Y cells at 1 hour FCCP 0.54 ± 0.12 SEM, at
2 hours 0.24 ± 0.04 SEM, at 3 hours 0.07 ± 0.05, at 6 hours 0.04 ±0.02 SEM; n=3,
*p<0.05, **p<0.01, ***p<0.001).
Since Miro proteins are part of a mitochondrial trafficking machinery, the stability of
other key proteins, following FCCP treatment, was analysed. TRAK1, a trafficking
adaptor which is known interact with Miro and is part of the transport complex (Brickley
et al., 2005; Wang and Schwarz, 2009; MacAskill et al., 2009a) and the mitochondrial
fusion GTPase Mfn1, a key regulator of mitochondrial dynamics and known substrate
of the PINK1/Parkin pathway (which also interacts with Miro Misko et al., 2010), was
monitored. FCCP-induced Mfn1 loss was observed to occur rapidly upon mitochondrial
damage and was facilitated by Parkin overexpression similar to previous reports (Ziviani
et al., 2010; Gegg et al., 2010). However, TRAK1 protein levels did not decrease under
these conditions, rather a trend to increase was observed (Fig. 3.2 A).
As previously described, PINK1 acts upstream of Parkin to recruit the ligase to the OMM
of damaged mitochondria (Narendra et al., 2010b). To investigate whether PINK1 was
involved in damage-induced Miro loss, SH-SY5Y cells expressing PINK1 shRNA or a
non silencing shRNA were used. PINK1 down regulation in these cells was previously
characterised (Wood-Kaczmar et al., 2008; Gandhi et al., 2009). Similar to the pro-
gressive loss of Miro1/2 detected in Fig. 3.2, FCCP treatment induced a decrease in
Miro1/2 levels in non silencing shRNA expressing SH-SY5Y cells transiently transfected
with YFPParkin, however this effect was blocked by the expression of PINK1 RNAi (Fig.
3.3, Miro1/2 normalised mean intensity in non silencing shRNA in control 1.0, at 1 hour
FCCP 0.50 ± 0.15, 2 hours FCCP 0.37 ± 0.16, 3 hours FCCP 0.39 ± 0.20, 6 hours
FCCP 0.31 ± 0.12; Miro1/2 mean intensity in PINK1 shRNA expressing cells in control
1.0, at 1 hour FCCP 0.84 ± 0.22, at 2 hours FCCP 0.80 ± 0.30, at 3 hours FCCP 0.78
± 0.30, at 6 hours FCCP 0.58 ± 0.23, n=4, p<0.05). As expected also Mfn1 loss was
inhibited in PINK1 knock down cells, whereas TRAK1 levels showed a trend to increase
in both PINK1 and non silencing shRNA expressing cells (Fig. 3.3 A).
To further investigate the impact on Miro regulation in pathological conditions, hu-
man patient-derived fibroblasts carrying a homozygous deletion of exons 3 and 4 of the
PARK2 gene encoding Parkin were used. Control fibroblasts and PD patient-derived
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Figure 3.3: Miro1 loss is dependent on PINK1.
SH-SY5Y cells stably expressing either non silencing (NS) shRNA or PINK1 specific
shRNA and transfected with YFPParkin were treated with FCCP (10 μM) for the in-
dicated time points. In (A) is shown a representative western blot of a FCCP time
course experiment. Miro1/2 loss is inhibited by the specific knock down of PINK1. (B)
Quantification of this effect (n=4, significance is calculated comparing treated samples
to control, 0h. *p<0.05, **p<0.01).
CHAPTER 3. MIRO1 REGULATION BY THE UBIQUITIN LIGASE PARKIN 88
cells, lacking Parkin, were subjected mitochondrial disruption with FCCP (1 to 6 hours
treatment) and the loss of Miro 1/2 was investigated by western blotting. Compared to
control fibroblasts, where treatment with FCCP induced a progressive loss of Miro 1/2,
in Parkin deficient fibroblasts Miro 1/2 levels were unchanged (Fig. 3.4 ). Furthermore,
as in the dopaminergic SH-SY5Y cells, in the control fibroblasts the levels of Mfn1 de-
creased, whereas the levels of TRAK1 remained stable over time. Thus Miro levels upon
mitochondrial damage, in dopaminergic neuroblastoma cells and in human fibroblasts,
are controlled by the PINK1/Parkin pathway. Moreover, the regulation of Miro levels
is disrupted in fibroblasts derived from a patient with PD and lacking the E3 ubiquitin
ligase Parkin.
Ubiquitination of Miro by a PINK1 and Parkin complex upon mito-
chondrial damage
The previously described results support a key role for the PINK1/Parkin pathway in
regulating Miro levels upon mitochondrial damage in human dopaminergic SH-SY5Y
cells and fibroblasts. To examine whether Miro interacts with the key proteins of
this pathway, co-immunoprecipitation experiments were performed in FlagParkin over-
expressing SH-SY5Y cells. These cells were transiently transfected with GFP, GFP
tagged Miro1 (GFPMiro1), or GFPMiro1 together with myc tagged PINK1 (PINK1myc).
FCCP (10 μM, 1 hour) or vehicle (DMSO) treated cells were lysed and GFPMiro1, or
GFP (as control) were immunopurified. Complexes were resolved on a SDS-PAGE,
western blotted and probed with antibodies to recognise the proteins of interest. The
interaction between Miro and PINK1 could be readily detected, as previously reported
in HEK 293 cells (Weihofen et al., 2009; Wang et al., 2011b; Liu et al., 2012). Moreover,
in agreement with Parkin being recruited to the mitochondrial membrane only upon
mitochondrial damage, the formation of a complex between Miro and Parkin could only
be observed when PINK1 was overexpressed and upon FCCP-induced mitochondrial
damage (Fig. 3.5).
The loss of Miro1/2 at its expected molecular weight upon mitochondrial damage (as
shown in Fig. 3.2 and Fig. 3.3) is likely due to Miro ubiquitination by Parkin. Since
protein ubiquitination implies the addition of one or several ubiquitin molecules to lysine
residues of a protein, this post translational modification (PTM) results in a progressive
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Figure 3.4: Miro1 degradation is impaired in patient-derived fibroblast lacking Parkin.
FCCP treatment (10 μM) of human control fibroblasts triggers the loss of Miro1/2 as well
as Mfn1 (left panel), however FCCP-induced mitochondrial damage in human fibroblasts
derived from a PD patient carrying a deletion of exons 3 and 4 of the PARK2 gene does
not cause loss of Miro1/2 or Mfn1 (right panel).
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Figure 3.5: Miro1 interacts with the mitochondrial quality control proteins PINK1 and
Parkin.
Co-immunoprecipitation experiments carried out in SH-SY5Y cells stably overexpressing
FlagParkin and transfected with GFP, GFPMiro1, GFPMiro1 and PINK1myc. Following
FCCP (10 μM, 1 hour) or vehicle, cells were lysed and GFP (as a control) or GFPMiro1
were immunoprecipitated. Samples were resolved by SDS-PAGE and western blotted.
Membranes were probed for Flag (FlagParkin), myc (PINK1myc) and GFP (GFP or
GFPMiro1). PINK1myc is shown to co-immunoprecipitate with Miro1 in control and
treated conditions, but mitochondrial depolarisation is needed for Parkin to participate
in the complex.
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increase of the protein’s molecular weight, which, in a western blot, determines a high
molecular weight smear (or laddering) of the protein of interest. To investigate whether
Miro1 was indeed ubiquitinated by Parkin upon mitochondrial damage, COS-7 cells
were transfected with GFPMiro1, GFPMiro1 and mycParkin, GFPMiro1 and PINK1myc,
or GFPMiro1, PINK1myc and mycParkin along with HAubiquitin.GFPMiro1 was immuno-
precipitated from FCCP (10 μM, 1 hour) or vehicle (DMSO) treated samples in a strin-
gent buffer (RIPA), samples were resolved, western blotted and immunoprecipitates were
probed with an anti HA antibody to detect HAubiquitin conjugated to the immunopu-
rified Miro. Ubiquitination assays show a robust increase in GFPMiro1 ubiquitination,
which can be seen as a high molecular weight smear in the GFPMiro1 immunoprecipi-
tates, upon FCCP treatment in cells overexpressing Parkin alone, but not PINK1 alone.
Co-expression of Parkin together with PINK1 led to a further significant potentiation
of GFPMiro1 ubiquitination, suggesting a cooperative role of the two proteins (Fig. 3.6,
ubiquitinated Miro1 when no Parkin or PINK1 are expressed with FCCP 0.88 ± 0.23,
and DMSO 1.0, when Parkin is OE with FCCP 2.17 ± 0.33, and DMSO 1.0, *p=0.027,
when PINK1 is OE with FCCP 0.88 ± 0.18, and DMSO 1.0, not significant, when PINK1
and Parkin are OE with FCCP 3.85 ± 0.48, and DMSO 1.0, **p=0.006, n=4).
To confirm that the HAubiquitin positive high molecular smear was indeed Miro1 ubiqui-
tination, purified ubiquitinated Miro1 samples were subjected to digestion with deubiq-
uitinases (DUBs), a class of enzymes that specifically hydrolyses poly-ubiquitin chains.
To this aim the enzymes vOTU (viral Ovarian Tumor Ubiquitinase) and USP21 (Ubiq-
uitin Specific Protease 21) were used. vOTU is a DUB that can cleave ubiquitin chains
(but not mono-ubiquitin attached to substrate proteins) whereas USP21 is a very ac-
tive, chain aspecific DUB (Ye et al., 2011; Akutsu et al., 2011). Ubiquitinated GFPMiro1
samples extracted and purified from Parkin OE SH-SY5Y previously treated with the
mitochondrial uncoupler FCCP (10 μM, 1 hour), were subjected to digestion with either
vOTU or USP21. Samples were resolved on a dual acrylamide percentage SDS-PAGE (8
and 15%) and western blotted on PVDF membrane (which has smaller pores than nitro-
cellulose) due to the small size of mono-ubiquitin (8 kDa). Western blot analysis showed
that incubation with USP21 resulted in the complete cleavage of GFPMiro1 ubiquitin
chains, rescue of the protein at its expected molecular weight (100 kDa) and release of
mono-ubiquitin. Incubation with vOTU, instead, resulted in an incomplete cleavage of
the GFPMiro1 bound ubiquitin chains, with the long ones being cleaved, and residual
short chains, likely mono- or multi-mono-ubiquitination. A partial rescue of the protein
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Figure 3.6: Miro1 is ubiquitinated by Parkin.
COS-7 cells transfected with GFPMiro1, GFPMiro1 and mycParkin, GFPMiro1 and
PINK1myc, or GFPMiro1, PINK1myc and mycParkin along with HAubiquitin. Cells were
treated with FCCP (10 μM, 1 hour) or vehicle (DMSO), lysed and GFPMiro1 was im-
munopurified. Samples were resolved by SDS-PAGE. Membranes were probed with
anti-HA, anti-GFP and anti-myc antibodies. Western blot analysis shows that FCCP
treatment triggers Miro1 ubiquitination detected as a HA positive high molecular weight
smear, when mycParkin or PINK1myc and mycParkin were overexpressed, but not with
PINK1mycoverexpression only (*p=0.027, **p=0.006, n=4 independent experiments).
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at 100 kDa and release of free ubiquitin were also observed. These data further confirm
that the HAubiquitin positive smear is exclusively Miro1 poly-ubiquitination (Fig. 3.7).
FCCP-dependent ubiquitination of endogenous Miro1/2
To further characterise Miro1 ubiquitination, damage-induced modification of endoge-
nous Miro1/2 was examined. Neuronal dopaminergic SH-SY5Y cells were transfected
with YFPParkin and HAubiquitin. FCCP (10 μM, 1 hour) or vehicle (DMSO) treated
samples were lysed and either incubated with non specific IgG (to control for non specific
binding) or with an antibody that specifically recognises Miro1 and 2. Antibody/antigen
complexes were then purified by incubation with protein A-conjugated beads and re-
solved by SDS-PAGE. Western blot analysis showed that endogenous Miro1/2 was
robustly ubiquitinated (Fig. 3.8 A), in a similar fashion to heterologously expressed
GFPMiro1.
Moreover, a similar experiment was carried out to confirm that endogenous ubiquitin
takes part in Parkin-mediated Miro1/2 ubiquitination. Dopaminergic SH-SY5Y cells
stably overexpressing FlagParkin were treated with FCCP (10 μM, 1 hour) or vehicle
(DMSO). Samples were subjected to immunoprecipitation by incubation with a Miro1/2
specific antibody or non specific IgG as a control, followed by the addition of protein
A-conjugated beads to purify the protein complexes. Samples were resolved by SDS-
PAGE and western blotted. Membranes were probed with an antibody that specifically
detects endogenous mono- and poly-ubiquitin (FK2), which confirmed the presence of en-
dogenous ubiquitin in the FCCP-induced Miro1/2 ubiquitination smear. Whole lysates
(inputs) were probed Miro1/2, FlagParkin and actin antibodies to confirm similar loading
(Fig. 3.8 B).
PINK1 dependency of Miro ubiquitination
PINK1 is known to act upstream of Parkin and, as previously shown in Fig. 3.3, specific
knock down of PINK1 blocks Parkin-dependent degradation of Miro1 and Mfn1. More-
over overexpression of this mitochondrial serine threonine kinase potentiates Parkin-
dependent ubiquitination of Miro1 in COS-7 cells (Fig. 3.6). To examine whether
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Figure 3.7: Miro1 ubiquitin chains are cleaved by vOTU and USP21.
vOTU and USP21 digested GFPMiro1, purified from FCCP treated (10 μM, 1 hour)
Parkin OE SH-SY5Y cells. Samples were resolved by SDS-PAGE, western blotted, and
membranes were probed with anti-HA and anti-GFP antibodies. Incubation with vOTU
results in shortening of Miro1 ubiquitin chains to small chains, likely mono- or multi-
mono-ubiquitination, whereas incubation with USP21 results in the complete cleavage
of Miro1 ubiquitination. In both cases there is a rescue of GFPMiro1 at 100 kDa and
release of free ubiquitin (8 kDa).
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Figure 3.8: Endogenous Miro1 is ubiquitinated upon mitochondrial damage.
(A) Ubiquitination assay of endogenous Miro1/2 in SH-SY5Y cells, heterologously ex-
pressing YFPParkin and HAubiquitin. Following FCCP (10 μM, 1 hour) or vehicle
(DMSO) treatment, cells were lysed and incubated with either an antibody recognis-
ing Miro1/2 or a non specific IgG as a control. Following incubation with protein A-
conjugated beads to purify the antibody/antigen complexes, samples were resolved by
SDS-PAGE and western blotted. Mitochondrial depolarisation induced robust ubiquiti-
nation of Miro1/2 as visualised by the increase in the HA positive smear. The membrane
was stripped and reprobed with anti-Miro1/2 antibody to confirm the presence of the
immunopurified protein (n=3 independent experiments). (B) Parkin OE SH-SY5Y cells
were treated with FCCP (10 μM, 1 hour) or DMSO. Lysates were subjected to im-
munoprecipitation with Miro1/2 or IgGs. Immunopurified samples and whole lysates
were run on a SDS gel and western blotted. FCCP treatment induces Parkin-dependent
ubiquitination of endogenous Miro1/2, which can be detected with an antibody against
endogenous mono- and poly-ubiquitin (FK2). Immunopurified samples were reprobed
with anti-Miro1/2 antibody to confirm the IP, and whole lysates (bottom panel) were
probed for Miro1/2, FlagParkin and Actin to confirm similar loading (n=3 independent
experiments).
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PINK1 is necessary for Parkin-mediated ubiquitination of Miro1, ubiquitination as-
says were performed in control shRNA or PINK1 specific shRNA expressing SH-SY5Y
cells transiently transfected with YFPParkin to enhance mitophagy. Analysis of en-
dogenous Miro1/2 ubiquitination by western blotting showed that FCCP-dependent,
Parkin-mediated Miro1/2 ubiquitination was drastically blocked when PINK1 was si-
lenced, further confirming the essential role of the kinase in the recruitment and activa-
tion of Parkin on damaged mitochondria (Fig. 3.9, ubiquitinated Miro mean intensity
in PINK1 shRNA cells 0.16 ± 0.07 compared with ubiquitinated Miro1 intensity in non
silencing shRNA expressing cells 1.0; **, p = 0.006; ***, p = 0.0008, n=3 independent
experiments).
Mitochondrial damage-dependent regulation of the interaction between
Miro1 and the TRAKs
Since Miro1 together with the TRAK adaptors form a complex that couples the mito-
chondria to the cellular motors, to investigate the impact of Miro1 ubiquitination on
mitochondrial transport, Miro1 binding to the kinesin adaptors TRAK1 and TRAK2
following mitochondrial damage was investigated. Parkin OE SH-SY5Y cells were het-
erologously transfected with either GFPTRAK1 or GFPTRAK2, alone (to control for as-
pecific binding) or together with mycMiro1. Co-immunoprecipitation experiments from
FCCP (10 μM, 1 hour) or vehicle (DMSO) treated samples were analysed by west-
ern blotting. Mitochondrial damage triggered mycMiro1 laddering (as seen in the im-
munoprecipitated sample and in the inputs), but did not affect its interaction with
GFPTRAK1 (Fig. 3.10 GFPTRAK1/Miro1 co-immunoprecipitation upon FCCP treat-
ment 1.17 ± 0.11, compared to 1.0 in control). Unexpectedly, an increase in the levels of
overexpressed GFPTRAK2 upon FCCP treatment was consistently observed (Fig. 3.10,
GFPTRAK2 levels upon FCCP treatment 1.90 ± 0.09, compared to 1.0 in control condi-
tions, **p=0.01, n=3). This mirrored an increase in the binding of mycMiro1 to TRAK2,
possibly due to the higher levels of the protein (Fig. 3.10, GFPTRAK2/Miro1 coIP upon
FCCP treatment 3.18 ± 0.79, compared to 1.0 in control, *p=0.04, n=3 independent
experiments).
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Figure 3.9: Miro1 ubiquitination is dependent on the mitochondrial kinase PINK1.
Endogenous Miro1/2 ubiquitination assays in SH-SY5Y cells stably expressing either a
non silencing (NS) shRNA or a PINK1 specific shRNA and transiently transfected with
YFPParkin and HAubiquitin. Following treatment with FCCP (10 μM, 1 hour) or DMSO,
cells were lysed and incubated with either an antibody against Miro1/2 or non specific
IgGs to control for aspecific binding. Protein complexes were purified by incubation with
protein A-conjugated beads, resolved by SDS-PAGE and western blotted. As visualised
by the increase in the HA positive smear, FCCP treatment induced robust ubiquitination
of Miro1/2 in non silencing shRNA expressing cells, but not in PINK1 shRNA expressing
SH-SY5Y cells. The membrane was stripped and reprobed with anti-Miro1/2 antibody
to confirm the presence of the immunopurified protein (**p = 0.006; *** p = 0.0008,
n=3 independent experiments).
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Figure 3.10: Mitochondrial damage regulation of Miro1 interaction with the TRAK
proteins.
(A) Co-immunoprecipitation experiments carried out in Parkin OE SH-SY5Y cells tran-
siently transfected with GFPTRAK1 or GFPTRAK2, alone or with mycMiro1. Sam-
ples were resolved, western blotted and membranes probed with anti-GFP, anti-myc,
anti-Flag and anti-actin antibodies. Treatment with FCCP (10 μM, 1 hour) de-
termined mycMiro1 laddering, but did not affect its interaction with GFPTRAK1.
GFPTRAK2 levels were instead altered by FCCP treatment, this increase mirrored an
increased interaction with mycMiro1. (B, C) Quantification of TRAKs levels in the co-
immunoprecipitation and in the input after FCCP treatment were normalised to their
control (n=3 independent experiments, *p=0.04, **p=0.01).
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Discussion
In this Chapter multiple experiments have demonstrated the mitochondrial damage-
induced turnover and ubiquitination of the Miro mitochondrial trafficking complex. Us-
ing neuronal dopaminergic SH-SY5Y cells as a model system, a robust loss of Miro was
detected upon mitochondrial impairment. This process was found to be facilitated by
Parkin overexpression and inhibited by PINK1 down regulation (Fig. 3.2 and Fig. 3.3),
similar to recent reports in HEK 293 cells (Wang et al., 2011b; Liu et al., 2012) and in
agreement with the current model that places PINK1 and Parkin as master regulators
of mitophagy. In fact, if PINK1 is essential for Parkin translocation, activation and pos-
sibly stabilisation on the OMM, Parkin is necessary for the initiation of mitophagy and
the recruitment of the autophagic machinery. Miro1 regulation following mitochondrial
impairment was found to be disrupted in a PD patient-derived fibroblasts, which lack
functional Parkin, indicating that this pathway might be affected in PD.
Miro loss at its expected molecular weight corresponded to a robust increase in the
ubiquitination of the protein which determined its shift to higher molecular weights.
In this Chapter the damage-induced loss of Miro was examined and an initial charac-
terisation of its ubiquitination was carried out, however, an in depth analysis of Miro1
processing following ubiquitination will be analysed in Chapter 4. The Mitofusins, key
GTPases involved in mitochondrial fusion, are one of the first described substrates of
the PINK1/Parkin pathway. Damage-induced degradation of these proteins following
their ubiquitination by Parkin is believed to promote the segregation of damaged mito-
chondria from the functional mitochondrial network by targeting their fusion machinery.
It is possible that Miro ubiquitination/degradation has a similar role in the isolation of
impaired organelles. Wang and collaborators have shown that Parkin-dependent degra-
dation of Miro causes mitochondrial arrest (Wang et al., 2011b). However, it is still
unclear whether ubiquitination of Miro has a role per sé in the regulation of mito-
chondrial transport or it is solely a necessary step in the protein’s degradation. Miro
is a key protein in the mitochondrial transport machinery, coupling mitochondria to
the cellular motors and trafficking adaptors, Miro mediates mitochondrial transport.
Miro ubiquitination could directly impact on the trafficking of mitochondria, for exam-
ple facilitating retrograde versus anterograde mitochondrial trafficking, or the ubiquitin
chains could sterically hinder Miro association (or functional interaction) with the mi-
crotubule motor proteins leading to mitochondrial arrest. Ubiquitination of Miro1 could
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also mediate novel protein-protein interactions which could promote the regulation of
mitochondrial trafficking or mitophagy. For example HDAC6 has been shown to bind
poly-ubiquitinated proteins and link them to the dynein motors, mediating their traf-
ficking to the cell soma (Kawaguchi et al., 2003). HDAC6 was also reported to promote
the activation of an actin-remodelling machinery that favours autophagosome–lysosome
fusion. P62 instead links poly-ubiquitinated proteins to LC3, a key component of the
autophagosome, thus promoting autophagy (Lee et al., 2010).
Once damaged mitochondria are isolated, an appropriate machinery should be in place
to promote their degradation. This is likely to be particularly important in very complex
cells like neurons, where mitochondria can be damaged in the periphery (at the tip of the
axon, or in the dendritic arborization). Although in neurons, autophagosomes have been
shown to form distally and mature on their way to the cell soma where they can then fuse
with the lysosomes and degrade their cargo (Maday et al., 2012), Cai and colleagues have
reported that, in cortical neurons, mitochondrial damage-induced mito-autophagosomes
are only formed in the neuronal soma, where they are then degraded (Cai et al., 2012).
Recently, however, Ashrafi and colleagues have shown that damaged mitochondria can
be cleared at a peripheral level in neurons (Ashrafi et al., 2014), suggesting that both
mechanisms can occur, possibly depending on the extent of damage and on the overall
health of the cell. When peripheral isolated damaged mitochondria need to be carried
back to the cell soma, an appropriate machinery that identifies them and transports
them should be in place. It would be interesting to know whether ubiquitination of
Miro could have a role in this mechanism, possibly switching the transport directionality
upon damage (before Miro1 is degraded) or, for example, moving from a Miro1-based
transport to a Miro2-based transport. Miro2 has half the amount of lysine residues
compared to Miro1, suggesting the possibility of a different ubiquitination-dependent
regulation between the two proteins. Miro2-mediated mitochondrial trafficking has not
been thoroughly studied, however, it would be interesting to investigate whether the two
mechanisms are different.
Recent reports have shown that mitochondria-derived vesicles (MDV) can be targeted
to lysosomes and peroxisomes (Soubannier et al., 2012; Neuspiel et al., 2008). Formation
of these vesicles is promoted by oxidative stress. Interestingly MDVs are formed in a
Drp1 and mitochondrial membrane potential independent way, and can contain both
inner and outer mitochondrial membranes, preserving membrane polarization. MDVs
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are also found to be engulfed in multivesicular bodies (MVB), that in turn deliver them
to lysosomes for degradation (Soubannier et al., 2012). MDVs generation was found
to be associated with local and restricted accumulation of PINK1 and Parkin recruit-
ment (Mclelland et al., 2014), therefore it would be interesting to investigate whether
formation of these structures could mediate the degradation of distal mitochondria by
delivering them to the lysosomes.
Interestingly, TRAK1 levels were found to be stable following mitochondrial damage
(Fig. 3.2 and Fig. 3.4). TRAK1 and TRAK2 are known not to be only restricted
to mitochondria, but also to be associated with other cellular compartments, such as
endosomes (Kirk et al., 2006; Webber et al., 2008; MacAskill et al., 2009a). Thus mi-
tochondrial damage could, in principle, relocate these proteins to other cellular com-
partments and promote mitochondrial arrest. According to this, a previous report has
found TRAK1 to be removed from the mitochondria when PINK1 and Parkin were
co-expressed (Wang et al., 2011b), however, in the experiments described in this Chap-
ter variations in the levels of PINK1 or Parkin did not impact on Miro1 or TRAK1
levels as described in the above cited report. FCCP-triggered mitochondrial damage in-
duced Miro1 ubiquitination, yet this did not affect the Miro1/TRAK1 interaction (Fig.
3.10). This suggests that, at least one hour after mitochondrial damage, the levels of
TRAK1 on the mitochondria are unaffected. Unexpectedly, heterologously expressed
GFPTRAK2 levels were found to be increased upon FCCP treatment in the neuronal,
Parkin OE SH-SY5Y cells. This increase in the protein amount mirrored an increased
interaction with Miro1 following mitochondrial damage. The enhanced TRAK2 lev-
els could be either due to increased translation (which is unlikely since the protein is
heterologously expressed, hence the mRNA lacks its UTR domains necessary for the
translation regulation), or to decreased degradation, which could be favoured by sta-
bilising post-translational modifications or changes in protein interactions. The role of
TRAK1 and TRAK2 post-translational modifications in their stability has not been in-
vestigated, however, both TRAKs have several phosphorylation sites and are known to
be O-GlcNAcylated by OGT on conserved serine residues (Iyer et al., 2003; Trinidad
et al., 2012). Recently Pekkurnaz and colleagues have shown that glucose-induced O-
GlcNAcylation of TRAK1 reduces mitochondrial trafficking (Pekkurnaz et al., 2014),
therefore increased TRAK levels on the mitochondria does not necessarily translate to
positive regulation of mitochondrial trafficking.
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Following one hour incubation with FCCP Miro1 is ubiquitinated but not degraded
(see Chapter 4), in addition, the TRAK adaptors can still bind the protein. The current
model of the mitochondrial transport machinery predicts Miro to bind the kinesin motors
and the TRAKs to bind to both Miro and the kinesins (MacAskill and Kittler, 2010). It
would be interesting to investigate whether, when Miro is degraded, the TRAKs can be
still localised to the mitochondria, or they are recruited to other cellular compartments.
Moreover if the TRAKs can be bound to the mitochondria in the absence of Miro, it
would be interesting to know whether they are able to mediate mitochondrial trafficking
and whether this can be promoted in both antero- and retrograde directions. Alter-
natively, due to their dual localisation (mitochondria/endosomes) these proteins could
promote the delivery of damaged mitochondria to the endosomal/lysosomal pathway
(Webber et al., 2008).
Overall in this Chapter the damage-induced, PINK1/Parkin-dependent regulation of
Miro has been analysed. Although Miro1 ubiquitination and degradation has been estab-
lished and has been confirmed by other groups, many open questions remain concerning
how this modification can affect mitochondrial trafficking and processing of the damaged
mitochondrion. The functional consequence of the increase in TRAK2 is unclear and
further work will be needed to shed light on the role of this protein in mitophagy.
Chapter 4
Characterisation of Miro1
ubiquitination
Introduction
As shown in Chapter 3 mitochondrial damage triggers PINK1 and Parkin-dependent
Miro1 ubiquitination. However, whether this modification only results in the rapid
degradation of the protein and consequent mitochondrial arrest, or it is an active sig-
nalling component of a cascade that initiates with mitochondrial damage and leads to
correct mitochondrial disposal is still unclear. Wang and collaborators have shown that,
upon mitochondrial damage, Miro was found to be phosphorylated on serine 156, thre-
onine 298 and threonine 299. However, only serine 156 phosphorylation was shown to
be required for Miro degradation by Parkin (Wang et al., 2011b). Nevertheless, whether
Miro1 phosphorylation by PINK1 is crucial for its recognition and ubiquitination by
Parkin is still under debate (Liu et al., 2012).
As previously described Miro proteins are characterised by several signalling domains:
two EF-hand calcium binding domains flanked by two GTPase domains. Miro EF-hands
have been shown to have a crucial role in sensing calcium levels. In fact calcium binding
to these domains is likely to induce a change in the protein’s conformation, that leads
to the uncoupling of Miro (and the mitochondrion) from the kinesin motor proteins
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(MacAskill et al., 2009b). The GTPase domains function is instead less clear. Constitu-
tively active or inactive GTPase domain 1 has been associated with distinct recruitment
capabilities of the trafficking adaptor TRAK2 (MacAskill et al., 2009a), possibly affect-
ing the transport directionality. Whether regulation of these Miro signalling domains,
either by calcium binding to the EF-hands or GTP/GDP binding to the GTPase do-
mains, could modulate Miro processing and therefore mitochondrial transport following
damage, would be interesting to explore.
Ubiquitination can target one (e.g. PCNA) or more (e.g. Arc, EGFR) specific lysines
within a protein, or more broadly can target lysines within a specific protein domain
(e.g. p53) (Hoege et al., 2002; Mabb et al., 2014; Haglund et al., 2003b; Carter et al.,
2007). Human Miro1 comprises of approximately 40 lysines (and Miro2 20) and the
identification of which lysine residue(s) on Miro are targeted by ubiquitination, would
be extremely important to further study the role of this post-translational modification
in mitochondrial transport and mitophagy.
Ubiquitin can be attached to a substrate protein as a single molecule or as a polymeric
chain. In fact, ubiquitin contains seven lysines (K6, K11, K27, K29, K33, K48, K63) and
one methionine (M1) that can act as acceptor sites for further ubiquitination, resulting
in the formation of poly-ubiquitin chains (see Fig. 1.7 in the introduction). Protein
mono-ubiquitination is often associated with endocytosis and signalling (Haglund et al.,
2003a), whereas, more complex long ubiquitin chains are often linked to different cellu-
lar processes. Depending on which residue within the ubiquitin molecule mediates the
chain formation, this will determine the topology of the chain. In fact, structural and
NMR analysis of polymeric chains has shown that K6 and K48-mediated chains display
a compact structure (where adjacent moieties interact with each other), whereas K63
and M1-linked chains are linear. Interestingly K11-mediated linkage can be found in
both open and closed conformations (Komander and Rape, 2012). Moreover ubiquitin
chains can be either homogeneous, when the same linkage-type is repeated across the
whole chain, or mixed, when multiple linkages are involved in the chain elongation. The
different chain conformations determined by the specific linkages are likely to deter-
mine interaction with specific partners which ultimately will result in specific cellular
outcomes. Among the eight different chain types, only a few (referred as typical) have
been extensively characterised. K48-mediated linkage, for example, has been strongly
associated with proteasomal degradation (Mallette and Richard, 2012), whereas K63-
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linked chains have been shown not to have a degradative function, but to be primarily
associated with signalling and protein-protein interaction (Chen and Sun, 2009). The
remaining chain types are often referred as atypical, due to their poor characterisation.
Only recently these atypical chains are starting to be studied, K6-type linkage has been
suggested to have a non-degradative role, whereas K11-mediated ubiquitination seems to
be associated with protein degradation. K27-mediated ubiquitin chains have been found
to accumulate on damaged mitochondria, while K29- and K33-type chains have been
associated with both degradative and non-degradative roles (Kulathu and Komander,
2012).
An open question remains as to what determines the chain type. When RING domain
or U-Box ligases are involved, it is likely that the conjugating E2 enzyme defines the
linkage type, whereas with HECT and RING-in-between-RING (RBR) domain ligases,
such as Parkin, that form a thioester intermediate with ubiquitin molecules, the ligases
themselves are believed to determine the chain composition (Komander and Rape, 2012).
In this Chapter the temporal dynamics of Miro1 ubiquitination/degradation upon mi-
tochondrial damage in the dopaminergic cell line SH-SY5Y have been analysed by bio-
chemical and immunocytochemistry experiments. The role of S156, T298 and T299
phosphorylation in Miro1 ubiquitination and degradation has been investigated using
phospho-null and phospho-mimic (only for S156) Miro1 constructs. The possible inter-
play between Miro1 signalling domains and its ubiquitination has been analysed using
ΔEF mutant Miro1 (lacking the calcium binding ability) and GTPase active (V13), or
inactive (N18) mutants. In order to characterise further the role of Miro1 ubiquitination,
ubiquitin mutants that allow either one specific chain type, or every chain type apart
from a specific one have been used. Data on ubiquitin chain linkage have been further
corroborated by restriction analysis with specific deubiquitinases (UbiCRest).
Results
Kinetics of Miro ubiquitination and degradation
Miro ubiquitination could lead to its rapid degradation and removal from the OMM, al-
ternatively Miro could remain on the mitochondrial membrane in an ubiquitinated form
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where it may act in other ubiquitination-mediated processes such as signalling. To better
understand the dynamics of Miro1 ubiquitination and degradation, ubiquitination assays
were performed where Parkin OE SH-SY5Y cells, transiently transfected with GFPMiro1
and HAubiquitin, were incubated for several time points, from 5 minutes to 3 hours with
the mitochondrial uncoupler FCCP (10 μM). Cell lysates were collected, GFPMiro1 was
immunopurified and samples were resolved by SDS-PAGE. Western blot analysis showed
that the HA positive ubiquitination smear of GFPMiro1 could be detected as little as
20 minutes after mitochondrial damage, and appeared to remain stable for at least one
hour, reaching its maximum intensity at 40-60 minutes after FCCP treatment. This in-
crease in the protein ubiquitination corresponded to a loss of GFP positive Miro1 at its
expected molecular weight, 100kDa. Thus, at 1 hour of FCCP treatment Miro1 appears
to be fully ubiquitinated, hence undetectable at 100 kDa. At later time points (120-180
minutes) HA positive GFPMiro1 ubiquitination smear decreased, corresponding to the
actual degradation of the protein by proteasomal activity. This effect could in fact be
blocked by pre-incubation of the samples with the proteasomal inhibitor MG-132 (30
μM, 30 minutes pre-incubation, Fig. 4.1. In (B) the mean intensities of ubiquitinated
GFPMiro1 at 0 minutes 0.12 ± 0.08, at 5 minutes 0.08 ± 0.03, at 10 minutes 0.09 ±
0.04, at 20 minutes 0.41 ± 0.09, at 40 minutes 1.24 ± 0.23, at 60 minutes 1.0 ± 0.0, at
120 minutes 0.52 ± 0.09, at 180 minutes 0.37 ± 0.08; immunoprecipitated GFPMiro1 at
0 minutes 1.0 ± 0.0, at 5 minutes 1.09 ± 0.14, at 10 minutes 0.95 ± 0.10, at 20 minutes
0.71 ± 0.18, at 40 minutes 0.16 ± 0.10, at 60 minutes 0.05 ± 0.03, at 120 minutes 0.02 ±
0.01, at 180 minutes 0.01 ± 0.01; n=3, ***p<0.005. In (C) mean intensity of GFPMiro1
ubiquitination at 180 minutes with MG-132 1.33 ± 0.24 compared to 0.37 ± 0.08 at 180
min without MG-132, immunoprecipitated GFPMiro1 at 180 minutes with MG-132 0.15
± 0.05, compared to immunoprecipitated GFPMiro1 at 180 minutes without MG-132
0.01 ± 0.01, n=3, **p=0.006).
MG-132 treatment has been reported not only to block proteasomal activity, but also
to affect mitophagy (Tanaka et al., 2010). Inhibition of Miro1 degradation by MG-132,
instead of being specifically caused by proteasomal impairment, could therefore be due
to an overall block of mitophagy. To better understand which pathway was involved
in Miro1 degradation, the effect of proteasomal block was compared to that of au-
tophagy inhibition by Bafilomycin 1A. Bafilomycin 1A is an inhibitor of the vacuolar type
H+-ATPase (V-ATPase) which blocks the acidification of the lysosomes, therefore in-
hibiting autophagy. Parkin OE SH-SY5Y cells heterologously expressing GFPMiro1 and
CHAPTER 4. CHARACTERISATION OF MIRO1 UBIQUITINATION 107
Figure 4.1: Temporal dynamics of Miro1 ubiquitination and degradation.
(A) FlagParkin stably overexpressing SH-SY5Y cells were incubated with FCCP (10
μM) for several time points before ubiquitination assays were performed. Samples were
resolved and western blotted, membranes were probed for HA and GFP. HA positive
GFPMiro1 ubiquitination can be detected after 20 minutes incubation with the mito-
chondrial uncoupler and peaks after 40-60 minutes. Although the GFP positive Miro1
band disappears at 60 minutes, an actual decrease in the higher molecular weight species
(ubiquitinated GFPMiro1) indicating protein degradation is detected only after 120 min-
utes (2 hours). Pre-treatment with the proteasomal blocker MG-132 (30 μM, 30 minutes)
resulted in the accumulation of ubiquitinated Miro1. (B) Graph quantifying GFP pos-
itive Miro1 bands (immunoprecipitated, dashed line) and HA positive ubiquitination
smear intensity (full line) in (A). Average intensities of GFPMiro1 (IP) are normalised to
GFPMiro1 (IP) at 0 minutes, while Miro1 ubiquitination smear intensities are normalised
to the smear intensity at 60 minutes, n=3 independent experiments, ***p<0.005. (C)
Bar graph showing the quantification of the effect of MG-132 in (A), n=3 independent
experiments, **p=0.006.
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HAubiquitin were pre-incubated with either MG-132 (30 μM, 30 minutes), Bafilomycin
1A (1 μM, 30 minutes), or their respective vehicles (EtOH or DMSO) and treated with
FCCP (10 μM) for 3 hours to allow GFPMiro1 ubiquitination and degradation. Western
blot analysis of the samples revealed that MG-132 treatment, but not Bafilomycin 1A
treatment, blocked Miro1 degradation, resulting in an accumulation of the ubiquitinated
form (HA positive ubiquitination smear) of GFPMiro1 (Fig. 4.2). This result confirms
that ubiquitinated GFPMiro1 is processed by the proteasome.
To further investigate Miro stability on the OMM upon mitochondrial damage, immuno-
histochemical experiments were performed. GFPMiro was expressed together with the
mitochondrial intermembrane space-targeted fluorescent protein mito-LSS (Large Stoke
Shift)-mKate2 in Parkin OE SH-SY5Y cells. Cells were treated for several time points
(1-6 hours), fixed and imaged with a laser scanning confocal microscope. Fluorescence
in both channels was quantified with ImageJ and the levels of GFPMiro1 were normalised
to mito-LSS-mKate2. In agreement with the biochemical results (Fig. 4.1), GFPMiro1
levels were found to be stable on the OMM for at least 60 minutes after induction of
mitochondrial damage with FCCP and well beyond the initial fast ubiquitination, as
can be observed by the relatively stable levels of GFPMiro1 fluorescence signal. Only
at later stages (after 2 hours) GFPMiro1 fluorescence intensity began to decrease (Fig.
4.3 and Fig. 4.4, GFPMiro1 intensity normalised to mito-LSS-mKate2 intensity at 0
hours 1.0, at 1 hour 0.83 ± 0.14, at 2 hours 0.52 ± 0.09, at 3 hours 0.35 ± 0.003, at 6
hours 0.33 ± 0.01, n=3, **p<0.01, ***p<0.005), correlating closely with the observed
delayed degradation of ubiquitinated Miro (Fig. 4.1). These results demonstrate that in
human dopaminergic neuroblastoma cells Miro is initially rapidly ubiquitinated on the
OMM where it appears to remain in an ubiquitinated form before undergoing a slower
degradation and removal, dependent on proteasomal activity.
Miro1 degradation is VCP independent
Similar to Miro, Parkin-dependent ubiquitination of the Mitofusins has been shown to
lead to the degradation of the proteins by the proteasome. In particular valsolin con-
taining protein (VCP) or p97, an ATPase that generally participates in the extraction
of ubiquitinated proteins from the ER to promote their clearance, has been shown to
mediate the extraction of poly-ubiquitinated Mitofusins from damaged mitochondria,
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Figure 4.2: Miro1 degradation is blocked by proteasomal inhibition, but not by au-
tophagy inhibition.
Ubiquitination assay of Parkin OE SH-SY5Y cells transiently overexpressing GFPMiro1
and HAubiquitin. Treatment with FCCP (10 μM, 180 minutes) was preceded by incuba-
tion with the proteasomal inhibitor MG-132 (30 μM, 30 minutes), the lysosomal inhibitor
Bafilomycin 1A (1 μM, 30 minutes), or the respective vehicles (EtOH and DMSO). Miro1
degradation is blocked by MG-132 pre-treatment, but not by the pre-treatment with the
lysosomal inhibitor Bafilomycin 1A, as shown by the HA positive Miro1 ubiquitination
smear (n=1).
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Figure 4.3: Mitochondrial damage-induced Miro1 degradation.
FlagParkin OE SH-SY5Y cells co-transfected with GFPMiro1 and the mitochondrial
marker mito-LSS-mKate2. Confocal imaging of a FCCP (10 μM) time course exper-
iment (0-6 hours) shows a decrease over time of the GFPMiro1 fluorescence compared to
signal of mito-LSS-mKate2, scale bar = 20 µm.
CHAPTER 4. CHARACTERISATION OF MIRO1 UBIQUITINATION 111
Figure 4.4: Quantification of FCCP-dependent GFPMiro1 loss from the OMM.
Quantification of the GFPMiro1 fluorescence intensity normalised to the fluorescence
of the mitochondrial intermembrane space-targeted mito-LSS-mKate2 as shown in Fig.
4.3. Miro1 starts to be degraded only after 2 hours of FCCP (10 μM) treatment n=3
independent experiments, **p<0.01, ***p<0.005.
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allowing their degradation by the proteasome (Tanaka et al., 2010). VCP could there-
fore be involved in the retrotranslocation of ubiquitinated Miro1 from the mitochondrial
membrane. To address this idea, previously characterised SH-SY5Y cells stably overex-
pressing a control shRNA or a VCP specific shRNA were used (Bartolome et al., 2013).
mycMiro1, FlagParkin and HAubiquitin transfected cells were subjected to a FCCP (10
μM) time course (0, 1 and 3 hours) to allow the protein ubiquitination and consequent
degradation. Cells were then lysed and mycMiro1 was immunopurified. Samples were
resolved by SDS-PAGE and western blotted. If VCP was necessary for Miro1 retro-
translocation, knock down of the ATPase would result in a accumulation of Miro1 ubiq-
uitinated species. However, analysis of the HA positive mycMiro1 ubiquitination smear
showed that the protein was equally degraded in control and VCP shRNA expressing cells
(Fig. 4.5, n=3), indicating that VCP does not contribute to Miro1 processing. However,
as detected in the whole cell lysates, Mfn1 loss did not appear to be drastically blocked
by the knock down of VCP (Fig. 4.5), suggesting that other mechanisms could be in
place for the extraction of these ubiquitinated proteins from damaged mitochondria in
neuroblastoma SH-SY5Y cells.
Role of Miro1 phosphorylation in its damage-induced ubiquitination /
degradation
Wang and collaborators have demonstrated that PINK1 can phosphorylate Miro1 on ser-
ine 156, threonine 298 and threonine 299 in in vitro kinase assays. Moreover, they showed
that PINK1-dependent Miro1 phosphorylation at S156 was required for its degradation
(Wang et al., 2011b). However, whether S156 has a crucial role in the PINK1/Parkin-
dependent processing of Miro1 is currently under debate (Liu et al., 2012). To study the
role of this residue in the ubiquitination and degradation of Miro1, S156 was mutated
to phospho-null Miro1 (S156A), which cannot be phosphorylated due to the lack of an
hydroxyl group on its side chain, and phospho-mimic Miro1 (S156E), which mimics the
negative charge given by the phosphate group with the negative charge present on the
glutamic acid side chain. Phospho-null and phospho-mimic GFPMiro1 mutants were
transfected along with HAubiquitin into Parkin OE SH-SY5Y cells. Cells were treated
with FCCP (10 μM, 1 hour) or vehicle (DMSO) and ubiquitination assays were per-
formed in order to investigate the contribution of this residue in the damage-induced
processing of Miro1. Western blot analysis revealed no difference in the ubiquitination of
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Figure 4.5: Miro1 loss is VCP-independent.
(A) Control or VCP shRNA overexpressing SH-SY5Y cells were transfected with
mycMiro1, FlagParkin and HAubiquitin. Cells were subjected to a FCCP (10 μM) time
course (0, 1, 3 hours), lysed and mycMiro1 was immunopurified. Immunopurified samples
and whole lysates were resolved by SDS-PAGE and western blotted. Miro1 HA posi-
tive ubiquitination smear was similar in control or VCP shRNA overexpressing cells,
indicating that VCP is not required for ubiquitinated Miro1 processing. Parkin expres-
sion is confirmed in the whole cell lysates. (B) Quantification of Miro1 HA positive
ubiquitination smear. Values are normalised to control (n=3 independent experiments).
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S156A or S156E Miro1 mutants compared to WT. Moreover, both mutants were readily
lost at their expected molecular weight (100kDa, Fig. 4.6).
Even though it did not affect Miro1 ubiquitination or loss upon 1 hour FCCP treat-
ment (10 μM), PINK1-dependent phosphorylation of Miro1 at S156 could modulate the
stability of the protein, for example by facilitating the temporal dynamics of Miro1 ubiq-
uitination/degradation. To investigate this, a time course experiment was performed,
where WT or phospho-null S156A GFPMiro1 were transiently transfected into Parkin
OE SH-SY5Y cells. Cells were then treated for several time points (20, 40, 60 min-
utes) with FCCP (10 μM), so that a delay in ubiquitination of the phospho-null mutant
could be detected. However, also at early stages no difference could be detected in
the ubiquitination dynamics between WT and phospho-null S156A GFPMiro1 (Fig. 4.7,
ubiquitinated S156A Miro1 mean intensity at 0 minutes 0.19 ± 0.08, at 20 minutes 0.57
± 0.17, at 40 minutes 1.75 ± 0.47, at 60 minutes 1.0, ubiquitinated wild type Miro1
mean intensity at 0 minutes 0.04 ± 0.004, at 20 minutes 0.29 ± 0.08, at 40 minutes 0.96
± 0.22, at 60 minutes 1.0; n=3 independent experiments), suggesting that in this model
system the phosphorylation of Miro1 at S156 is not required for its FCCP-triggered
ubiquitination/degradation.
Since Miro1 was found to be phosphorylated on T298 and T299 in the presence of
PINK1 (Wang et al., 2011b), the role of these residues in the damage-induced regulation
of Miro1 was also analysed. To this end a double phospho-null construct was made
where both threonines were mutated to alanines (GFPMiro1 T298A/T299A). Parkin OE
SH-SY5Y cells were transiently transfected with WT or T298A/T299A GFPMiro1 and
ubiquitination assays were performed following FCCP-induced mitochondrial damage
(10 μM, 1 hour). Analysis of the western blot experiments revealed that mutation of
threonines 298 and 299 to alanines did not impact on Miro1 ubiquitination or loss as can
be seen comparing the WT or T298A/T299A GFPMiro1 ubiquitination smear or inputs
(Fig. 4.8, n=3 independent experiments).
Contribution of Miro1 signalling domains in damage-induced Miro pro-
cessing
Miro1 is characterised by the presence of several signalling domains. Two EF calcium
binding hands, essential for the calcium dependent regulation of mitochondrial traffick-
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Figure 4.6: Miro1 phosphorylation at S156 does not affect its ubiquitination dynamics.
Ubiquitination assays of Parkin OE SH-SY5Y cells transiently transfected with WT,
phospho-null S156A, or phospho-mimetic S156E GFPMiro1 along with HAubiquitin. Cells
were treated with FCCP (10 μM) or vehicle (DMSO) for 1 hour, GFPMiro1 was im-
munopurified and samples analysed by western blot. Membranes were probed with anti
GFP, HA and Flag antibodies. S156A and S156E GFPMiro1 mutants show no difference
in ubiquitination (HA positive smear) compared to WT GFPMiro1 (n=3 independent
experiments).
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Figure 4.7: S156 phosphorylation does not facilitate FCCP-dependent Miro1 ubiquiti-
nation/loss.
(A) Parkin OE SH-SY5Y cells transiently transfected with WT or S156A GFPMiro1 and
HAubiquitin were subjected to a FCCP (10 μM) time course before the ubiquitination
assay was carried out. Samples were resolved western blotted and membranes were
probed with anti GFP, HA Flag and actin antibodies. Analysis of the intensities of the
samples treated with FCCP (10 μM) for 20, 40 and 60 minutes revealed no significant
difference in the ubiquitination dynamics of S156A mutant compared to WT GFPMiro1.
(B) Quantification of this effect, full lines represent the quantification of the HA positive
ubiquitination smear, whereas dashed lines represent the quantification of the GFP
positive immunopurified protein (n=3 independent experiments).
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Figure 4.8: T298 T299 are not required for the regulation of FCCP-mediated Miro1
ubiquitination and loss.
Parkin OE SH-SY5Y cells transfected with WT or T298A/T299A GFPMiro1 along with
HAubiquitin, were treated with FCCP (10 μM, 1 hour) or vehicle (DMSO) before ubiq-
uitination assays were carried out. Western blot analysis shows no difference in the
ubiquitination of WT or T298A/T299A mutant GFPMiro1 detected by the HA posi-
tive high molecular weight smear, or in the loss of the protein detected by GFP in the
immunoprecipitated samples or in the inputs. Similar loading is confirmed by actin
immunoreactivity (n=3 independent experiments).
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ing, are flanked by two GTPase domains, whose function is less well characterised. To
investigate whether the regulation of Miro via its signalling domains could affect the
damage-induced ubiquitination of the protein, previously described GFPMiro1 mutants
lacking the calcium sensitivity (ΔEF, with the double mutation E208K and E328K), con-
stitutively active GTPase1 (V13) and inactive (N18) were used (Fransson et al., 2003,
2006). Parkin OE SH-SY5Y cells transfected with ΔEF, V13, N18 or WT GFPMiro1
were FCCP (10 μM, 1 hour) or vehicle (DMSO) treated, GFPMiro1 was immunopuri-
fied from the samples and ubiquitination was tested by western blotting. Analysis of
GFPMiro1 ubiquitination smears revealed no difference between WT and the mutant
forms of Miro1 (Fig. 4.9, n=2).
Lysine residues involved in Miro1 ubiquitination
Identifying the lysine residues within Miro1 that mediate its ubiquitination would be of
crucial importance in the study of the damage-induced regulation of this protein. Mass
spectrometry reports have found a few Miro1 lysine residues to be ubiquitinated, in par-
ticular K153, K182, K187, K194 and more recently K572 (Wagner et al., 2011; Sarraf
et al., 2013; Kazlauskaite et al., 2014a). In order to investigate the importance of these
different residues, a lysine-null Miro1 construct was created, where all the lysines (41
residues) were substituted by arginines (Miro1 allR, synthesised by Invitrogen) to then
reintroduce by site-directed mutagenesis the single lysines of interest. Since the exten-
sive mutagenesis could affect the protein folding and/or subcellular localisation and the
lack of lysines would impede allR Miro1 processing by the ubiquitin-proteasome system,
this mutated construct expression and localisation were tested by immunocytochemistry
and western blotting. AllR mycMiro1 was expressed in HeLa cells and its subcellular lo-
calisation was analysed and compared with that of WT mycMiro1. Although the cells
where the expression of the construct was higher exhibited an altered and aggregated
mitochondrial network, when allR mycMiro1 was expressed at lower levels, the mitochon-
drial network appeared normal, and allR mycMiro1 showed a mitochondrial localisation
similar to WT mycMiro1 (Fig. 4.10 A). To further test the construct expression and
Parkin-mediated processing, WT or allR mycMiro1 were expressed in HeLa cells together
with YFPParkin. Following FCCP (10 μM, 1 hour) or vehicle (DMSO) treatment, cells
were lysed, samples resolved by SDS-PAGE and western blotted. AllR mycMiro1 was
expressed at lower levels compared to WT, however, FCCP treatment did not induce
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Figure 4.9: Miro1 EF hand and GTPase domains do not influence the protein FCCP-
induced ubiquitination.
Parkin OE SH-SY5Y cells transiently transfected with WT, ΔEF, V13 or N18 GFPMiro1
together with HAubiquitin were subjected to FCCP (10 μM, 1 hour) or vehicle (DMSO)
treatment. Western blotted samples were probed with anti HA, GFP and Flag anti-
bodies. Analysis of immunopurified GFPMiro1 showed no difference in the HA positive
ubiquitination smear of the mutants compared to WT (n=2 independent experiments).
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a loss of the protein at its expected molecular weight or its laddering as with the WT
protein. To control that the expression of allR Miro1 does not alter the processing of
other PINK1/Parkin substrates the levels of Mfn1 were tested. FCCP induced a loss in
the fusion protein when coexpressed with both Miro1 constructs, indicating that allR
mycMiro1 does not affect Parkin mediated ubiquitination of other substrates (Fig. 4.10
B).
K27-type ubiquitination of Miro by a PINK1 and Parkin complex in
dopaminergic neuroblastoma cells
Ubiquitin can be bound to lysine residues of a substrate protein as a single molecule
or in the form of a polymeric chain. In fact, the initial methionine or one of the seven
lysines within ubiquitin can act as acceptor sites for the attachment of successive ubiq-
uitin moieties. Depending on which residue within ubiquitin mediates the formation of
the chain, it will lead to different chain conformations that will, affect the functional
outcome of ubiquitination. To further investigate the role of Miro ubiquitination, chain
composition was initially studied taking advantage of ubiquitin mutants where six of
the seven lysines were mutated to arginines (referred as K only, Fig. 4.11 on the left),
therefore permissive of only one chain type. Parkin OE SH-SY5Y cells were transfected
with WT HAubiquitin, or the different ubiquitin mutants (K6, K11, K27, K29, K33,
K48, K63). Cells were treated with the mitochondrial uncoupler FCCP (10 μM, 1 hour)
and cell lysates were subjected to immunoprecipitation with either IgG (to control for
aspecific binding) or anti Miro1/2 specific antibody. Immunopurified samples and in-
puts were resolved on a SDS-PAGE and western blotted. Analysis of the HA positive
Miro1/2 high molecular weight smear revealed that K27 ubiquitin was the K only ubiq-
uitin mutant most prominently incorporated in endogenous Miro1/2 chains, K11 and
K29 HAubiquitin mutants also took part in Miro1/2 chain formation, whereas there was
very little K6, K33, K48 and K63-mediated Miro1/2 ubiquitination found (Fig. 4.12,
n=3 independent experiments).
To further confirm the contribution of K27 linkage in Miro1 ubiquitin chains, HAubiquitin
mutants in which only one lysine was mutated to arginine (referred as K-to-R mutants,
Fig. 4.11 on the right), and therefore blocking a specific chain type, were used. In
particular Parkin OE SH-SY5Y cells were heterologously transfected with WT, K6R,
CHAPTER 4. CHARACTERISATION OF MIRO1 UBIQUITINATION 121
Figure 4.10: Characterisation of allR mycMiro1.
A) Representative images of HeLa cells overexpressing either WT mycMiro1 or allR
mycMiro1 (low expression - unaltered mitochondrial network). Cells were fixed and
immunostained for mycMiro1 (red) and the mitochondrial marker TOM20 (blue). When
expressed at low levels AllRmycMiro1 showed a mitochondrial localisation similar to WT.
Scale bar = 20 μm. B) WT or allR mycMiro1 were overexpressed along with YFPParkin in
HeLa cells. Following FCCP treatment (10 μM, 1 hour) cells were lysed, samples resolved
by SDS-PAGE and western blotted. Myc immunoreactivity shows that, although allR
mycMiro1 is expressed at lower levels compared to WT, mitochondrial damage does not
cause laddering of the mutated protein. Mfn1 loss is triggered by FCCP treatment when
coexpressed both with WT and allR mycMiro1. Actin bands confirm similar loading
(n=2).
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Figure 4.11: Example of K-only and K-to-R ubiquitin mutants.
On the left a representation of a K48 ubiquitin only mutant, where every lysine apart
from K48 is mutated to arginine. This mutant is only permissive of K48-linked chains.
On the right, a representation of a K-to-R (K48R) ubiquitin mutant, where only ly-
sine 48 is mutated to R. This mutant allows the formation of every chain apart from
the K48-mediated ones. The 3D structure of ubiquitin was generated with PyMOL
(PDB=1UBQ).
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Figure 4.12: Analysis of Miro1 ubiquitin chains with K only ubiquitin mutants.
Ubiquitination assays performed in SH-SY5Y cells stably overexpressing FlagParkin and
transfected with either wild type HAubiquitin or several K only ubiquitin mutants, that
allow only specific chain types (K6, K11, K27, K29, K33, K48, K63). Endogenous
Miro1/2 was immunopurified from control or FCCP treated cells (10 μM, 1 hour), sam-
ples were resolved by SDS-PAGE and western blotted. Membranes were probed with
anti HA, Miro1/2, Flag and actin antibodies. Analysis of the HA positive Miro1/2 high
molecular weight smear reveals that endogenous Miro1/2 is primarily ubiquitinated in a
K27-dependent manner, and that K11 and K29 can also take part in Miro1/2 chain for-
mation (top panel). Inputs show similar expression of the HAubiquitin mutants (bottom
panel, n=3 independent experiments).
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K11R, K27R, the double mutant K27R/K29R or K48R. Following mitochondrial damage
triggered with FCCP (10 μM, 1 hour), cell lysates were collected and subjected to
immunoprecipitation with a non specific IgG or a Miro1/2 specific antibody. Samples
were resolved by SDS-PAGE and western blotted. Interestingly, analysis of the HA
positive Miro1 smear showed that only the K27R and K27R/K29R mutants were able
to reduce endogenous Miro1/2 ubiquitination, confirming the results obtained with the
K only HAubiquitin mutants. No difference was detected comparing WT HAubiquitin to
K6R, K11R and K48R mutants (Fig. 4.13, n=3).
Ubiquitin mutants are a tool to investigate chain linkage composition, however, overex-
pression of these mutants could bias the chain formation favouring the specific linkages
permitted. Moreover K mutations on ubiquitin could alter the conformation of the pro-
tein, possibly affecting the interaction of these mutants with E2 enzymes, E3 ligases,
or altering the chain conformation itself and consequently the interaction with ubiqui-
tin binding proteins or deubiquitinases (DUBs). To further investigate Miro1 ubiquitin
chain composition without affecting the chain formation, chain specific DUBs were used
in ubiquitin chain restriction (UbiCRest) analysis (Mevissen et al., 2013). To this end
Parkin OE SH-SY5Y cells were transiently transfected with GFPMiro1 and HAubiquitin.
After FCCP treatment (10 μM, 1 hour), ubiquitinated GFPMiro1 was immunopurified on
high affinity GFP-TRAP beads and incubated with several DUBs of distinct specificities.
Reactions were stopped by addition of denaturing Laemmli sample buffer and proteins
resolved on a dual acrylamide percentage gel (8%-15%). Proteins were transferred onto
a PVDF membrane and probed with anti HA and anti GFP antibodies. USP21 is a
highly active, ubiquitin-specific, but linkage-aspecific DUB (Ye et al., 2011). As seen
in the previous chapter (Fig. 3.7), western blot analysis of the USP21 reaction showed
that this enzyme efficiently cleaves GFPMiro1 ubiquitin chains, generating unmodified
GFPMiro1 (100 kDa), mono-ubiquitin (8 kDa, white arrowhead) and a small amount of
mono-ubiquitinated GFPMiro1. An enzyme that specifically recognizes and cleaves K27
linkages has not been identified to date. However, OTUD2, an enzyme from the ovarian
tumor ubiquitinases, shows linkage-preference for K11, K27, K29, and K33 linkages and
is the only DUB cleaving K27 chains efficiently (Mevissen et al., 2013). Incubation of
GFPMiro1 with increasing concentrations of OTUD2 results in a progressive shorten-
ing of high-molecular weight GFPMiro1 ubiquitination, partial rescue of GFPMiro1 at
its expected molecular weight and the formation of HA positive bands at 20 and 30
kDa (black arrowheads), which are likely to be ubiquitin dimers or trimers. The latter
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Figure 4.13: Analysis of Miro1 ubiquitin chains with K-to-R ubiquitin mutants.
Ubiquitination assays performed in SH-SY5Y cells stably overexpressing FlagParkin and
transfected with either wild type HAubiquitin or several K-to-R ubiquitin mutants, which
block one specific chain type (K6R, K11R, K27R, K27R/K29R, K48R). Endogenous
Miro1/2 was immunopurified from control or FCCP treated cells (10 μM, 1 hour), sam-
ples were resolved by SDS-PAGE and western blotted. Membranes were probed with
anti HA, Miro1/2, Flag and actin antibodies. Analysis of the HA positive Miro1/2 high
molecular weight smear reveals that only the K27R and the K27R/K29R HAubiquitin
mutants affect endogenous Miro1/2 ubiquitination (top panel). Inputs show similar
expression of the HAubiquitin mutants (bottom panel, n=3 independent experiments).
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could be released from mixed-linkage chains on GFPMiro1. In contrast, incubation of
GFPMiro1 with the highly active, but Met1/linear chain specific DUB Otulin (Keusekot-
ten et al., 2013), does not affect GFPMiro1 ubiquitination (Fig. 4.14). This confirms
that GFPMiro1 comprises atypical polyubiquitin chain linkages, most likely K27-chains.
Discussion
In this Chapter the ubiquitination of Miro1 has been extensively investigated. Both
biochemical and immunohistochemical time course experiments, performed in neuronal
dopaminergic SH-SY5Y cells, have shown that, although Miro1 ubiquitination occurs
rapidly (within 20 minutes), its degradation is delayed to later time points (2-3 hours).
This suggests that the protein, which is stable in its ubiquitinated form on the OMM
for at least one hour, may participate in the regulation of damaged mitochondria. The
role of S156 and T298/T299 has been studied, however, in the model used, PINK1-
dependent phosphorylation of these residues did not impact on Miro1 turnover. Finally,
Miro1 chain type was characterised using several ubiquitin mutants (both K only and
K-to-R) and DUB restriction analysis (UbiCRest).
According to the current model, damage-induced degradation of Miro results in the
block of mitochondrial transport (Wang et al., 2011b). Whilst the data described in
the previous Chapter support the PINK1/Parkin-dependent loss of Miro, the analysis
of the kinetics of Miro ubiquitination described in this Chapter, shows that the loss of
Miro at its expected molecular weight is primarily due to a shift of the ubiquitinated
protein to higher weight species. Moreover immunohistochemical experiments confirm
that this ubiquitinated form of Miro1 is stable on the OMM for at least one hour before
being degraded by the proteasome, suggesting that Miro ubiquitination, rather than
ubiquitination-induced Miro degradation, may directly act as a rapid signal on the OMM
for mitochondrial arrest. Various mechanisms could underpin this, as mentioned in the
discussion of Chapter 3. Ubiquitination of Miro could mediate the recruitment of other
factors such as p62 and/or HDAC6 to the mitochondrial trafficking complex to promote
the transport to the cell soma and clustering of damaged mitochondria prior to their
clearance by mitophagy. Moreover, Miro ubiquitination may also either directly, or
by recruitment of HDAC6 and/or p62, impede its association with the motor proteins
leading to mitochondrial arrest.
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Figure 4.14: DUB restriction analysis confirms K11, K27 and K29 contribution to Miro1
ubiquitin chains.
Parkin OE SH-SY5Y cells were transfected with GFPMiro1 and HAubiquitin. Mitochon-
drial damage was triggered with FCCP (10 μM, 1 hour) and ubiquitinated GFPMiro1
was immunopurified. GFPMiro1 retained on GFP-TRAP beads was then incubated
with increasing amounts of OTUD2 (that specifically cleaves K11, K27, K29 and K33
mediated ubiquitin linkages), Otulin (cleaves Met-linked chains) or USP21 (chain type
aspecific DUB). Samples were first probed with anti-HA antibody to visualise GFPMiro1
ubiquitination smear and ubiquitin released from the chains and, after stripping, re-
probed with anti-GFP antibody to detect GFPMiro1. OTUD2 triggers the shortening
of GFPMiro1 ubiquitination, releases HA positive 20-30kDa species (black arrowheads),
probably ubiquitin trimers and dimers, and results in a partial rescue of the GFP pos-
itive Miro1 at 100kDa. Incubation with Otulin does not alter GFPMiro1 ubiquitination
smear, asterisk indicates cross-reactivity between Otulin and the anti-HA antibody due
to a high homology sequence. USP21 cleaves GFPMiro1 ubiquitin chains almost com-
pletely, releasing mono-ubiquitin (8 kDa, white arrowhead) and rescuing unmodified
GFPMiro1.
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At later time points (after 2 hours from damage induction) Miro is finally degraded by
the proteasome. The mechanism by which Miro1 degradation occurs has not yet been
explored. Valsolin containing protein (VCP) or p97, an ATPase that normally partici-
pates in the extraction of misfolded ubiquitinated proteins from the ER to promote their
clearance in a process called ERAD (endoplasmic-reticulum-associated protein degrada-
tion), has been shown to mediate the extraction of poly-ubiquitinated Mitofusins from
damaged mitochondria (Tanaka et al., 2010). In a similar way VCP could promote the
extraction from the mitochondrion and subsequent degradation of Miro1, however, re-
sults presented in Fig. 4.5 do not support the role of this protein in Miro1 processing
and degradation. Nevertheless a few reports have shown the recruitment of proteaso-
mal subunits to damaged mitochondria, indicating that this complex could be directly
shuttled to the damaged organelles to degrade the OMM proteins (Shiba-Fukushima
et al., 2012; Chan et al., 2011). The reason why the selective degradation of the OMM
proteins is needed for the autophagic clearance of damaged mitochondria to occur is
still unclear, yet it would be interesting to selectively block the degradation of specific
proteins (for example by targeting key lysine residues that mediate ubiquitination) to
understand how this would affect mitophagy.
Wang and colleagues have shown that PINK1 phosphorylates Miro on S156 and that
this phosphorylation is crucial for the subsequent Parkin-dependent degradation of the
protein (Wang et al., 2011b). Mutation of this key residue should therefore block Miro
ubiquitination and could be used to study the role of this post-translational modification
in mitophagy. However, in Parkin OE dopaminergic neuroblastoma SH-SY5Y cells,
mutation of S156 to non phosphorylatable alanine (S156A) neither blocked Miro loss nor
it delayed its ubiquitination kinetics (Fig. 4.6 and Fig. 4.7). Phosphorylation of Miro1
by PINK1 to regulate Miro stability and ubiquitination may, therefore, be cell specific,
possibly due to different expression levels of PINK1, Parkin, or of other regulatory factors
such as Miro protein phosphatases. In a similar way, PINK1-dependent phosphorylation
of T298 and T299 on Miro1 was found not to affect the ubiquitination dynamics of the
protein (Fig. 4.8). These data are in agreement with a more recent study (Liu et al.,
2012) and, in addition, in a screen of 16 putative PINK1 substrates (including Miro2)
only Parkin was found to be robustly phosphorylated by PINK1 in vitro (Kondapalli
et al., 2012).
With two EF hand domains and two GTPase domains Miro1 can be defined as a sig-
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nalling hub. Miro’s two EF hands determine the calcium-dependent mitochondrial stop
(Wang and Schwarz, 2009; MacAskill et al., 2009b), whereas the function of the two GT-
Pase domains is less clear. The first GTPase domain has been associated with different
affinities to the trafficking adaptor TRAK2, possibly affecting mitochondrial transport
or directionality (MacAskill et al., 2009a). However whether there is a signalling cross-
talk among these domains or they work separately is yet to be investigated. Since Miro1
ubiquitination is likely to modulate the protein’s functionality and consequently mito-
chondrial trafficking, a cross-talk mechanism could be in place between Miro1 signalling
domains and its ubiquitination. Using calcium insensitive ΔEF, constitutively active
(V13) or inactive (N18) GTPase1 Miro1 mutants, Miro1 ubiquitination was analysed,
however these mutants did not interfere with Parkin-dependent Miro1 ubiquitination
(Fig. 4.9).
The identification of Miro1 lysine residues ubiquitinated by Parkin is essential to further
investigate the role of this modification in mitochondrial trafficking and mitophagy.
Recently, Miro1 was found to be ubiquitinated on K152, K182, K187, K194 and K572
(Wagner et al., 2011; Sarraf et al., 2013; Kazlauskaite et al., 2014a). To investigate role
of these residues, a Miro1 construct where all the lysines were mutated into arginines
(allR Miro1) will be used. The lack of lysine residues could affect many aspects of this
mutant protein processing, from its subcellular localisation, to its function and turn over.
AllR Miro1 was shown to be localised on mitochondria, however whether the presence
of this mutant affects mitochondrial functionality should be tested with a membrane
potential-dependent dye, such as TMRM. Moreover the processing and functionality of
this ubiquitination-deficient construct should be analysed. By interfering with Parkin-
mediated ubiquitination allR Miro1 may allow the study of the role of Miro1-dependent
mitochondrial trafficking in mitophagy.
Ubiquitin chain topology can determine the cellular outcome of ubiquitination. To
characterise further Parkin-dependent Miro processing, the composition of its ubiquitin
chains was analysed utilising ubiquitin mutants and UbiCRest experiments. Miro1 was
found to be mainly modified with atypical K27-linked ubiquitin chains as seen with
both K only and K-to-R ubiquitin mutants, moreover, a partial contribution of K11
and K29 was detected in the K only experiments (Fig. 4.12 and Fig. 4.13). Miro1
chain composition was also tested taking advantage of linkage specific DUBs. Since
a K27-linkage specific DUB has not been found to date, OTUD2, a deubiquitinase of
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the family of the ovarian tumor ubiquitinases, which shows a preference for K11, K27,
K29 and K33-type linkages was used (Mevissen et al., 2013). This enzyme was able
to cleave Miro1 ubiquitin chains confirming the contribution of the K27, K11 and K29
linkage (Fig. 4.14). OTUD2-dependent cleavage of Miro1 chains was not, however,
complete. This could be due to the fact that the enzyme OTUD2 is not very active,
but it could also suggest that other chain-linkages, could be involved in the formation
of Miro1 ubiquitin chains. A recent report showed Miro1 to be ubiquitinated, in vitro,
in a K6, K11, K33, K48 and K63 manner by mass spectrometry (Kazlauskaite et al.,
2014a). Such a different result might be due to the difference between an in vitro versus
an in vivo system. Within cells, in fact, Miro1 is ubiquitinated at the mitochondrion
and many co-factors (or different E2s) could favour specific chain types. Thus a more
extensive DUB restriction assay, or mass spectrometry experiments will be required to
fully characterise Parkin-mediated Miro1 ubiquitin chains.
Interestingly, K27-linked ubiquitin chains have so far only been observed in connection
with Parkin (Geisler et al., 2010). Moreover, the modification with this chain type does
not seem to lead to Miro1 immediate degradation, which is consistent with previous
proteomic analysis showing that K27 chains are not significantly enriched when the pro-
teasome is inhibited, in contrast to K48 or K11 chains (Kim et al., 2011). This suggests
that this chain type may have other roles. For example, K27-linked poly-ubiquitin chains
have previously been correlated to p62 translocation to damaged mitochondria (Geisler
et al., 2010). An interesting question is whether ubiquitin chains are stable, or they
can be remodelled over time. For example, protein ubiquitination could switch from a
pro-signalling to a pro-degradative linkage. To this end analysis of Miro1 ubiquitination
could be analysed immediately after damage as well as prior to degradation.
In this Chapter, Miro1 ubiquitination was thoroughly characterised. Miro1 was found
to be ubiquitinated rapidly upon mitochondrial damage, however its degradation was
delayed. The protein is therefore stable on the OMM in its ubiquitinated form for at
least one or two hours, suggesting an alternative signalling role for this post-translational
modification. Moreover atypical K27-linked ubiquitin chains, previously associated with
mitophagy, were found on Miro, suggesting that this chain-type could have a peculiar role
in the targeting of damaged mitochondria for mitophagy. Mass spectrometry analysis
of Miro1 ubiquitin chains is however needed to further confirm these results.
Chapter 5
Parkin regulation and mitophagy
Introduction
Mitochondrial damage triggers a cascade of events that ultimately results in mitochon-
drial clearance by mitophagy. As previously described, following the loss of the mito-
chondrial membrane potential, PINK1 accumulates on the OMM. This is a crucial step in
the activation of the mitophagy cascade. Once stabilised at the OMM, PINK1 not only
recruits Parkin, a cytosolic E3 ubiquitin ligase, to the mitochondrion, but also promptly
activates (within 10 minutes after mitochondrial damage) the ligase by phosphorylation
of serine 65 at the N-terminal Ubl domain (Kondapalli et al., 2012; Shiba-Fukushima
et al., 2012). Parkin, normally exists in a closed, autoinhibited conformation. Structural
analysis has shown that the Ubl domain binds the RING1 domain, possibly hindering
the E2 binding site, while the RING0 domain blocks the catalytic C431 residue, that is
located on the RING2 domain, and is crucial for the ligase activity (Trempe et al., 2013;
Wauer and Komander, 2013; Riley et al., 2013). Activation of this ligase is therefore
a tightly regulated multi-step process. Phosphorylation at S65 has been suggested to
release Parkin N-terminal Ubl domain, allowing the ligase to be active. Indeed phospho-
rylated Parkin was shown to catalyse the formation of free ubiquitin chains (Kondapalli
et al., 2012) and oxyester intermediates were found between ubiquitin and wild type and
phospho-mimic, but not phospho-null Parkin (on a C431S backbone to allow the forma-
tion of a stable oxyester bond) (Iguchi et al., 2013). Even though these assays prove the
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activation of Parkin in principle, further experiments are needed to investigate the role
of serine 65 phosphorylation in the ubiquitination of Parkin substrates. Since defects in
the translocation to damaged mitochondria would impact on the ligase activity, Parkin
enzymatic function needs to be studied alongside its subcellular localisation, which is
indeed controversial. Sarraf and colleagues have in fact found Parkin phospho-null and
phospho-mimic mutants to exhibit recruitment dynamics to damaged mitochondria sim-
ilar to WT Parkin, whereas Shiba-Fukushima and collaborators reported a translocation
defect for these mutants (Shiba-Fukushima et al., 2012; Sarraf et al., 2013).
Recruitment and activation of Parkin are not, however, the only steps controlled by
the mitochondrial kinase, PINK1. Three reports have in fact recently demonstrated
that PINK1 is the first kinase to phosphorylate ubiquitin (Koyano et al., 2014; Ka-
zlauskaite et al., 2014b; Kane et al., 2014). A post translational modification of a post
translational modification that adds another level of complexity to the regulation of
mitophagy. Once accumulated at the OMM, PINK1 phosphorylates both Parkin and
ubiquitin at the same conserved serine 65 (in the Ubl on Parkin). Koyano and colleagues
have shown that expression of phospho-mimic S65D ubiquitin promotes the activity of
phospho-mimic S65E Parkin by analysing its auto-ubiquitination state in vitro and in
vivo. However expression of the ubiquitin phospho-mimic mutant failed to recruit Parkin
to mitochondria in the absence of mitochondrial damage (Koyano et al., 2014). These
data suggest that PINK1 promotes the formation of a “cloud” of activated Parkin and
ubiquitin surrounding damaged mitochondria (only 0.05% of total ubiquitin is in fact
phosphorylated upon damage, Koyano et al., 2014) to promote the ubiquitination of the
OMM proteins and therefore mitophagy. Ubiquitin phosphorylation is yet another step
in the complex activation of Parkin, but whether this modification is also crucial for
ubiquitin incorporation into multimeric chains, or whether specific ubiquitin chains can
be favoured by this post-translational modification has not yet been explored.
Once Parkin is fully activated and stabilised on damaged mitochondria, it can ubiq-
uitinate its substrates. Several proteins have been shown to be ubiquitinated by this
E3 ligase: for example the Mitofusins (1 and 2), VDAC1, Drp1, TOM20 and 40 and,
as described in the previous chapters, Miro (Geisler et al., 2010; Wang et al., 2011a;
Ziviani et al., 2010; Yoshii et al., 2011; Poole et al., 2010; Liu et al., 2012; Sarraf et al.,
2013; Wang et al., 2011b). Whether ubiquitination of each single protein exerts a spe-
cific function during mitophagy or it is the overall ubiquitination of the mitochondrion
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that is essential for the autophagic signalling cascade is debated. Nevertheless, the pres-
ence of several ubiquitinated proteins on the mitochondrion drives the recruitment of
elements of the autophagic machinery and the formation of autophagosome-like struc-
tures, that will result in the formation and maturation of the autophagosome. This
autophagic organelle will then fuse with acidified lysosomes causing the degradation of
the mitochondrion.
In this Chapter the role of serine 65 phosphorylation on Parkin ligase activity will be
investigated by analysing the levels of Miro1 ubiquitination, using phospho-null (S65A)
and phospho-mimic (S65E) Parkin mutants in HeLa and SH-SY5Y cells. Moreover, an
in depth analysis of phospho-null and phospho-mimic Parkin recruitment dynamics to
damaged mitochondria and the role of Miro1 as part of an acceptor complex for Parkin
will be investigated by immunofluorescence experiments. Finally the role of PINK1-
dependent ubiquitin phosphorylation on Parkin activity will be studied.
Results
PINK1-dependent phosphorylation of Parkin on S65 results in impaired
ligase function
Several reports have recently shown that PINK1 phosphorylates Parkin on its serine 65.
This modification is thought to determine a conformational change that promotes the
activation of the protein, as shown by the formation of ubiquitin chains in vitro or by
the detection of oxyester intermediates between ubiquitin and wild type and phospho-
mimic, but not phospho-null Parkin (on a C431S backbone) (Kondapalli et al., 2012;
Shiba-Fukushima et al., 2012; Iguchi et al., 2013). Shiba-Fukushima and colleagues have
shown that mutation of S65 on Parkin to phospho-null S65A delays the degradation of
OMM proteins (Shiba-Fukushima et al., 2012), however, whether the phosphorylation of
this residue is important for substrate ubiquitination by Parkin in response to mitochon-
drial damage, has not been tested. To this aim, YFPParkin was mutated to phospho-null
S65A and phospho-mimic S65E. PINK1-mediated phosphorylation of Parkin upon mito-
chondrial damage was tested taking advantage of the PhosTag™ technology. PhosTag™
is a compound that is added together with MnCl2 to the SDS-PAGE gel solution. While
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being resolved on the gel, phosphorylated proteins bind to PhosTag™, which causes a
delay in the migration of these species. As a result, phosphorylated proteins will run
slower than their unphosphorylated counterparts and antibodies will recognise unphos-
phorylated/faster moving bands and phosphorylated/slower moving bands (Fig. 5.1).
HeLa cells, which do not express endogenous Parkin (Denison et al., 2003), were tran-
siently transfected with WT or S65A YFPParkin. Cells were treated with FCCP (10
μM, 1 hour) to induce mitochondrial damage or vehicle (DMSO), lysed and proteins
resolved either on a conventional SDS-PAGE gel or on a PhosTag™ gel. Proteins were
then western blotted on a PVDF membrane and probed with an anti-GFP antibody.
Upon FCCP treatment a slow migrating GFP positive band could be detected in the
PhosTag™ gel, but not in the conventional SDS-PAGE gel (Fig. 5.2). Moreover this
band was prevented by the S65A mutation in Parkin, indicating that this slower migrat-
ing band is phosphorylated Parkin at S65. FCCP treatment also induced the formation
of another GFP positive WT YFPParkin band which could be detected in both conven-
tional and PhosTag™ gels, but is absent in the YFPParkinS65A samples. This band is
likely to represent an auto-ubiquitinated form of Parkin, which is prevented by the S65A
mutation (Fig. 5.2).
To investigate the role of serine 65 on Parkin ligase activity on impaired mitochon-
dria, Miro1 ubiquitination was studied. HeLa or SH-SY5Y cells were transfected with
WT, phospho-null S65A or phospho-mimic S65E YFPParkin along with mycMiro1 and
HAubiquitin. Cells were treated with FCCP (10 μM, 1 hour) or vehicle (DMSO), lysed,
and mycMiro1 was immunoprecipitated. Immunoprecipitated samples and inputs were
resolved by SDS-PAGE, western blotted and ubiquitination of mycMiro1 was detected
with an anti-HA antibody. In contrast to the robust mycMiro1 ubiquitination triggered
by FCCP when WT YFPParkin was expressed, mycMiro1 ubiquitination was greatly re-
duced when YFPParkinS65A was expressed both in HeLa and in SH-SY5Y cells (Fig. 5.3
and Fig. 5.4), similar to recent data obtained with in vitro assays (Kazlauskaite et al.,
2014a), and supporting a key role for PINK1-dependent phosphorylation of Parkin in
Miro1 ubiquitination.
Although YFPParkinS65E expression led to reduced FCCP-dependent ubiquitination of
Miro1 compared to WT, Miro expression levels appeared reduced under basal condi-
tions with this mutant (Fig. 5.3 and Fig. 5.4), suggesting constitutive activity of
phospho-mimic S65E Parkin to regulate Miro. This could be potentially due to impaired
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Figure 5.1: PhosTag™ technology.
(A) Addition of the phosphate binding PhosTag™ to acrylamide gels results in the slower
migration of phosphorylated proteins. (B) With conventional acrylamide gels phospho-
rylated and unphosphorylated forms of a protein run according to their molecular weight
and cannot be distinguished, however, these different species can be separated and vi-
sualised as two separate bands on PhosTag™ gels. Modified from Wako Chemicals.
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Figure 5.2: Parkin is phosphorylated on S65.
WT or S65A YFPParkin transfected HeLa cells were treated with FCCP (10 μM, 1 hour)
or vehicle (DMSO). Lysates were either resolved on a PhosTag™ gel (left panel) or on
a conventional SDS-PAGE gel (right panel) and probed with an anti GFP antibody.
FCCP treatment (10 μM, 1 hour) triggers the phosphorylation of YFPParkin WT, but
not S65A, as can be visualised by the high molecular weight GFP positive band in the
PhosTag™ gel. An extra band, slightly lower than phospho-Parkin, is present both in the
PhosTag™ and conventional gel (white arrowhead) and is likely to be an ubiquitinated
form of Parkin (n=1).
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Ubl domain-mediated inhibition of the ligase (Chaugule et al., 2011). In Parkin S65E
overexpressing cells mitochondrial damage induced further Miro loss and ubiquitina-
tion suggesting that additional regulatory mechanisms may contribute to mitochondrial
damage-induced activation of Parkin (Fig. 5.3 and Fig. 5.4).
S65 on Parkin is important for the ligase recruitment to damaged mi-
tochondria
The role of Parkin in mitophagy is not only dependent on its ubiquitin ligase activity,
but also on its ability to be recruited to damaged mitochondria, where it exerts its func-
tion. Consequently regulation of both processes needs to be studied in order to examine
the effect of Parkin mutations in mitophagy. In addition to the characterisation of the
ligase activity of phospho-null and phospho-mimic YFPParkin mutants on Miro1 ubiqui-
tination, the recruitment and stabilisation of these mutants onto mitochondria was also
investigated. For this aim a good mitochondrial marker was needed. Since Chan and
colleagues have shown that several OMM proteins, including TOM20 (often used as a
mitochondrial marker), are degraded upon induction of mitophagy (Chan et al., 2011),
TOM20 stability following mitochondrial damage was assessed. In particular HEK 293
cells transiently transfected with YFPParkin, were treated with the mitochondrial uncou-
pler FCCP (10 μM, 1 hour) or DMSO. Lysates were collected, resolved on a SDS-PAGE
gel and western blotted. The levels of TOM20 were similar after mitochondrial damage
(1 hour, Fig. 5.5), in agreement with the data reported by Chan and colleagues, where
30 μM CCCP triggered Parkin-dependent TOM20 loss only after 4 hours (Chan et al.,
2011). TOM20 was therefore used as a mitochondrial marker within this time period.
To investigate the recruitment dynamics of the Parkin mutants to damaged mitochon-
dria, HEK 293 cells were transiently transfected with WT, phospho-null or phospho-
mimic YFPParkin. Mitochondrial damage was triggered with FCCP (10 μM, 1 hour),
cells were fixed and representative images were taken with a confocal microscope from
previously blinded samples. The recruitment of YFPParkin mutants to mitochondria was
analysed as integrated fluorescence colocalisation of YFPParkin and the OMM TOM20.
Following 1 hour FCCP treatment nearly 80% of wild type YFPParkin was recruited to
the damaged mitochondria, however this translocation was inhibited by the phospho-
null S65A mutation and reduced by the phospho-mimic S65E mutant (Fig. 5.6 A and
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Figure 5.3: Miro1 ubiquitination by Parkin S65 mutants in HeLa cells.
HeLa cells transfected with WT, S65A or S65E YFPParkin, mycMiro1 and HAubiquitin,
were treated with FCCP (10 μM, 1 hour) or vehicle (DMSO), and mycMiro1 was im-
munopurified. Western blotted samples were probed with anti HA, myc, GFP and actin
antibodies. Expression of the phospho-null YFPParkinS65A mutant reduces the FCCP-
induced mycMiro1 HA positive ubiquitination smear and blocks the subsequent loss of
the protein, detected with an anti myc antibody. When phospho-mimetic YFPParkinS65E
is expressed mycMiro1 levels are lower, as detected by the myc positive bands in the in-
puts and in the immunoprecipitated sample, however mitochondrial damage results in
a further decrease of the protein (n=3 independent experiments).
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Figure 5.4: Miro1 ubiquitination by Parkin S65 mutants in neuronal SH-SY5Y cells.
Neuronal SH-SY5Y cells transfected with WT, S65A or S65E YFPParkin, mycMiro1 and
HAubiquitin, were treated with FCCP (10 μM, 1 hour) or vehicle (DMSO). mycMiro1
was immunopurified and samples western blotted. Expression of the phospho-null
YFPParkinS65A mutant reduces the FCCP-induced mycMiro1 HA positive ubiquitina-
tion smear and the protein loss. When phospho-mimetic YFPParkinS65E is expressed,
some residual HA positive Miro1 ubiquitination smear can be detected. Myc positive
Miro1 levels are lower, as detected in the inputs and in the immunoprecipitated samples,
moreover mitochondrial damage results in a further decrease of the protein.
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Figure 5.5: The OMM protein TOM20 is stable after 1 hour FCCP treatment.
HEK 293 cells were transfected with YFPParkin and treated with FCCP (10 μM, 1 hour)
to induce mitochondrial damage or DMSO as a control. Western blot analysis of the
lysates shows that the levels of TOM20 are unaltered after 1 hour of mitochondrial
damage (n=1).
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Fig. 5.7, percentage of S65A Parkin on mitochondria 33.27 ± 1.46%, percentage of
S65E Parkin on mitochondria 52.97 ± 4.68 %, compared to wild type Parkin on mi-
tochondria 78.19 ± 4.86 %, n=9-14, #p<0.05, ###p<0.005. * indicates significance
between treated/untreated samples, # indicated significance within a treatment group,
#p<0.05, **p<0.01, ###/***p<0.005).
The lack of recruitment of Parkin phospho-mutants could be due to either a block or
a delay of Parkin translocation onto damaged mitochondria. To address this HEK 293
cells transfected with WT S65A or S65E YFPParkin and treated for 2 hours with the
mitochondrial uncoupler FCCP (10 μM) were analysed. After 2 hours of mitochondrial
damage both mutants were recruited to the OMM to the same extent as WT Parkin.
This suggests that the translocation dynamics are delayed or the stability of these mu-
tants on the OMM is reduced (Fig. 5.6 B and Fig. 5.7, percentage of S65A Parkin on
mitochondria 53.97 ± 6.57%, percentage of S65E Parkin on mitochondria 60.90 ± 7.62%,
compared to wild type Parkin on mitochondria 71.33 ± 6.98%, n=9-14 from 3 indepen-
dent experiments, *** p<0.005), in agreement with a previous report (Shiba-Fukushima
et al., 2012).
To investigate whether Miro1 had a role in regulating phospho-null and phospho-mimic
YFPParkin translocation and stabilisation on the OMM, HEK 293 cells were transfected
with mCherryMiro1 together with WT, S65A or S65E YFPParkin. Mitochondrial dam-
age was triggered by incubation with FCCP (10 μM) for 1 or 2 hours prior to fixation.
Interestingly mCherryMiro1 was found to significantly increase the recruitment and sta-
bilisation of both the S65A and S65E mutants at early time points to an extent similar
to WT Parkin, as seen by the increase in integrated colocalisation of the YFP signal
with TOM20 fluorescence (Fig. 5.8 and Fig. 5.10, percentage of S65A Parkin on mi-
tochondria at 1 hour when Miro1 is OE 63.55 ± 5.24%, percentage of S65E Parkin on
mitochondria 72.82 ± 4.85% compared to wild type Parkin on mitochondria 61.69 ±
2.55%, n=12-14 from 3 independent experiments, ***p<0.005). A similar translocation
was also detected after 2 hours of mitochondrial damage (Fig. 5.9 and Fig. 5.10, per-
centage of S65A Parkin on mitochondria 61.63 ± 6.56 %, percentage of S65E Parkin
on mitochondria70.53 ± 4.97%, compared to wild type Parkin on mitochondria 67.41 ±
4.86%, n=12-13 from 3 independent experiments, ***p<0.005).
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Figure 5.6: Parkin mutants show delayed recruitment to damaged mitochondria after
mitochondrial damage in HEK 293 cells.
Confocal images of HEK 293 cells transfected with WT, S65A or S65E YFPParkin, and
treated with FCCP (10 μM) for 1 (A) or 2 (B) hours.YFPParkin fluorescent signal is
represented in green and TOM20 positive mitochondria are represented in blue. Scale
bar = 20 μm.
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Figure 5.7: Quantification of WT, S65A and S65E Parkin recruitment to damaged
mitochondria in HEK 293 cells.
Graph showing the quantification of Parkin translocation onto mitochondria following
1 and 2 hours FCCP treatment (10 μM), as shown in Fig. 5.6. Translocation was mea-
sured as integrated colocalisation of the YFPParkin signal with the mitochondrial marker
TOM20 signal, n=9-14 from 3 independent experiments, #p<0.05, ###p<0.005. * in-
dicates significance between treated/untreated samples, # indicated significance within
a treatment group, #p<0.05, **p<0.01, ###/***p<0.005.
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Figure 5.8: Miro1 facilitates the translocation of S65A and S65E Parkin mutants onto
damaged mitochondria in HEK 293 cells.
Overexpression of mCherryMiro1 (red) together with YFPParkin or the S65A and S65E
mutants (green) facilitates Parkin recruitment to the TOM20 positive mitochondria
(blue) after 1 hour FCCP treatment in HEK 293 cells. Scale bar = 20 μm.
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Figure 5.9: WT, S65A and S65E YFPParkin recruitment to damaged mitochondria after
2 hours FCCP treatment in HEK 293 cells overexpressing Miro1.
HEK 293 cells overexpressing WT, S65A and S65E YFPParkin (green) together with
mCherryMiro1 (red), were treated with FCCP (10 μM, 2 hours) before fixation. Mito-
chondria were labelled with the mitochondrial marker TOM20 (blue). Scale bar = 20
μm.
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Figure 5.10: Quantification of WT, S65A and S65E Parkin to damaged mitochondria in
the presence of Miro1.
Graph showing the quantification of Parkin translocation onto damaged mitochondria
following 1 and 2 hours FCCP treatment (10 μM) in HEK 293 cells overexpressing Miro1,
as shown in Fig. 5.8 and Fig. 5.9. Recruitment is measured as integrated colocalisation
of YFPParkin fluorescence with the mitochondrial marker TOM20 fluorescence. n=12-14
from 3 independent experiments, ***p<0.005.
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To further confirm the role of Miro1 in the recruitment and stabilisation of Parkin
phospho-null and phospho-mimic mutants, HeLa cells were used to exclude the possi-
bility of a contribution of endogenous Parkin. Cells were transfected with WT, S65A
or S65E YFPParkin with or without mCherryMiro1. Mitochondrial damage was triggered
with FCCP (10 μM, 1 hour), cells were fixed, stained and imaged on a confocal micro-
scope. Similar to HEK 293 cells, S65A and S65E Parkin mutants exhibited impaired
recruitment to damaged mitochondria in HeLa cells (Fig. 5.11). Moreover, even though
mCherryMiro1 overexpression promoted the translocation onto damaged mitochondria of
the Parkin mutants, this appeared to happen only in a subset of cells, rather than with
different degrees of translocation like in HEK 293 cells. To quantify the percentage of
cells displaying Parkin recruitment to damaged mitochondria, blinded samples were then
manually scored (recruitment Vs no recruitment). When WT YFPParkin was expressed,
mitochondrial damage induced the translocation of Parkin onto damaged mitochondria
in the totality of transfected cells in the presence or absence of mCherryMiro1 overex-
pression. However, both phospho-null (S65A) and phospho-mimic (S65E) YFPParkin
failed to translocate onto damaged mitochondria. Importantly, like in HEK 293 cells,
co-expression of mCherryMiro1 in HeLa cells promoted the recruitment and stabilisa-
tion of Parkin phospho-mutants. In particular phospho-null (S65A) translocation onto
mitochondria was detected in a subpopulation of the transfected cells, whereas S65E
translocated in the majority of transfected cells (Fig. 5.11, 100% of WT YFPParkin
transfected cells showed Parkin enrichment on damaged mitochondria in the presence
or absence of mCherryMiro1 overexpression, no translocation was observed when S65A
or S65E Parkin mutants were expressed in the absence of Miro1 coexpression, whereas
16.42 ± 2.0% of S65A Parkin expressing cells and 88.83 ± 5.0% of S65E Parkin express-
ing cells showed Parkin translocation on mitochondria when Miro1 was co-expressed;
44-79 cells from 3 independent experiments, #p<0.05, **p<0.01, ***/###p<0.005).
These data further suggest that following mitochondrial damage Miro1 could act as a
component of a Parkin acceptor complex on the OMM.
CHAPTER 5. PARKIN REGULATION AND MITOPHAGY 148
Figure 5.11: Miro1 promotes the translocation of S65E YFPParkin onto damaged mito-
chondria in HeLa cells.
(A) Confocal images of HeLa cells transfected with WT, S65A or S65E YFPParkin with
or without mCherryMiro1. Mitochondrial damage was triggered with FCCP (10 μM,
1 hour) prior to fixation. In green YFPParkin fluorescence, in blue the mitochondrial
marker TOM20, in red mCherryMiro1. FCCP treatment did not trigger S65A or S65E
YFPParkin recruitment to mitochondria (left panels), however mCherryMiro1 overexpres-
sion promoted this translocation in a subpopulation of S65A expressing cells and in the
majority of S65E transfected cells (right panels). Scale bar = 20 μm (B) Cells that
exhibited WT or mutant YFPParkin recruitment to mitochondria were scored manually
from previously blinded samples (44-79 cells from 3 independent experiments, #p<0.05,
**p<0.01, ***/###p<0.005).
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Role of Parkin S65 on mitochondrial trafficking
Parkin S65E phospho-mimic mutant was shown to facilitate Miro1 turnover in basal con-
ditions, suggesting that expression of this mutant could influence mitochondrial trans-
port. To address this question mitochondrial trafficking in hippocampal neurons was
analysed. Neuronal cultures were transfected at 8 days in vitro (DIV) with the mito-
chondrial marker mtDsRed2 together with either GFP, WT YFPParkin, S65A YFPParkin
or S65E YFPParkin. At 10 DIV axons of GFP/YFP and mtDsRed2 positive cells were
morphologically identified (thin process at least 3 times longer than the other thicker pro-
cesses - dendrites), and mtDsRed2 labelled mitochondria imaged over 2 minutes. The
percentage of moving mitochondria was analysed. Expression of WT, S65A or S65E
YFPParkin caused no difference in the mitochondrial motility, compared to GFP expres-
sion (Fig. 5.12 A, B, 21.2 ± 4.4% of moving mitochondria with GFP overexpression,
20.0 ± 5.7% with WT YFPParkin , 26.0 ± 3.8% with S65A YFPParkin and 25.4 ± 2.7%
with S65E YFPParkin; n=8-11 from 3 independent experiments). Since ubiquitin, in its
phosphorylated form, was recently found to further activate Parkin (Kane et al., 2014;
Kazlauskaite et al., 2014b; Koyano et al., 2014), mitochondrial trafficking in hippocam-
pal neurons was investigated in cells overexpressing S65E YFPParkin with or without
HAubiquitin. Hippocampal cultures were transfected at 8 DIV with the mitochondrial
marker mtDsRed2 together with S65E YFPParkin with or without HAubiquitin. At 10
DIV axons mtDsRed2 labelled mitochondria of YFP positive neurons, were imaged over
2 minutes. The percentage of moving mitochondria was analysed and HAubiquitin co-
expression with phospho-mimic S65E YFPParkin was found to reduce the number of
moving mitochondria compared to control (Fig. 5.12 C and D, 17.6 ± 3.3 % of mov-
ing mitochondria when S65E YFPParkin and HAubiquitin were expressed, while 29.9 ±
3.0% of mitochondria were moving when S65E YFPParkin only was expressed, n=9-11
from 3 independent experiments, p=0.015). After being imaged, cells were fixed and
HAubiquitin expression was confirmed by immunofluorescence. Although exciting these
experiments are preliminary. In fact, whether this effect can be blocked by phospho-
null Parkin mutant, and whether ubiquitin expression itself can influence mitochondrial
trafficking need to be investigated.
CHAPTER 5. PARKIN REGULATION AND MITOPHAGY 150
Figure 5.12: Regulation of mitochondrial trafficking by Parkin S65 mutants in hippocam-
pal neurons.
(A) Hippocampal neurons were transfected with GFP, WT YFPParkin, S65A YFPParkin
or S65E YFPParkin, together with the mitochondrial marker mtDsRed2 at 8 DIV. MtD-
sRed2 live imaging was performed at 10 DIV in GFP/YFP positive axons. In each
condition static images and kymographs are represented. Kymographs were created by
projecting sequential line scans through the process of interest onto the y-axis, so that
stationary mitochondria are seen as straight lines and moving mitochondria as diagonal
lines. Mitochondrial movement was imaged for 2 minutes. Scale bar = 20 μm. (B)
Bar graph quantifying the percentage of moving mitochondria shows that expression
of Parkin or its phospho-mutants does not affect mitochondrial motility (n=8-11, from
3 independent experiments). (C) Hippocampal neurons were transfected with S65E
YFPParkin and mtDsRed2 with or without HAubiquitin at 8 DIV. At 10 DIV mitochon-
drial trafficking was imaged in axons. Static images and kymographs are shown for
each condition. Scale bar = 20 μm. (D) Graph quantifying the percentage of moving
mitochondria shows that HAubiquitin overexpression inhibits mitochondrial trafficking
(n=9-11 axons from 3 independent experiments, *p=0.015).
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Role of ubiquitin phosphorylation in Miro1 ubiquitination
Three reports have recently demonstrated that upon mitochondrial damage ubiquitin is
phosphorylated by PINK1 on conserved serine 65, and that this modification is a fur-
ther step in the complex activation of Parkin during mitophagy (Kane et al., 2014; Ka-
zlauskaite et al., 2014b; Koyano et al., 2014). Phospho-ubiquitin was found to promote
the activation/auto-ubiquitination of phospho-mimic 65E Parkin, and oxyester bonds
were found between Parkin (C431S, to allow the formation of the oxyester bond) and
phospho-mimic 65D ubiquitin, suggesting the activation of the E3 ligase (Kazlauskaite
et al., 2014b; Koyano et al., 2014). However, the role of ubiquitin phosphorylation
in Parkin-dependent substrate ubiquitination has not been explored to date. To in-
vestigate whether by promoting the activation of Parkin, phosphorylation of ubiquitin
regulates the rate of ubiquitination of the OMM proteins, WT, phospho-null S65A or
phospho-mimic S65E ubiquitin were heterologously expressed in Parkin OE SH-SY5Y
cells together with mycMiro1. Cells were subjected to mitochondrial damage with the
ionophore FCCP (10 μM, 1 hour), mycMiro1 was immunopurified, samples were resolved
by SDS-PAGE and western blotted. Unexpectedly, the incorporation of phospho-mimic
S65E mutant in Miro1 ubiquitin chains (HA positive high molecular weight smear) upon
FCCP treatment was drastically reduced, whereas phospho-null S65A ubiquitin showed
a similar incorporation in Miro1 ubiquitination to WT ubiquitin (Fig. 5.13, n=3). This
suggests that phosphorylation of ubiquitin could have a role in the structural activation
of Parkin, but not in the ubiquitin chain elongation.
Discussion
A complex, multi-step regulation controls Parkin function. Upon mitochondrial damage,
this E3 ubiquitin ligase is recruited by PINK1 from the cytosol to damaged mitochon-
dria, PINK1 then induces the release of Parkin auto-inhibition by phosphorylating the
ligase Ubl domain at S65 and, by phosphorylating ubiquitin, PINK1 promotes a further
activation of Parkin. In this Chapter the role of S65-dependent activation and regulation
of the E3 ubiquitin ligase Parkin has been investigated. In particular the role of this
residue on Parkin ligase activity and recruitment dynamics to damaged mitochondria
has been explored with phospho-null and phospho-mimic Parkin constructs in HeLa,
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Figure 5.13: Analysis of ubiquitin phospho-mutants incorporation in Miro1 ubiquitin
chains.
Parkin OE SH-SY5Y cells were transiently transfected with mycMiro1 together with
WT, 65A or 65E HAubiquitin. Cells were treated with FCCP (10 μM, 1 hour) or vehicle
(DMSO), mycMiro1 was immunopurified and samples were run on a SDS-PAGE gel.
Western blotted samples were probed with anti HA, myc, Flag and actin antibodies.
HA positive Miro1 ubiquitination smear was similar when WT or phospho-null S65A
mutant were expressed, whereas phospho-mimic S65E ubiquitin was less incorporated
in Miro1 ubiquitin chains. Expression of the ubiquitin mutants, as shown in the inputs,
is similar (bottom panel, n=3 independent experiments).
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SH-SY5Y and HEK 293 cells. Following mitochondrial damage phospho-mimic Parkin
was shown to ubiquitinate Miro to a smaller extent than WT, however, this mutant
was still able to promote the protein turnover. Oppositely, expression of phospho-null
Parkin blocked FCCP-dependent Miro1 loss. Moreover, both mutants were shown to
have delayed translocation dynamics onto damaged mitochondria and interestingly, Miro
was found to facilitate the stabilisation of the Parkin mutants on the OMM. Lastly, the
role of phospho-ubiquitin in Parkin ligase activity has been studied by analysing Miro1
ubiquitination. Although phosphorylation of ubiquitin was reported to activate Parkin,
phospho-mimic 65E ubiquitin was found to be less prominent in Miro1 ubiquitin chains.
PINK1-dependent phosphorylation of serine 65 on Parkin has been suggested to activate
Parkin by causing the release of the autoinhibitory Ubl domain, favouring the ligase ac-
tive conformation. In fact S65 phosphorylation of Parkin has been shown to promote the
ligase self-ubiquitination and the formation of free ubiquitin chains (Shiba-Fukushima
et al., 2012; Kondapalli et al., 2012), however, little is known on the effect of this crucial
residue on the ubiquitination of Parkin substrates during mitophagy. Taking advantage
of phospho-null and phospho-mimic Parkin mutants, Miro1 ubiquitination was studied
in HeLa cells and in neuronal SH-SY5Y cells. Mutation of serine 65 to non phosphorylat-
able alanine resulted in decreased Miro1 ubiquitination, and the consequent stabilisation
of the protein after mitochondrial damage (Fig. 5.3 and Fig. 5.4), in agreement with
a recent study in vitro (Kazlauskaite et al., 2014a). In contrast, despite having a de-
creased ubiquitin ligase activity following FCCP treatment, expression of phospho-mimic
S65E Parkin caused a reduction in the levels of Miro1, which was further enhanced by
mitochondrial damage, suggesting an increased basal activity of this mutant. These
data agree with a recently published report, where reduced Miro and Mitofusin levels
were detected upon expression of a phospho-mimic Parkin mutant in vivo in Drosophila
(Shiba-Fukushima et al., 2014). It is possible that the negative charge given by the
phospho-mimic glutamate causes a conformational change in Parkin that might induce
an “activated” state of the protein in the absence of mitochondria damage. S65E Parkin
could therefore more easily interact with and ubiquitinate its substrates leading to an
increase in their turnover and a consequent decrease in their steady state levels.
Among the various disease-associated Parkin mutants, many are characterised by im-
paired ligase function, however others are unable to be recruited to the mitochondria
and cannot, therefore, promote mitophagy. Parkin function is in fact, not only depen-
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dent on its enzymatic activity, but also on its spatial regulation. For this reason, to
better understand the role of Parkin phosphorylation in the ligase function, the translo-
cation of Parkin S65 mutants to damaged mitochondria was investigated. Although
S65E Parkin was found to be enriched on damaged mitochondria, both mutants showed
impaired recruitment dynamics compared to WT Parkin at early time points in HEK 293
cells (Fig. 5.6 A and Fig. 5.7). The translocation of phospho-null and phospho-mimic
Parkin was not however blocked, but rather delayed to later time points (Fig. 5.6 B and
Fig. 5.7). Unexpectedly, when expressed in HeLa cells phospho-null and phospho-mimic
Parkin mutants completely failed to be recruited onto damaged mitochondria, unlike
what was previously reported by Shiba-Fukushima and colleagues (who documented a
partial recruitment) or by Sarraf and collaborators (who did not detect any difference
in the translocation of WT, phospho-null or phospho-mimic Parkin) (Shiba-Fukushima
et al., 2012; Sarraf et al., 2013). This effect might be possibly due to different expres-
sion levels of the Parkin constructs and/or the OMM proteins in the different HeLa cell
lines used. Altogether these results suggest that PINK1-dependent phosphorylation of
Parkin could have a role in the stabilisation of the ligase onto the mitochondria, possibly
favouring its interaction with PINK1 or its substrates. Alternatively, mutations at S65
could affect Parkin self association, which has been suggested to promote its activation
and stabilisation onto mitochondria (Lazarou et al., 2013).
Interestingly, Miro levels were found to stabilise phospho-null and phospho-mimic Parkin
mutants onto damaged mitochondria both in HEK 293 and in HeLa cells (Fig. 5.8, Fig.
5.9, Fig. 5.10 and Fig. 5.11). Unlike HEK 293 cells, where Parkin mutants showed
different levels of recruitment (in the absence of Miro), HeLa cells either displayed a
clear recruitment of Parkin onto the mitochondria or the ligase appeared to remain
cytosolic, possibly due to the lack of endogenous Parkin that might facilitate the mutants
translocation. These results suggest that Miro, and potentially other OMM Parkin
substrates such as Mfn2 (Chen and Dorn II, 2013), may play an additional role in
stabilising Parkin on the OMM. Therefore substrate binding by Parkin in conjunction
with its phosphorylation, could work together to stabilise the E3 ligase on the OMM of
damaged mitochondria, providing a mechanism to regulate Parkin levels to the levels of
its substrates on the mitochondria.
Parkin overexpression has been previously described to induce Miro degradation, thus
promoting a decrease in mitochondrial transport (Wang et al., 2011b). In this work
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however, expression of YFPParkin did not drastically affect Miro1 levels (for example in
Fig. 5.4 mycMiro1 levels are similar in untreated cells, transfected or not with Parkin)
or impaired mitochondrial transport (Fig. 5.12 A and B). This lack of Parkin-mediated
regulation of Miro in control conditions could be due to the fact that the ligase, although
overexpressed, is not recruited to polarised mitochondria. S65E phospho-mimic Parkin,
suggested to exhibit an activated conformation, was shown to facilitate Miro1 basal
turnover (Fig. 5.3 and Fig. 5.4), suggesting that this mutant could affect mitochondrial
transport. Analysis of mitochondrial motility in the presence of phospho-mimic S65E
Parkin, however, showed no difference compared to WT Parkin or GFP control (Fig. 5.12
A and B). Recently, however, three reports showed that ubiquitin, in its phosphorylated
form, further activates Parkin (Kane et al., 2014; Koyano et al., 2014; Kazlauskaite
et al., 2014b). Indeed, preliminary experiments showed that overexpression of ubiquitin
together with S65E phospho-mimic Parkin caused a reduction of mitochondrial transport
in axons of hippocampal neurons (Fig. 5.12 C and D), in agreement with the idea of
ubiquitin to promote Parkin S65E basal activity.
PINK1-mediated ubiquitin phosphorylation on the conserved S65 was recently found to
be an additional step in the tight regulation of mitochondrial quality control. Phosphory-
lated ubiquitin was shown to promote phospho-mimic S65E Parkin auto-ubiquitination
in vitro, and oxyester bonds were found between Parkin C431S (to allow the formation
of stable oxyester bonds) and phospho-mimic 65D ubiquitin in the absence of mitochon-
drial depolarization (Kane et al., 2014; Koyano et al., 2014), suggesting that ubiquitin
phosphorylation could promote Parkin activation/function. Unexpectedly, in Parkin
OE SH-SY5Y cells Miro1 was ubiquitinated in a comparable way when WT or S65A
HAubiquitin were expressed. Additionally, its ubiquitination was drastically reduced in
the presence of phospho-mimic S65E HAubiquitin (Fig. 5.13). Koyano and colleagues
have shown that Parkin is able to conjugate both phosphorylated and unphosphorylated
ubiquitin molecules (Koyano et al., 2014), therefore it is possible that when phospho-null
ubiquitin was expressed, phosphorylation of endogenous ubiquitin was sufficient to fully
activate Parkin, which in turn could conjugate S65A ubiquitin. Meanwhile, if ubiqui-
tin phosphorylation is a key process in Parkin activation, but not in the incorporation
of ubiquitin into polymeric chains, S65E HAubiquitin could bind and activate Parkin,
but not necessarily take part in the assembly of Miro1 ubiquitin chains, which could
be formed by the endogenous protein (that would not be detected by the anti-HA an-
tibody). For this reason, it would be interesting to test the contribution of endogenous
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ubiquitin in Miro1 ubiquitination when the phospho-null and phospho-mimic ubiqui-
tin mutants are expressed to investigate whether phospho-ubiquitin-dependent Parkin
activation and phospho-ubiquitin incorporation into chains are two separate processes.
Moreover, phospho-mimic S65D ubiquitin should be used instead of S65E, since it has
been shown to promote phospho-mimic Parkin self-ubiquitination (Koyano et al., 2014).
An open question is whether phosphorylation of ubiquitin can influence the ubiquitin
chain linkage. In this case the the selective activation of ubiquitin kinases or phos-
phatases could either favour or impede specific chain types, affecting the outcome of
ubiquitination.
Overall in this Chapter the phosphorylation-dependent regulation of Parkin and mi-
tophagy have been studied. Parkin phosphorylation at S65 has been found to be crucial
both for the prompt recruitment of the ubiquitin ligase to damaged mitochondria and
for its enzymatic function. Interestingly Miro1 was found to promote the translocation
of the Parkin mutants onto impaired mitochondria, suggesting that Miro could be part
of a Parkin acceptor complex that promotes the stabilisation of Parkin on the OMM,
although mitochondrial damage was necessary for this to happen. Finally phospho-
mimic ubiquitin, recently shown to activate Parkin, was found not to take part in Miro1
ubiquitination, however further experiments will be needed to thoroughly investigate
the function of this phosphorylation in the ubiquitin chain assembly process and in the
linkage preference.
Chapter 6
Final Discussion
Mitochondria play a central role within the cell. These organelles provide energy, buffer
calcium and they are involved in several cellular processes from cell differentiation and
growth to apoptosis. Mitochondria are not just randomly distributed within the cell,
but they are actively transported across the cytoplasm to areas of high energy demand
and calcium buffering requirements. Mitochondrial trafficking is accomplished by a set
of proteins that forms the mitochondrial transport machinery. Miro proteins are atypi-
cal Rho GTPases localised on mitochondria. By the interaction with the kinesin motors
these proteins mediate mitochondrial trafficking along the cytoskeletal tracks (MacAskill
et al., 2009b). Miro also interacts with the TRAK adaptors, that have been reported
to bind both kinesin and dynein motors (Brickley et al., 2005; Brickley and Stephen-
son, 2011; Glater et al., 2006; van Spronsen et al., 2013), suggesting that this motor
complex regulates mitochondrial transport in both antero and retrograde directions.
Mitochondria however, not only need to be trafficked where necessary, but also need to
be retrieved when dysfunctional. Work from Miller and Sheetz has shown that in neu-
rons mitochondrial transport is linked to mitochondrial functionality (Miller and Sheetz,
2004). The authors have in fact showed that anterogradely moving mitochondria were
characterised by higher membrane potential than retrogradely moving ones. Moreover,
treatment with antimycin A, which inhibits complex III of the ETC, resulting in ROS
formation and inhibition of the ATP production, favoured retrograde transport of the
axonal organelles, thus suggesting that mitochondrial damage induces a switch in the
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transport directionality. Damaged, depolarised mitochondria need to be isolated from
the functional mitochondrial network and then cleared by mitophagy.
In the last decade our knowledge on the role of PINK1 and Parkin in mitochondrial
quality control and mitophagy has greatly improved. PINK1 and Parkin have been
shown to orchestrate recognition, isolation and mitophagy-targeting of damaged mito-
chondria. However, less is known on how mitochondrial clearance is regulated, the fate
of ubiquitinated proteins and the steps that determine and follow the formation of the
autophagosome. In particular, mitophagy was assumed to occur at somatic level (Ma-
day et al., 2012; Cai et al., 2012), and an open question remains as to what mechanism
underlies the retrieval of damaged mitochondria. Miro, that together with TRAK was
found in a complex with PINK1 (Weihofen et al., 2009), represents an optimal candidate
to play a role in cross-talk between mitochondrial trafficking and quality control.
Summary
In this thesis the role of Miro as a substrate of the PINK1/Parkin pathway has been in-
vestigated. Mitochondrial damage was shown to trigger PINK1/Parkin-dependent Miro
loss in dopaminergic SH-SY5Y cells. To further confirm the role of Parkin in this path-
way, damage-induced Miro degradation was shown to be disrupted in human fibroblasts
derived from a PD patient lacking Parkin. Moreover, Miro was found to interact with
and be ubiquitinated by Parkin upon mitochondrial damage. To investigate whether
Miro1 ubiquitination affected its interaction with other components of the trafficking
machinery, Miro binding to the TRAKs was tested. Interestingly, however, no change
was detected, suggesting that the complex was preserved.
Miro ubiquitination could lead to its rapid degradation, or alternatively the protein
could be retained on the OMM in its ubiquitinated form. Further analysis of Miro1
ubiquitination and degradation dynamics demonstrated that although the protein was
found to be rapidly ubiquitinated (20 minutes FCCP), it appeared to be stable on the
OMM for at least one hour following treatment with the mitochondrial uncoupler FCCP,
suggesting that ubiquitinated Miro1 could have a signalling role prior to its degrada-
tion by the proteasome. While working on this project a paper came out from the
CHAPTER 6. FINAL DISCUSSION 159
Schwarz lab, showing that mitochondrial damage leads to the prompt block of mito-
chondrial transport caused by the rapid degradation of Miro1. Moreover, they showed
that Parkin-dependent Miro1 loss was induced by PINK1-mediated phosphorylation of
serine 156 (Wang et al., 2011b). To further analyse Miro1 ubiquitination and poten-
tially study the role of a ubiquitination-deficient mutant, Miro1 serine 156 phospho-null
and phospho-mimic mutants were made. These mutants, however, were shown to have
similar ubiquitination and degradation dynamics, in agreement with another study (Liu
et al., 2012). Depending on the chain linkage, poly-ubiquitination can have several cel-
lular outcomes. Miro1 ubiquitination was therefore studied using ubiquitin mutants and
chain-specific deubiquitinases. Interestingly, Miro1 was found to be ubiquitinated pri-
marily in a K27-linked manner, but also K11 and K29-linkages were detected, whereas
no K48 chain type contribution was found, in agreement with the slower degradation of
the protein.
Recent studies have reported the crucial role that PINK1 plays in the recruitment and
activation of Parkin. PINK1 in fact, not only binds and phosphorylates Parkin on serine
65 to promote the activation of the ligase, but also phosphorylates ubiquitin, which
further activates Parkin. To investigate the role of serine 65 in Parkin ligase activity,
Miro1 ubiquitination following mitochondrial damage was studied using phospho-null
and phospho-mimic Parkin contructs. Both mutants exhibited a lower activity compared
to wild type, however, interestingly, expression of phospho-mimic S65E Parkin seemed to
regulate steady-state Miro1 levels, suggesting a constitutive role of this mutant. Parkin
mutants also exhibited a delayed recruitment onto damaged mitochondria, however,
expression of Miro1 promoted their recruitment and stabilisation, suggesting that Miro is
part of a Parkin acceptor complex on damaged mitochondria. Incorporation of phospho-
null and phospho-mimic ubiquitin mutants in Miro1 ubiquitin chains was also analysed,
however in this assay phospho-mimic S65E ubiquitin was not found to be enriched in
Miro1 ubiquitin chains.
Mitochondrial damage-dependent regulation of the traffick-
ing machinery
Miro1, a key component of the mitochondrial trafficking complex, was found to in-
teract with the mitochondrial quality control protein PINK1 (Weihofen et al., 2009).
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This raised the interesting possibility of Miro being a substrate of the PINK1/Parkin
pathway, and mitochondrial trafficking being regulated upon damage. In this work the
regulation of Miro1 upon mitochondrial depolarisation was studied, and Miro was found
to be rapidly and consistently ubiquitinated in a PINK1/Parkin dependent manner.
While working on this, a paper from Thomas Schwartz lab was published and showed
that Parkin overexpression or mitochondrial damage triggered a drastic loss in Miro1
content (although no ubiquitination was reported) and this loss was associated with mi-
tochondrial arrest. The authors consequently suggested a model whereby mitochondrial
damage triggers the rapid degradation of Miro, which results in the uncoupling of the
organelles from the cytoskeletal tracks (Wang et al., 2011b). In Chapter 4, combined
analysis of Miro1 ubiquitination and degradation dynamics in dopaminergic SH-SY5Y
cells, revealed that Miro was rapidly ubiquitinated by Parkin, nevertheless the protein
resulted to be stable on the OMM for at least one hour following mitochondrial dam-
age, before being turned over by the proteasome. Hence mitochondrial arrest could be
determined by a change in the Miro1 interactome following ubiquitination, rather than
its degradation. For example Miro ubiquitination could result in a change in the pro-
tein affinity with the mitochondrial trafficking complex, or determine the recruitment of
other proteins to promote mitochondrial arrest (see model in Fig. 6.1). The affinity of
ubiquitinated Miro1 with the trafficking adaptors TRAK1 and TRAK2 was analysed,
and the interaction with TRAK1 resulted unchanged, whereas binding to TRAK2 was
increased. Interestingly TRAK2 levels were found to be also increased following FCCP
treatment. Since the TRAKs have been previously reported to facilitate the delivery of
endosomes to lysosomes (Webber et al., 2008; Kirk et al., 2006), this result hints at the
possibility of these proteins having a role in the delivery of damaged mitochondria to the
autophagic pathway. Due to their binding to the kinesins, dyneins and Miro, the TRAK
adaptors are key components of the mitochondrial transport machinery, however the
interaction between Miro itself and the motor proteins should be analysed to investigate
the stability of the complex upon mitochondrial damage.
In general mitochondrial stopping can be promoted by uncoupling of the organelles from
the microtubules, but could also be favoured by their interaction with docking molecules
as discussed in the introduction. No anchor has been reported so far to participate in
damage induced mitochondrial arrest, however it would not be surprising if this could
partly account for mitochondrial arrest.
CHAPTER 6. FINAL DISCUSSION 161
Intracellular signalling leading to Miro ubiquitination
In their report Wang and collaborators showed that PINK1 phosphorylates Miro on
serine 156 and threonines 298 and 299, making Miro1 a PINK1 substrate. Moreover,
phosphorylation of serine 156 in particular, was shown to be required for the protein
recognition/degradation by Parkin, suggesting a mechanism whereby PINK1 primes
substrates for Parkin to ubiquitinate (Wang et al., 2011b). By utilising phospho-null
and phospho-mimic contracts, the role of serine 156 in Miro1 ubiquitination was studied,
however no difference in the ubiquitination and loss of Miro was found in this work
(Fig. 4.6, Chapter 4), in agreement with another report (Liu et al., 2012). Moreover,
since Miro1 phosphorylation could influence its ubiquitination/degradation dynamics,
rendering the protein more prone to a rapid turn over, the ubiquitination dynamics of
phospho-null Miro1 were assessed, however mutant Miro1 appeared to be ubiquitinated
and degraded in a similar way to WT Miro in these experiments (Fig. 4.7, Chapter 4).
This could be due to different expression levels of Miro and/or Parkin, or to possible
additional regulators which could be cell specific (i.e. phosphatases).
In the last couple of years a huge progress has been made in the understanding of
PINK1 and Parkin regulation. Initially, two independent groups demonstrated that
Parkin is activated on damaged mitochondria by PINK1, via the phosphorylation of
serine 65. Phosphorylation of this residue on Parkin’s Ubl domain leads to a switch
from an autoinhibited to an active conformation of the ligase (Kondapalli et al., 2012;
Shiba-Fukushima et al., 2012). Does Parkin phosphorylation affect the protein recruit-
ment and stabilisation to damaged mitochondria? In Chapter 5 the dynamics of Parkin
phospho-null and phospho-mimic mutants translocation on damaged mitochondria were
analysed. Interestingly these mutants exhibited a delayed recruitment, with phospho-
null Parkin being less recruited than phospho-mimic at earlier time points (Fig. 5.6
and Fig. 5.7, Chapter 5), in HEK 293 cells (similarly in HeLa cells) both mutants
were not translocated following 1 hour FCCP. More importantly however, Miro1 was
found to promote the recruitment and stabilisation of phospho-null and phospho-mimic
Parkin in both cell types. This suggests that the presence of Parkin substrates on the
OMM acts as an acceptor complex to stabilise the protein onto damaged mitochon-
dria. Recently Mfn2 was found to act in a similar way, stabilising Parkin on the OMM
(Chen and Dorn II, 2013), suggesting the possibility that tuning the levels of Parkin
substrates on the OMM could favour the recruitment of Parkin mutants exhibiting a
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translocation defect. In Chapter 5 the activity of these mutants was also tested, by
analysing their ability to ubiquitinate Miro1 upon mitochondrial damage in both HeLa
and dopaminergic SH-SY5Y cells. Phospho-null Parkin leads to substantially reduced
Miro ubiquitination which correlates with increased stability of the protein, whereas the
phospho-mimic mutant had the opposite effect, apparently increasing Miro turnover un-
der basal conditions. This leads to the interesting idea that phospho-mimic S65E Parkin
could reside in the cytoplasm in a partly activated conformation, likely to regulate its
substrates at steady-state levels. Although mitochondrial transport was not affected by
the expression of WT, phospho-null or phospho-mimic Parkin in primary hippocampal
neurons, preliminary results suggest that ubiquitin co-expression with phospho-mimic
Parkin could determine a reduction in the number of moving mitochondria, promoting
Parkin S65E basal activity (Fig. 5.12, Chapter 5).
Following the finding that established PINK1 as a Parkin kinase, three reports have
shown that PINK1 not only phosphorylates Parkin, but it also phosphorylates ubiquitin
on the same conserved serine 65. This implies that upon PINK1 accumulation on the
OMM, damaged mitochondria become surrounded by phosphorylated ubiquitin, which
has been proposed to promote Parkin activity and possibly stabilisation (Kane et al.,
2014; Kazlauskaite et al., 2014b; Koyano et al., 2014). This adds a completely new level
of complexity to the regulation of the ubiquitination process, hinting at the possibil-
ity of further kinases and phosphatases to regulate this post-translational modification.
Moreover the control of ubiquitin phosphorylation in response to the activation of dif-
ferent pathways suggests an even more stringent spatial control of the ubiquitination
process. In addition, phosphorylation of ubiquitin could either facilitate or block the
formation of specific chain-linkages, for example due to the proximity of S65 to K63,
K63-type ubiquitin chain formation could be impaired following phosphorylation. In
this study the role of phospho-ubiquitin in the potentiation of Parkin ligase activity
has been investigated by analysing Miro ubiquitination in the presence of phospho-null
and phospho-mimic ubiquitin constructs in dopaminergic SH-SY5Y cells overexpressing
Parkin. Unexpectedly, phospho-mimic S65E ubiquitin was not found to be incorporated
into Miro1 ubiquitin chains upon mitochondrial damage, whereas phospho-null S65A
was incorporated at the same level as WT ubiquitin. This, however, could reflect the
fact that S65E might not act as a proper phospho-mimic, or phosphorylated ubiquitin
could bind and activate Parkin, but not take part in the chain elongation.
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OMM proteins ubiquitination and mitophagy
Parkin-dependent ubiquitination of mitochondrial proteins induces mitophagy by pro-
moting the recruitment of autophagy adaptors, such as p62 and HDAC6. However,
in addition to this bulk recruitment of autophagy-related proteins, ubiquitination of
distinct proteins can have specific effects in the regulation of the mitophagic cascade.
Notably, protein ubiquitination on the mitochondria is not only dependent on Parkin,
but also on the counteracting activity of protein deubiquitinases such as USP30, which
has been shown to promote the deubiquitination of Miro1 and TOM20, and USP15
(Bingol et al., 2014; Cornelissen et al., 2014). Interestingly, USP30 was reported to
counteract Parkin activity, but it was also found to be ubiquitinated and degraded in a
Parkin-dependent manner (Bingol et al., 2014). This suggests that when mitochondrial
damage is limited, a balance between Parkin-mediated ubiquitination and USP30/15-
dependent deubiquitination is in place, however increased stabilisation of Parkin on
mitochondria following extensive damage shifts this balance letting the ubiquitination
process to prevail.
Fusion and fission machinery
The first and most well characterised proteins reported to be ubiquitinated and de-
graded by Parkin upon mitochondrial damage were the Mitofusins (Gegg et al., 2010;
Poole et al., 2010; Ziviani et al., 2010; Glauser et al., 2011; Rakovic et al., 2011). Prior
to Parkin-dependent ubiquitination, Mfn2 was recently found to be phosphorylated by
PINK1, which in turn facilitates its interaction with Parkin and the ligase recruitment
to impaired mitochondria, ultimately favouring mitophagy (Chen and Dorn II, 2013).
Once ubiquitinated, the Mitofusins were shown to be extracted from the mitochondrial
membrane by the VCP/p97 retrotranslocase, and to be then degraded by the proteasome
(Tanaka et al., 2010). Depletion of Mitofusins from the OMM of depolarised mitochon-
dria, is thought to promote the segregation of these organelles by preventing their fusion
with the functional network. Additionally, mitochondrial fragmentation has been shown
to be required for the elimination of depolarised mitochondria (Twig et al., 2008). In
agreement with this, analysis of the mitochondrial proteome following mitochondrial
damage showed a decrease in the OMM fusion machinery and an increase in Drp1, the
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major fission protein (Chan et al., 2011). Notably however Drp1 was also found to be a
substrate of Parkin (Wang et al., 2011a), so the initial increase in the protein stability
might be followed by a Parkin-dependent degradation of the protein.
VDAC1
Another target of the PINK1/Parkin pathway is the voltage-gated anionic channel
VDAC1. This protein has been shown to be ubiquitinated in a K27-dependent manner
by Parkin, associating for the first time this atypical ubiquitin chain linkage to Parkin-
dependent regulation of impaired mitochondria. K27-type VDAC1 ubiquitination was
reported to favour the recruitment of p62 onto damaged mitochondria (Geisler et al.,
2010), which in turn would promote the translocation of LC3 and the autophagosome
formation. However, whether this protein is or is not necessary for the selective clearance
of damaged mitochondria is debated (Geisler et al., 2010; Narendra et al., 2010a).
Miro
In this thesis Miro1 was reported to be a substrate of the PINK1/Parkin pathway. To
further understand the cellular outcome of Miro1 ubiquitination, in Chapter 4 the ubiq-
uitin chain linkage was investigated. Similar to VDAC1, Miro1 ubiquitination was found
to include atypical K27-linked ubiquitin chains (Fig. 4.12, Fig. 4.13 and 4.14, Chapter
4), further supporting the idea of this chain linkage having a role in mitophagy, possi-
bly promoting the recruitment of p62 (Fig. 6.1 B). Moreover, Miro1 ubiquitination did
not lead to Miro1 immediate degradation, which is consistent with previous proteomic
analysis showing that K27 chains are not significantly enriched when the proteasome
is inhibited, in contrast to K48 or K11 chains (Kim et al., 2011). This suggests that
the chain type may have other more specific roles, such as mediating mitophagy. In
addition, at later stages, Miro was shown to be degraded by the proteasome (Fig. 4.1
and Fig. 4.2, Chapter 4 and Fig. 6.1 C), similar to the Mitofusins (Tanaka et al., 2010).
This step however, appeared to be independent of the retrotranslocase VCP (Fig. 4.5).
Proteasomal block has been reported to impair mitophagy (Tanaka et al., 2010), sug-
gesting that specific protein degradation mediated by the ubiqutin-proteasome system
is required for subsequent mitochondrial clearance.
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Whilst working on this project three other papers reported Miro1 to be ubiquitinated in
a PINK1/Parkin-dependent manner (Liu et al., 2012; Sarraf et al., 2013; Kazlauskaite
et al., 2014a). In particular, Kazlauskaite and colleagues have also investigated Miro1
ubiquitin chain composition and reported that by mass spectrometry of in vitro ubiq-
uitination assays they detected K6, K11, K33, K48 and K63 chains linkages associated
with Miro1 (Kazlauskaite et al., 2014a). The lack of K27 and K29 linkages in these
experiments might be due to the difference between in vitro and in vivo systems, since
mitochondria-associated cofactors or different E2 enzymes could promote specific chain
types. Mass spectrometry experiments to detect Parkin-mediated Miro1 ubiquitin chains
in vivo will be required to complete the characterisation of this post translational mod-
ification.
Further dissecting the role of Miro1 in mitophagy Liu and collaborators have analysed
the effect of Miro1 and Miro2 knock down in mitophagy. Interestingly the authors found
that in HeLa cells depletion of the Miro proteins favoured the perinuclear aggregation
of damaged mitochondria and OMM protein degradation, suggesting that the Miro pro-
teins could oppose the early stages of mitophagy, possibly by promoting mitochondria
movement towards the periphery. However, by impairing Miro-dependent mitochondrial
motility, knock down of the Miro proteins could itself promote a more perinuclear locali-
sation of mitochondria, therefore facilitating mitochondrial aggregation and mitophagy.
In addition, in Chapter 5, it was shown that tuning the levels of Miro1 expression could
promote the recruitment and stabilisation of Parkin S65A and S65E mutants onto dam-
aged mitochondria (Fig. 5.8 and Fig. 5.10, Chapter 5), suggesting that Miro is part of
an acceptor complex for Parkin (similar to Mfn2).
To further address the role of Miro in mitophagy, degradation deficient forms of the
protein could be helpful. A few reports have identified specific lysine residues within
Miro, K153, K182, K187, K194 and K572 to be targeted by Parkin (Wagner et al., 2011;
Sarraf et al., 2013; Kazlauskaite et al., 2014a), with K572 being the more prominent
(Kazlauskaite et al., 2014a). Studying mitophagy dynamics in the presence of Miro mu-
tants where these residues have been mutated into arginines, or in cells expressing Miro
allR mutant, will shed more light on the role of this protein in mitochondrial clearance,
and specifically it may allow the dissection between Miro1 role in mitochondrial traf-
ficking and in mitophagy. More generally, this assay would allow the analysis of the role
of mitochondrial trafficking in mitophagy, by determining whether Miro ubiquitination-
CHAPTER 6. FINAL DISCUSSION 166
dependent mitochondrial stopping is required for mitophagy to occur.
Minimal machinery required for the induction of mitophagy
The identification of each player in the PINK1/Parkin-dependent mitochondrial clear-
ance, as well as the dissection of every step that leads to mitophagy are of crucial
importance to target and modulate this process in PD. After the initial reports show-
ing that Parkin-dependent ubiquitination of OMM proteins of damaged mitochondria
triggered the recruitment of p62 and induced mitophagy (Geisler et al., 2010; Narendra
et al., 2010a), Narendra and colleagues attempted to induce mitophagy by targeting
ubiquitin molecules to polarised mitochondria with the FRB/FKBP heterodimerisa-
tion system. However, accumulation of ubiquitin on functional organelles did not pro-
mote the recruitment of the autophagic machinery and trigger mitophagy, suggesting
that protein poly-ubiquitination is probably needed for this process (Narendra et al.,
2010a). Subsequently, Tanaka and collaborators targeted Parkin itself with the same
FRB/FKBP system to mitochondria, failing again to induce mitophagy. Interestingly
however, mitophagy was found to be induced by the FRB/FKBP-mediated accumula-
tion of PINK1 (lacking its MTS domain), that in turn recruits Parkin to ubiquitinate
its OMM substrates (Lazarou et al., 2012). This agrees with the recent finding that
Parkin is activated by PINK1-dependent S65 phosphorylation (Kondapalli et al., 2012;
Shiba-Fukushima et al., 2012). More recently also PINK1-dependent ubiquitin phos-
phorylation has been shown to promote Parkin activation, in particular phospho-mimic
S65D ubiquitin was reported to promote phospho-mimic S65E Parkin self-ubiquitination
(Koyano et al., 2014). In Chapter 5 the transport of mitochondria in the presence of
S65E Parkin together with WT ubiquitin was shown to be reduced, although preliminary
and needing further controls, this experiment suggests that the presence of ubiquitin can
boost phospho-mimic Parkin basal activity to regulate mitochondrial trafficking. How-
ever, more experiments are needed to assess whether ubiquitin contribution is blocked
by phospho-null Parkin expression and whether ubiquitin itself can affect mitochondrial
transport. Using the FRB/FKBP system, it would be interesting to target polarised,
functional mitochondria with phospho-mimic S65E Parkin, in the presence of S65D
ubiquitin to see whether these components of the PINK-Parkin system are sufficient to
trigger OMM protein ubiquitination and to therefore induce mitophagy. Moreover, it
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Figure 6.1: Model of damage-dependent Miro1 processing and mitophagy initiation.
(A) Mitochondrial depolarisation triggers PINK1-dependent Parkin translocation onto
mitochondria and the formation of a complex with Miro. This leads to the ubiquiti-
nation of Miro by Parkin. Although interaction with TRAK2 increases, whether the
ubiquitination of Miro influences its interaction with the kinesin motors is still not
clear. (B) Ubiquitinated Miro on the OMM can serve as a acceptor of ubiquitin bind-
ing proteins involved in the autophagosome formation, such as p62. (C) At later time
points Miro is extracted from the OMM and degraded by the proteasome, while other
PINK/Parkin substrates, more stable on the OMM, further promote the recruitment
of p62 and possibly NBR1 and their interactor LC3. (D) The recruitment of LC3 to
damaged mitochondria promotes the formation of the autophagosome, that once mature
will fuse with acidified lysosomes to degrade its contents.
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would be interesting to reproduce this system in neurons, to investigate how targeting
S65E Parkin/S65D ubiquitin influences mitochondrial trafficking.
Different types of mitophagy
Extensive mitochondrial damage promotes the induction of PINK1/Parkin-dependent
mitophagy. Increasing evidence however, is showing that limited damage induces a lo-
calised activation of the PINK1/Parkin pathway to form small mitochondria-derived
vesicles (MDV) that determine the selective degradation of damaged portions of mito-
chondria (Soubannier et al., 2012; Mclelland et al., 2014). Mitochondrial elimination
needs to be coupled to biogenesis in order to support the cell metabolism, however this
is likely to be a energetically costly process. It is plausible that MDV-mediated quality
control serves as a constant repair mechanism to keep mitochondria functional. Whether
the first steps of mitophagy actually comprise the production of MDV to then switch to
a more global degradation of the organelle would be interesting to investigate.
FCCP model: advantages and disadvantages
The protonophores FCCP and CCCP, but also other mitochondrial uncouplers such as
valinomycin, antimycin A and oligomycin, have been widely used to study mitochondrial
damage. These drugs, however, cause an extensive mitochondrial damage that, if on one
hand can be helpful for identifying regulators and modifiers of mitophagy, on the other
hand they make the investigation of the fine regulation of mitochondrial damage in living
cells and neurons challenging. In addition, proton ionophores have been reported to also
affect other cellular components such as the microtubule cytoskeleton (Maro et al., 1982),
representing a clear caveat in the investigation of mitochondrial trafficking dynamics.
More subtle, or locally defined ways of damaging mitochondria will be therefore needed
for a finer dissection of this pathway. For example mito-KillerRed is a mitochondrially
targeted protein that, when photo-activated, induces local ROS production leading to
confined mitochondrial damage (Bulina et al., 2006; Wang et al., 2012). Moreover,
mitochondrial damage triggered by more physiological stimuli, such as ischaemia, could
be used to investigate mitochondrial dynamics.
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Future directions
In the recent years remarkable advances have been made in the elucidation of the path-
ways underlying mitophagy. However, the signalling mechanisms controlling mitochon-
drial clearance and the role of mitochondrial trafficking in this process still remain to be
fully elucidated. In this thesis, several aspects of PINK1/Parkin-dependent ubiquitina-
tion and degradation of the mitochondrial transport protein Miro1 have been analysed.
In Chapter 4 Miro was shown to be rapidly ubiquitinated, however the protein remained
stable in its ubiquitinated form on the OMM for some time (at least one hour from
the onset of mitochondrial damage) before being turned over by the proteasome. This
suggests a signalling role for the protein, however whether ubiquitination of Miro reg-
ulates the transport of damaged mitochondria towards the cell soma or participates in
the recruitment of the autophagic machinery on the OMM, still requires investigation.
Ubiquitination-deficient Miro mutants might be of help to further dissect this pathway
by separating the Parkin-dependent regulation of the protein from its trafficking role.
Analysis of the transport machinery composition will also shed light on the damage-
dependent regulation of mitochondrial trafficking. Interestingly, increased levels of the
TRAK2 adaptor, and of its interaction with Miro were described in Chapter 3. Experi-
ments aimed to further understand the role of this protein in mitophagy might hint at
exciting new perspectives on mitochondrial clearance.
According to the latest studies, phosphorylated ubiquitin further activates Parkin on the
OMM. It is therefore possible that accumulation of phospho-mimic Parkin on the OMM
(via the FRB/FKBP heterodimerisation) in the presence of phospho-mimic ubiquitin is
sufficient to trigger OMM protein ubiquitination and the initiation of the mitophagic
cascade. In this case, on one hand this system could be used to confirm that activa-
tion and localisation of Parkin on the OMM is sufficient to trigger mitophagy, and on
the other hand it would allow the investigation of the consequences of OMM protein
ubiquitination on mitochondrial trafficking and fission/fusion dynamics.
Mitochondrial uncouplers have been widely used to study mitophagy. These compounds,
however, drastically depolarise all the mitochondrial network, challenging the cells to
counteract such damage and degrade the organelles, thus resulting deprived of their
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major energy source. Under physiological conditions mitophagy is thought to occur more
seldomly, targeting few depolarised mitochondria while leaving the functional organelles
unaffected. It would be therefore important to investigate mitochondrial dynamics and
quality control following a more physiological, or spatially constricted damage in order
to confirm and further analyse the mechanisms of mitochondrial clearance.
Most of the studies on mitochondrial quality control and mitophagy have been performed
in cell lines and transgenic fibroblasts. However, since deficiencies in these pathways are
likely to affect neuronal function and survival (in particular in PD), mitophagy should be
examined in neurons, where, due to their extreme structural complexity, quality control
mechanisms could be differently regulated or they could exhibit distinct spatial control.
Concluding remarks
To maintain a functional mitochondrial network cells need to identify and clear dam-
aged organelles that cannot sustain the cells metabolism. Mitochondrial quality control
systems are in place to recognise, isolate and target for degradation these impaired or-
ganelles. These pathways have been found to be affected in neurodegenerative disorders,
such as Parkinson’s disease, further highlighting their importance.
In this thesis the regulation of the mitochondrial transport protein Miro1 following mito-
chondrial damage has been investigated. Miro has been shown to be a substrate of the
PINK1/Parkin mitochondrial quality control system. Interestingly, Parkin-dependent
Miro1 ubiquitination was not found to induce immediate degradation of the protein,
suggesting a signalling role for this modification in mitophagy. Moreover, Miro1 was
shown to favour the translocation of Parkin phosphorylation mutants on the OMM,
providing evidence of a new role for this trafficking protein in mitochondrial quality
control.
A clearer understanding of the initiation, progress and regulation of mitophagy in neu-
rons, will allow a better comprehension of how these pathways are affected in neurode-
generative disorders and in particular in Parkinson’s disease, hopefully opening new
avenues for improved targeting of drug therapies.
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